<SEC-DOCUMENT>0001213900-24-084859.txt : 20241003
<SEC-HEADER>0001213900-24-084859.hdr.sgml : 20241003
<ACCEPTANCE-DATETIME>20241003083008
ACCESSION NUMBER:		0001213900-24-084859
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20240929
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241003
DATE AS OF CHANGE:		20241003

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		241349978

	BUSINESS ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0216403-8k_180life.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ATNF="http://180lifesciences.com/20240929">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_ATNF_180lifesciences.com_20240929 -->
<!-- Field: Set; Name: xdx; ID: xdx_045_20240929_20240929 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000005" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20240929.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-09-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-29</xbrli:startDate>
        <xbrli:endDate>2024-09-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-292024-09-29_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-29</xbrli:startDate>
        <xbrli:endDate>2024-09-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-292024-09-29_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-29</xbrli:startDate>
        <xbrli:endDate>2024-09-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>FORM&#160;<span id="xdx_90F_edei--DocumentType_c20240929__20240929_zM6AJwy7UDzi"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>PURSUANT TO SECTION 13
OR 15(d)&#160;OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>SECURITIES EXCHANGE ACT
OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Date of Report (Date of earliest
event reported):&#160;<span id="xdx_90D_edei--DocumentPeriodEndDate_c20240929__20240929_zhf6D5fX9eFh"><ix:nonNumeric contextRef="AsOf2024-09-29" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">September 29, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityRegistrantName_c20240929__20240929_zlNBMac6lBr8"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000012" name="dei:EntityRegistrantName">180 LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20240929__20240929_ziGr9gXj0aja"><ix:nonNumeric contextRef="AsOf2024-09-29" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_901_edei--EntityFileNumber_c20240929__20240929_z3XPAFFQ7aMg"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000014" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20240929__20240929_zh3QcQsZEic8"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000015" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/>
of Incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20240929__20240929_zynREOw3ogOi" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000016" name="dei:EntityAddressAddressLine1">3000 El Camino Real</ix:nonNumeric></span></b><b><span style="font-size: 10pt">, <span id="xdx_908_edei--EntityAddressAddressLine2_c20240929__20240929_zPRhXEEFmbGk"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000017" name="dei:EntityAddressAddressLine2">Bldg. 4</ix:nonNumeric></span></span></b><b><span style="font-size: 10pt">, <span id="xdx_90E_edei--EntityAddressAddressLine3_c20240929__20240929_zCK5mLbnxKc5"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000018" name="dei:EntityAddressAddressLine3">Suite 200</ix:nonNumeric></span></span></b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20240929__20240929_zhlduvTMqiJ2" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000019" name="dei:EntityAddressCityOrTown">Palo Alto</ix:nonNumeric></span></b><b><span style="font-size: 10pt">, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20240929__20240929_zET32P35FHl3"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000020" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></span></b></p></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20240929__20240929_zSVwBkUKXctj"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000021" name="dei:EntityAddressPostalZipCode">94306</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code:&#160;<b><span style="text-decoration: underline">(<span id="xdx_900_edei--CityAreaCode_c20240929__20240929_z5aA4fL26rae"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000022" name="dei:CityAreaCode">650</ix:nonNumeric></span>)&#160;<span id="xdx_900_edei--LocalPhoneNumber_c20240929__20240929_zm1OiukkhGfl"><ix:nonNumeric contextRef="AsOf2024-09-29" id="Fact000023" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Check the appropriate&#160;box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see&#160;</i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.15pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--WrittenCommunications_c20240929__20240929_zXNKlHBQbrda"><ix:nonNumeric contextRef="AsOf2024-09-29" format="ixt:booleanfalse" id="Fact000024" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--SolicitingMaterial_c20240929__20240929_zHfxIvbKPnxk"><ix:nonNumeric contextRef="AsOf2024-09-29" format="ixt:booleanfalse" id="Fact000025" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20240929__20240929_zay1jOjtncej"><ix:nonNumeric contextRef="AsOf2024-09-29" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20240929__20240929_zV5aAUOitWI5"><ix:nonNumeric contextRef="AsOf2024-09-29" format="ixt:booleanfalse" id="Fact000027" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e 4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Securities registered pursuant
to Section 12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20240929__20240929__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zFnmd9QtJzzg"><ix:nonNumeric contextRef="From2024-09-292024-09-29_custom_CommonStockParValue0.0001PerShareMember" id="Fact000028" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20240929__20240929__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zabY1XlUsD04"><ix:nonNumeric contextRef="From2024-09-292024-09-29_custom_CommonStockParValue0.0001PerShareMember" id="Fact000029" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_90F_edei--SecurityExchangeName_c20240929__20240929__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z5ZMY1qcxsw"><ix:nonNumeric contextRef="From2024-09-292024-09-29_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>
    Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20240929__20240929__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zJ2Rz4Nrg3A7"><ix:nonNumeric contextRef="From2024-09-292024-09-29_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000031" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20240929__20240929__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_ztnlebqfE4ch"><ix:nonNumeric contextRef="From2024-09-292024-09-29_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000032" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_907_edei--SecurityExchangeName_c20240929__20240929__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zPyjU3QcKiVa"><ix:nonNumeric contextRef="From2024-09-292024-09-29_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" id="Fact000033" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)&#160;or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20240929__20240929_znbg2YKRYzSb"><ix:nonNumeric contextRef="AsOf2024-09-29" format="ixt:booleanfalse" id="Fact000034" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Asset Purchase Agreement</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 29, 2024, 180 Life
Sciences Corp. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;, &#8220;<span style="text-decoration: underline">we</span>&#8221; and &#8220;<span style="text-decoration: underline">us</span>&#8221;), entered into an Asset Purchase
Agreement (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;)&#160;with Elray Resources, Inc. (&#8220;<span style="text-decoration: underline">Elray</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement,
Elray agreed to sell us certain source code and intellectual property relating to an online blockchain casino (the &#8220;<span style="text-decoration: underline">Purchased
Assets</span>&#8221;)&#160;in consideration for 1,000,000 shares of newly designated Series B Convertible Preferred Stock (the &#8220;<span style="text-decoration: underline">Preferred
Stock</span>&#8221;, and the shares of common stock issuable upon conversion thereof, the &#8220;<span style="text-decoration: underline">Conversion Shares</span>&#8221;)&#160;and
warrants to purchase 3,000,000 shares of common stock of the Company (the &#8220;<span style="text-decoration: underline">Warrants</span>&#8221; and the shares of common stock
issuable upon exercise thereof, the &#8220;<span style="text-decoration: underline">Warrant Shares</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement,
the Company and Elray made certain representations and provided certain warranties (which were required to be re-certified at closing)&#160;to
each other relating to, among other things: (a)&#160;the organization of the parties; (b)&#160;the authority of the parties to enter into
and affect the transactions contemplated by the Purchase Agreement; (c)&#160;required consents to complete the transaction; (d)&#160;no
conflicts existing in connection with the Purchase Agreement; (e)&#160;lack of litigation; (f)&#160;no brokers; (g)&#160;title to the
Purchased Assets (Elray); (h)&#160;intellectual property rights (Elray); (i)&#160;certain securities representations (Elray); (j)&#160;capitalization
of the Company (the Company); (k)&#160;the listing of our common stock on Nasdaq; and (l)&#160;others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement includes
(i)&#160;customary covenants of each of the parties and confidentiality requirements; and (iv)&#160;customary indemnification requirements
of the parties, subject to a $25,000 deductible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The closing of the transactions
contemplated by the Purchase Agreement were subject to certain customary conditions to closing, including the filing of the designation
of the Preferred Stock with the Secretary of State of Delaware, and the receipt by the Company of an opinion of Hempstead &amp; Co., LLC
to the effect that, as of the date of such opinion and subject to the assumptions, qualifications, limitations and such other factors
deemed relevant by Hempstead &amp; Co., LLC, as set forth in such opinion, the purchase price to be paid by the Company was fair, from
a financial point of view, to the Company, which opinion was received verbally on September 29, 2024, which conditions to closing were
either satisfied or waived by the parties on September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The acquisition contemplated
by the Purchase Agreement closed on September 30, 2024 (the &#8220;<span style="text-decoration: underline">Closing</span>&#8221; and such date, the &#8220;<span style="text-decoration: underline">Closing Date</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the Closing, Elray
agreed to provide support and assistance to the Company in connection with the building and launching of a fully operational casino operation
utilizing the Purchased Assets, at no cost to the Company for a period of six months following the Closing, provided that such assistance
shall not exceed 40 hours per week without the prior written approval of the Seller (the &#8220;<span style="text-decoration: underline">Post-Closing Assistance</span>&#8221;).
The Post-Closing Assistance will also require Elray to assist the Company with obtaining payment gateways and licensing where required,
acknowledging that the Company will require a front end (the &#8220;<span style="text-decoration: underline">Front-End Development</span>&#8221;). Following the Closing, at the
request of the Company, Elray and the Company shall negotiate in good faith to come to agreement on an arrangement whereby Elray will,
for an additional cost agreed to by Elray, help the Company complete the Front-End Development, or at the request of the Company, Elray
shall introduce the Company to a vendor that would sell such a front end for one or more casinos that will operate on the Purchased Assets
at a cost to be agreed between such vendor and the Company, in the Company&#8217;s sole discretion. The Company has sole discretion to
determine which, if any, vendor it retains for the Front End Development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement also restricts
Elray, in perpetuity, from copying, selling, assigning, hypothecating, or otherwise transferring the Purchased Assets to any other party,
without the prior written consent of the Company, and provides for the Company to be the sole owner of the Purchased Assets, except that
Elray shall be authorized to retain and use the Purchased Assets for its own benefit and utilize such assets to provide SAAS solutions
and hosted casino solutions to third party companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement,
we agreed to file a proxy statement with the SEC (the &#8220;<span style="text-decoration: underline">Proxy Statement</span>&#8221;)&#160;to seek stockholder approval for the
issuance of the Conversion Shares and Warrant Shares, under applicable rules of the Nasdaq Capital Market, as soon as reasonably practicable.
We also agreed to use our reasonable best efforts to: (i)&#160;cause the Proxy Statement to be mailed to our stockholders as promptly
as practicable following sign off from the Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) on such Proxy Statement,
or no later than the 20th day after such preliminary Proxy Statement is filed with the SEC, in the event the SEC does not notify the Company
of its intent to review such Proxy Statement, and (ii)&#160;ensure that the Proxy Statement complies in all material respects with the
applicable provisions of the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;) and Securities Exchange Act
of 1934, as amended (the &#8220;<span style="text-decoration: underline">Exchange Act</span>&#8221;). We are also required to hold a shareholders meeting to seek shareholder approval
for the issuance of the Conversion Shares and Warrant Shares promptly after the SEC has confirmed that it has no comments on such Proxy
Statement (the &#8220;<span style="text-decoration: underline">Stockholder Approval</span>&#8221;, and the date of such Stockholder Approval, the &#8220;<span style="text-decoration: underline">Stockholder Approval
Date</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The representations, warranties
and covenants of each party set forth in the Purchase Agreement have been made only for the purposes of, and were and are solely for the
benefit of the parties to, the Purchase Agreement, may be subject to limitations agreed upon by the contracting parties, including being
qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Purchase Agreement
instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that
differ from those applicable to investors. Accordingly, the representations and warranties may not describe the actual state of affairs
at the date they were made or at any other time, and investors should not rely on them as statements of fact. In addition, such representations
and warranties (i)&#160;will only survive consummation of the purchase as specifically set forth therein and (ii)&#160;were made only
as of the date of the Purchase Agreement or such other date as is specified in the Purchase Agreement. Moreover, information concerning
the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information
may or may not be fully reflected in the parties&#8217; public disclosures. Accordingly, the Purchase Agreement is included with this
filing only to provide investors with information regarding the terms of the Purchase Agreement, and not to provide investors with any
factual information regarding the Company, their respective affiliates or their respective businesses. The Purchase Agreement should not
be read alone, but should instead be read in conjunction with the other information regarding the Company and the Purchased Assets, that
will be contained in, or incorporated by reference into, the Proxy Statement the Company plans to file subsequent to the date hereof as
discussed above, as well as in the Form 10-K, Form 10-Q and other filings that the Company makes hereafter with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Series B Convertible Preferred Stock</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The rights and preferences of
the Series B Convertible Preferred Stock are discussed in greater detail below under <span style="text-decoration: underline">Item 5.03</span> and incorporated into this <span style="text-decoration: underline">Item
1.01</span> by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Common Stock Purchase Warrants</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Closing,
on September 30, 2024, we granted warrants to purchase 3,000,000 shares of common stock to Elray pursuant to a Common Stock Purchase Warrant
(the &#8220;<span style="text-decoration: underline">Warrant Agreement</span>&#8221;). The Warrants have an exercise price of $1.68 per share, the closing stock price of the Company&#8217;s
common stock on the last trading day prior to the parties&#8217; entry into the Purchase Agreement, and a term of seven years (through
September 30, 2031). The Warrants also provide for cashless exercise rights. No shares of common stock may be issued upon exercise of
the Warrants until or unless the Company has received Stockholder Approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">* * * * *</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foregoing description of
the Purchase Agreement and Warrant Agreement, is not complete and is subject to, and qualified in its entirety by reference to the Purchase
Agreement and Warrant Agreement, filed herewith as <span style="text-decoration: underline">Exhibits 2.1</span> and <span style="text-decoration: underline">4.1</span>, respectively, which are incorporated in this&#160;<span style="text-decoration: underline">Item
1.01</span>&#160;by reference in their entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 2.01 Completion of Acquisition or Disposition
of Assets.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchased Assets were acquired
on September 30, 2024, upon the Closing, as discussed in greater detail in <span style="text-decoration: underline">Item 1.01</span>, which information and disclosures are incorporated
by reference into this <span style="text-decoration: underline">Item&#160;2.01</span> in their entirety by reference.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 3.02</b>&#160;<b>Unregistered Sales of Equity
Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The disclosures in <span style="text-decoration: underline">Item
1.01</span> and <span style="text-decoration: underline">Item 5.03</span> relating to the Series B Convertible Preferred Stock and Warrants
are incorporated by reference into this <span style="text-decoration: underline">Item 3.02</span> in their entirety.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The offer and sale of the 1,000,000
shares of Series B Convertible Preferred Stock and the Warrants, issued in connection with the Closing, and the Conversion Shares and
Warrant Shares, were, and are, intended to be exempt from registration pursuant to Section 4(a)(2)&#160;and/or Rule 506 of Regulation
D of the Securities Act, since the foregoing offer, sales and issuances were/will not involve a public offering, the recipient has confirmed
that it is an &#8220;<span style="text-decoration: underline">accredited investor</span>&#8221;, and the recipient will acquire the securities for investment only and not with
a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offered without any general
solicitation by us or our representatives. The securities are subject to transfer restrictions, and the certificates evidencing the securities
will contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered
or sold absent registration or pursuant to an exemption therefrom.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If converted in full, the maximum
number of shares of common stock issuable upon conversion of the 1,000 shares of Series B Convertible Preferred Stock is 10,000,000 shares
of common stock; provided that the number of shares of common stock issuable upon conversion of the Series B Convertible Preferred Stock
is fixed at 40% of the Company&#8217;s outstanding shares of common stock (after issuance thereof)&#160;upon the date of Stockholder Approval,
as discussed below under <span style="text-decoration: underline">Item 5.03</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If exercised in full, the maximum
number of shares of common stock issuable upon exercise of the Warrants is 3,000,000 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 3.03 Material Modification to Rights of Security
Holders.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The disclosures set forth in&#160;<span style="text-decoration: underline">Item
5.03</span>&#160;of this Current Report on Form 8-K are incorporated into this&#160;<span style="text-decoration: underline">Item 3.03</span>&#160;by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 5.03 Amendments to Articles of Incorporation
or Bylaws; Change in Fiscal Year.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Series B Convertible Preferred Stock</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 30, 2024, in contemplation
of the closing of the transactions contemplated by the Purchase Agreement, and pursuant to the power provided to the Company by the Certificate
of Incorporation of the Company, as amended, the Company&#8217;s Board of Directors approved the adoption of, and filing of, a Certificate
of Designations of 180 Life Sciences Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series B
Convertible Preferred Stock (the &#8220;<span style="text-decoration: underline">Series B Designation</span>&#8221;), which was filed with, and became effective with, the Secretary
of State of Delaware on the same date. The Series B Designation designated 1,000,000 shares of Series B Convertible Preferred Stock which
were issued to Elray on the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The below is a summary of the
rights and preferences of the Series B Convertible Preferred Stock:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Voting Rights</i></b>.
Until such time, if ever, as Stockholder Approval is received, the Series B Convertible Preferred Stock only has rights to vote on amendments
to the Series B Designation (which are subject to the approval of a simple majority of the holders of Series B Convertible Preferred Stock),
and the Protective Provisions, discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Series B Preferred Stock
require the consent of the holders of at least a majority of the issued and outstanding shares of Series B Convertible Preferred Stock
to (a)&#160;increase or decrease (other than by redemption or conversion)&#160;the total number of authorized shares of Series B Convertible
Preferred Stock of the Company; (b)&#160;adopt or authorize any new designation of any Preferred Stock or amend the Certificate of Incorporation
of the Company in a manner which (i)&#160;provides any holder of common stock or preferred stock any rights upon a liquidation of the
Company which are prior and superior to those of the holders of the Series B Convertible Preferred Stock; or (ii)&#160;adversely affect
the rights, preferences and privileges of the Series B Convertible Preferred Stock; (c)&#160;effect an exchange, or create a right of
exchange, cancel, or create a right to cancel, of all or any part of the shares of another class of shares into shares of Series B Convertible
Preferred Stock; (d)&#160;alter or change the rights, preferences or privileges of the shares of Series B Convertible Preferred Stock
so as to affect adversely the shares of such series; and (e)&#160;issue any shares of Series A Preferred Stock or Series B Convertible
Preferred Stock, other than the Preferred Stock issued at the Closing (collectively, the &#8220;<span style="text-decoration: underline">Protective Provisions</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After Stockholder Approval,
in addition to the above voting rights, each holder of outstanding shares of Series B Convertible Preferred Stock shall be entitled to
cast the number of votes in connection with the Series B Convertible Preferred Stock shares held by such holder equal to the number of
whole shares of common stock into which the shares of Series B Convertible Preferred Stock held by such holder are convertible as of the
record date for determining stockholders entitled to vote on such matter. Fractional votes shall not, however, be permitted and any fractional
voting rights available on an as-converted to common stock basis (after aggregating all fractional shares into which shares of Series
B Convertible Preferred Stock held by each holder could be converted)&#160;shall be rounded down to the nearest whole share. Except as
provided by law or by the other provisions of the Certificate of Incorporation or the Series B Designation, holders of Series B Convertible
Preferred Stock shall vote together with the holders of common stock as a single class and there shall be no series voting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Dividend Rights</i></b>.
None, except that if the Company declares a dividend or makes a distribution of cash (or any other distribution treated as a dividend
under Section 301 of the Internal Revenue Code)&#160;on its common stock, each holder of Shares of Series B Convertible Preferred Stock
is entitled to participate in such dividend or distribution in an amount equal to the largest number of whole shares of common stock into
which all shares of Series B Convertible Preferred Stock held of record by such holder are convertible as of the record date for such
dividend or distribution or, if there is no specified record date, as of the date of such dividend or distribution. Notwithstanding the
foregoing, holders shall have no right of participation in connection with dividends or distributions made to the common stock stockholders
consisting solely of shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Liquidation Preference</i></b>.
In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary (each a &#8220;<span style="text-decoration: underline">Liquidation
Event</span>&#8221;), the holders of Series B Convertible Preferred Stock are entitled to receive prior and in preference to any distribution
of any of the assets of the Company to the holders of the common stock or securities junior to the Series B Convertible Preferred Stock
(other than the common stock)&#160;by reason of their ownership of such stock, but after any required distribution to any holders of Series
B Convertible Preferred Stock, an amount in cash per share of Series B Convertible Preferred Stock for each share of Series B Convertible
Preferred Stock held by them equal to the greater of (x)&#160;one times the Stated Value; and (y)&#160;the total amount of consideration
that would have been payable on such share upon a Liquidation Event, had such share of Series B Convertible Preferred Stock been converted
into common stock, immediately prior to such Liquidation Event (as applicable, the &#8220;<span style="text-decoration: underline">Liquidation Preference</span>&#8221;). The &#8220;<span style="text-decoration: underline">Stated
Value</span>&#8221; is $17.30 per share of Series B Convertible Preferred Stock, for a total aggregate Liquidation Preference of $17,300,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Conversion Rights</i></b>.
None prior to Stockholder Approval. After Stockholder Approval, at the option of the holder(s)&#160;thereof, each share of Series B Convertible
Preferred Stock is convertible into a number of shares of common stock of the Company as equals the Conversion Rate. The &#8220;<span style="text-decoration: underline">Conversion
Rate</span>&#8221; shall initially be 0.685 (or 685,000 shares in aggregate, which would represent 40% of the Company&#8217;s then outstanding
shares of common stock), as equitably adjusted, as applicable for stock splits and recapitalizations; provided that if at any time after
the original issuance date of the Series B Convertible Preferred Stock and prior to the Stockholder Approval Date, the Company shall actually
issue any additional shares of common stock of the Company (each a &#8220;<span style="text-decoration: underline">Dilutive Issuance</span>&#8221;), the Conversion Rate shall
be increased to a value equal to (x)(i)&#160;the total outstanding shares of common stock (&#8220;<span style="text-decoration: underline">Total Outstanding Shares</span>&#8221;)
on the date immediately following such Dilutive Issuance, divided by (ii)&#160;60%, minus (iii)&#160;the Total Outstanding Shares on the
date immediately following such Dilutive Issuance, divided by (y)&#160;1,000,000, rounded to the thousands place, as equitably adjusted,
as applicable for stock splits and recapitalizations (each a &#8220;<span style="text-decoration: underline">Dilutive Adjustment</span>&#8221;); provided that in no event will
the Conversion Rate be greater than ten. The effect of any change in the Conversion Rate shall not be retroactive and shall only apply
for conversions of Series B Convertible Preferred Stock following the date of any Dilutive Adjustment. The Conversion Rate is designed
to result in the holders of the Series B Convertible Preferred Stock receiving 40% of the then outstanding shares of common stock upon
conversion of the Series B Convertible Preferred Stock, subject to a maximum of 10 million shares of common stock, and further subject
to such conversion ratio being fixed upon Stockholder Approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Redemption Rights</i></b>.
None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">* * * *</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The description of the Series
B Designation above is not complete and is qualified in its entirety by the full text of the Series B Designation, filed herewith as&#160;<span style="text-decoration: underline">Exhibit
3.1</span>, and incorporated into this&#160;<span style="text-decoration: underline">Item 5.03</span>&#160;by reference in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 8.01.</b>&#160;<b>Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><i>Press
Release</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 3, 2024, the Company
published a press release announcing the closing of the Purchase Agreement. A copy of the press release is included herewith as&#160;<span style="text-decoration: underline">Exhibit
99.1</span>&#160;and the information in the press release is incorporated by reference into this&#160;<span style="text-decoration: underline">Item 8.01</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Nasdaq Equity Rule Compliance Extension</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As previously disclosed, on November
15, 2023, the Listing Qualifications department (the &#8220;<span style="text-decoration: underline">Staff</span>&#8221;) of The Nasdaq Stock Market LLC (&#8220;<span style="text-decoration: underline">Nasdaq</span>&#8221;)
notified the Company that it did not comply with the minimum $2,500,000 stockholders&#8217; equity requirement for continued listing set
forth in Nasdaq Listing Rule 5550(b) (the &#8220;<span style="text-decoration: underline">Equity Rule</span>&#8221;) and Nasdaq subsequently provided the Company an extension
until May 13, 2024, to regain compliance with the Equity Rule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Also as previously disclosed,
the Company was unable to regain compliance with the Equity Rule prior to May 13, 2024 and as a result, on May 14, 2024, the Company received
a delist determination letter from the Staff advising the Company that the Staff had determined to suspend the trading of the Company&#8217;s
common stock and public warrants at the opening of business on May 23, 2024 and to file a Form 25-NSE with the SEC, which would remove
the Company&#8217;s common stock and public warrants from listing and registration on The Nasdaq Stock Market, unless the Company timely
requested an appeal of the Staff&#8217;s determination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 17, 2024, the Company requested
an appeal of the Staff&#8217;s delisting determination, and on May 20, 2024, the Staff advised the Company that the delisting action referenced
in the Staff&#8217;s determination letter has been stayed, pending a final written decision by the Nasdaq Hearings Panel (&#8220;<span style="text-decoration: underline">Panel</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A Panel hearing was subsequently
held and the Panel determined to grant the Company&#8217;s request to continue its listing on Nasdaq, subject to the Company meeting certain
conditions, including filing on or before July 31, 2024, a public disclosure describing the transactions undertaken by the Company to
achieve compliance with Nasdaq&#8217;s continued listing rules and demonstrate long-term compliance with the Equity Rule and providing
an indication of its equity following those transactions. Subsequent to the Panel&#8217;s initial determination, the Company requested,
and was granted an extension until September 30, 2024, and more recently, on September 30, 2024, the Company was granted a further extension
until October 15, 2024, to regain compliance with the Equity Rule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The extension by the Panel is
subject to the following: (1) on or before October 15, 2024, the Company must file a public disclosure describing the transactions undertaken
by the Company to achieve compliance and demonstrate long-term compliance with the Equity Rule and providing an indication of its equity
following those transactions. The Company can do so by including in the public filing a balance sheet not older than 60 days with pro
forma adjustments for any significant transactions or events occurring on or before the report date. Alternatively, the Company can provide
an affirmative statement in its public filing that, as of the date of the report, the Company believes it has regained compliance with
the stockholders&#8217; equity requirement based upon the specific transaction or event described. In this later case, the Company must
also provide the Panel and Nasdaq with a balance sheet not older than 60 days with pro forma adjustments for all significant transactions
or events occurring on or before the report date, including adjustments for anticipated losses, if any, incurred through the date of the
balance sheet; and (2) in addition, on or before October 15, 2024, the Company must provide the Panel with income projections for the
next 12 months, with all underlying assumptions clearly stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Company&#8217;s common
stock and public warrants are delisted, it could be more difficult to buy or sell the Company&#8217;s common stock and public warrants
or to obtain accurate quotations, and the price of the Company&#8217;s common stock and public warrants could suffer a material decline.
Delisting could also impair the Company&#8217;s ability to raise capital and/or trigger defaults and penalties under outstanding agreements
or securities of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Nasdaq Equity Rule Compliance</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the acquisition
of the Purchased Assets, issuance of the 1,000,000 shares of Series B Convertible Preferred Stock and Warrants as described in <span style="text-decoration: underline">Items
1.01</span>, <span style="text-decoration: underline">2.01</span> and <span style="text-decoration: underline">5.03</span> hereof, as of the date of this Current Report on Form 8-K, the Company believes it has regained
compliance with the Equity Rule. The Company has previously provided the Panel and Nasdaq with a balance sheet not older than 60 days
with pro forma adjustments for all significant transactions or events occurring on or before the report date, including adjustments for
anticipated losses, if any, incurred through the date of the balance sheet taking into account the acquisition of the Purchased Assets;
and (2) has also provided the Panel and Nasdaq with income projections for the next 12 months, with all underlying assumptions clearly
stated. Such materials are subject to review by the Panel, which may, in its discretion, request additional information before determining
whether or not the Company has complied with the terms of the exception and/or regained compliance with the Equity Rule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above, there
is no assurance that Nasdaq will agree that we have regained compliance with the Equity Rule or that we will not continue to be subject
to delisting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Company&#8217;s common
stock and public warrants are delisted, it could be more difficult to buy or sell the Company&#8217;s common stock and public warrants
or to obtain accurate quotations, and the price of the Company&#8217;s common stock and public warrants could suffer a material decline.
Delisting could also impair the Company&#8217;s ability to raise capital and/or trigger defaults and penalties under outstanding agreements
or securities of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also note that Nasdaq will
continue to monitor the Company&#8217;s ongoing compliance with the stockholders&#8217; equity requirement and, if at the time of its
next periodic report the Company does not evidence compliance, it may be subject to delisting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 9.01.</b>&#160;<b>Financial Statements and
Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d)&#160;<span style="text-decoration: underline">Exhibits</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 9%; vertical-align: bottom"><span style="font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 90%; vertical-align: bottom"><span style="font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">2.1*#&#163;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea021640301ex2-1_180life.htm">Asset Purchase Agreement dated September 29, 2024, by and among Elray Resources, Inc., as seller and 180 Life Sciences Corp., as purchaser</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea021640301ex3-1_180life.htm">Certificate of Designations of 180 Life Sciences Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea021640301ex4-1_180life.htm">Common Stock Purchase Warrant to purchase 3,000,000 shares of common stock dated September 30, 2024, granted by 180 Life Sciences Corp. to Elray Resources, Inc.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">99.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ea021640301ex99-1_180life.htm">Press Release dated October 3, 2024</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed herewith.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">#</td><td style="text-align: justify">Certain schedules and exhibits have been omitted pursuant to
Item 601(b)(2)(ii)&#160;of Regulation S-K. A copy of any omitted schedule or Exhibit will be furnished supplementally to the Securities
and Exchange Commission upon request; provided, however that 180 Life Sciences Corp., Inc. may request confidential treatment pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or Exhibit so furnished.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#163;</td><td style="text-align: justify">Certain personal information which would constitute an unwarranted
invasion of personal privacy has been redacted from this exhibit pursuant to Item 601(a)(6)&#160;of Regulation S-K.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Forward- Looking Statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Current Report on Form
8-K contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation
Reform Act, as amended. Forward-looking statements are based on management&#8217;s current expectations and are subject to risks and uncertainties,
many of which are beyond our control, that may cause actual results or events to differ materially from those projected. These risks and
uncertainties, many of which are beyond our control, include risks described in the section entitled &#8220;<span style="text-decoration: underline">Risk Factors</span>&#8221;
and elsewhere in our Annual Reports on Form 10-K and in our other filings with the SEC, including, without limitation, our reports on
Forms 8-K and 10-Q, all of which can be obtained on the SEC website at&#160;<span style="text-decoration: underline">www.sec.gov</span>. Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management&#8217;s current
estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates
or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions
or circumstances on which any such statement is based, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Date: October 3, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Blair Jordan</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 31%"><span style="font-size: 10pt">Blair Jordan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Interim Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; background-color: white">8</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kUFuwjAQRU/AHUZRlwhsi26yayOKqkIbAaJs3TApFoknGjsUjtRb1nFAZdFalqzRzPv/j5wkw2RGT6ZChu3jcg5rrJtKe4QllshoCwwT2fNLCuFd4qdxnrX1sbyCGQUGA3M/UhMdGnH0aBzuUpBiLNRYTUCqVEjIF8mg62dkS7ND642uQNsd5EwNG/Saz73CWp/IUn2OVhtkZ8gGuZHo29+ghFTwSkf9RXxwMJ9nyWAYzyCZMbVNmJqePNqOhGmFdbBzPf17Y5qidZ7q9F1zt5xbU95ysdcOV3vN6N7KsGJNduWpOCyw/kAOkBRKSfFwyXNlwRM0FxpcxIFK6AUgKvzhfKOfa97oqkUxEkLIHDlm+Mf1VnYIjWY4dizc9TQ04XtiiKvnD1bdlfc= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ea021640301ex2-1_180life.htm
<DESCRIPTION>ASSET PURCHASE AGREEMENT DATED SEPTEMBER 29, 2024, BY AND AMONG ELRAY RESOURCES, INC., AS SELLER AND 180 LIFE SCIENCES CORP., AS PURCHASER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">E<B>xhibit 2.1</B></P>

<P STYLE="margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSET PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dated September 29, 2024,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>By and Among Elray Resources, Inc.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>as Seller</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>180 Life Sciences Corp.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>as Purchaser</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE I.
    DEFINITIONS</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions.</FONT></TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE II.
    THE TRANSACTION; RECITALS</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchased Assets.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed Liabilities.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded Assets.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Assignable Assets.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE III.
    CONSIDERATION</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer Taxes; Prorations.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Actions.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE IV.
    CLOSING</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Deliveries by Seller.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Deliveries by Purchaser.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Deliveries by Seller and Purchaser.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE V.
    REPRESENTATIONS AND WARRANTIES OF SELLER</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required Consents.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Conflict.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Employees.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchased Assets.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Representations.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data Room; Information Supplied.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Other Representations and Warranties.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE VI.
    REPRESENTATIONS AND WARRANTIES OF PURCHASER</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>14</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Capitalization.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing and Maintenance Requirements.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required Consents.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Conflict.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7.</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Investigation.</FONT></TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Status of Purchased Assets.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE VII.
    COVENANTS</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>15</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct of Purchased Assets Prior to the Closing.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access to Information.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Solicitation of Other Bids.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Certain Events.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Conditions.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public Announcements.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE VIII.
    CONDITIONS TO CLOSING</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>17</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to Obligations of All Parties.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to Obligations of Purchaser.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to Obligations of Seller.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Stock Shares.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE IX.
    INDEMNIFICATION</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>20</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification Procedures.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Limitations.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE X.
    TERMINATION</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>22</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination.</FONT></TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of Termination.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE XI.
    POST-CLOSING OBLIGATIONS</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>23</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assistance with Operations and Development.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Statement and Stockholder Meeting.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public Announcements.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Further Transfer of Purchased Assets.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE XII.
    MISCELLANEOUS PROVISIONS</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>25</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments and Waivers.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law; Assignments Prohibited; Successors and
    Assigns; No Third-Party Beneficiaries.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitation on Consequential Damages.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm&rsquo;s Length Negotiations.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remedies.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dispute Resolution.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JURY TRIAL WAIVER.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts, Effect of Facsimile, Emailed and Photocopied
    Signatures.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability; Entire Agreement.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.11.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation and Construction.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.12.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Parties.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.13.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further Assurances.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><B>Exhibits</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCECFF">
    <TD STYLE="width: 7%; text-align: center"><B>A</B></TD>
    <TD STYLE="width: 93%; text-align: justify">Certificate of Designations of 180 Life Sciences Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>B</B></TD>
    <TD STYLE="text-align: justify">Purchased Assets</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCECFF">
    <TD STYLE="text-align: center"><B>C</B></TD>
    <TD STYLE="text-align: justify">Bill of Sale</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>D</B></TD>
    <TD STYLE="text-align: justify">Intellectual Property Assignment</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSET PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Asset Purchase Agreement
(this &ldquo;<B><U>Agreement</U></B>&rdquo;) is made as of September 29, 2024, by and among Elray Resources, Inc., a Nevada corporation
(&ldquo;<B><U>Seller</U></B>&rdquo;), and 180 Life Sciences Corp., a Delaware corporation (&ldquo;<B><U>Purchaser</U></B>&rdquo;). Capitalized
terms used and not otherwise defined herein have the meanings specified or referred to in ARTICLE I.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Seller owns,
free and clear of any liens, pledges, pending, threatened or reasonably foreseeable claims, rights of third parties or any other Encumbrances,
the assets listed on&nbsp;<B><U>Exhibit B</U></B>&nbsp;attached hereto, which shall specifically include all Software Assets (as defined
below)(collectively, the &ldquo;<B><U>Purchased Assets</U></B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Purchaser
desires to purchase from Seller, and Seller desires to sell to Purchaser, all of the Purchased Assets on the terms and conditions set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the foregoing recitals and the mutual representations, warranties, covenants and promises contained herein, the adequacy
and sufficiency of which are hereby acknowledged by the parties, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
I.</FONT><BR>
DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Definitions.</B> In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this <U>Section 1.1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Affiliate</U></B>&rdquo; of a Person means any other Person that directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with, such Person. The term &ldquo;<B><U>control</U></B>&rdquo; (including the
corollary terms &ldquo;<B><U>controlled by</U></B>&rdquo; and &ldquo;<B><U>under common control with</U></B>&rdquo;) means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the
ownership of voting securities, by Contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Agreement</U></B>&rdquo; shall have the meaning set forth in the Preamble (including all schedules and exhibits attached
hereto), as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Business Day</U></B>&rdquo; means any day other than (i) a Saturday or a Sunday or (ii) a day on which banking institutions
are authorized or required by law to be closed in the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Closing Date</U></B>&rdquo; shall have the meaning specified in&nbsp;<U>Section 4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Closing</U></B>&rdquo; shall have the meaning specified in&nbsp;<U>Section 4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Consent</U></B>&rdquo; shall mean any approval, consent, ratification, permission, waiver or authorization (including
any Governmental Approval).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Contract</U></B>&rdquo; shall mean any agreement, contract, consensual obligation, promise, understanding, arrangement,
commitment or undertaking of any nature (whether written or oral and whether express or implied), whether or not legally binding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Damages</U></B>&rdquo; shall mean and include any loss, damage, injury, decline in value, lost opportunity, Liability,
claim, demand, settlement, judgment, award, fine, penalty, Tax, fee (including any legal fee, accounting fee, expert fee or advisory fee),
charge, cost (including any cost of investigation) or expense of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Designation</U></B>&rdquo; means the Certificate of Designations of 180 Life Sciences Corp. Establishing the Designations,
Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock, in the form attached hereto as <B><U>Exhibit
A</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Elray Rights</U></B>&rdquo; means the rights of, and ownership of, Seller in, and to, a copy of the Purchased Assets,
subject to the Exclusive Rights (as defined in <U>Section 11.5</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Encumbrance</U></B>&rdquo; shall mean any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance,
equity, trust, equitable interest, claim, preference, right of possession, lease, tenancy, license, encroachment, covenant, infringement,
interference, third party intellectual property right or claim, Order, proxy, option, right of first refusal, preemptive right, community
property interest, legend, defect, impediment, exception, reservation, limitation, impairment, imperfection of title (including, without
limitation, any claim of intellectual property ownership by any Person other than the Seller), condition or restriction of any nature
(including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction
on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise
or transfer of any other attribute of ownership of any asset).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Entity</U></B>&rdquo; shall mean any corporation (including any non-profit corporation), general partnership, limited
partnership, limited liability partnership, joint venture, estate, trust or company (including any limited liability company or joint
stock company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Front End</U></B>&rdquo; means the user interface (UI) of the website or software program utilizing the Purchased
Assets and includes the design and user-friendly interface for the online casino, and would require designing a homepage, game lobby,
and user account management system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Governmental Approval</U></B>&rdquo; shall mean any: (a) permit, license, certificate, concession, approval, consent,
ratification, permission, clearance, confirmation, exemption, waiver, franchise, certification, designation, rating, registration, variance,
qualification, accreditation or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental
Authority or pursuant to any Legal Requirement; or (b) right under any Contract with any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Governmental Authority</U></B>&rdquo; shall mean any: (a) nation, principality, state, commonwealth, province, territory,
county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government;
(c)&nbsp;governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency,
bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or Entity
and any court or other tribunal); (d) multinational organization or body; or (e) individual, Entity or body exercising, or entitled to
exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing or arbitral authority or power
of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Intellectual Property</U></B>&rdquo; means all tangible or intangible proprietary information and materials, including
without limitation, (i) all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereon,
and all patents, patent applications and patent disclosures, together with all continuations, continuations-in-part, divisions, reissues,
extensions and re-examinations thereof, (ii) all trademarks, service marks, trade dress, logos, trade names (all of the foregoing, whether
registered or unregistered), corporate names and limited liability company names, domain names (including <FONT STYLE="background-color: white">www.splitrockcasino.com&nbsp;or
any alternative name mutually agreed to by parties</FONT>), URLs, and social media accounts, together with all translations, adaptations,
derivations and combinations thereof, and all applications, registrations and renewals in connection therewith, (iii) all works of authorship
(whether registered or unregistered) and copyrights and all applications, registrations and renewals in connection therewith, (iv) all
trade secrets and confidential business information (including ideas, research and development, know-how, formulas, compositions, manufacturing
and production process and techniques, methods, schematics, technology, technical data, designs, drawings, flowcharts, block diagrams,
specifications, customer and supplier lists, pricing and cost information and business and marketing plans and proposals), (v) all software
and firmware (including data, databases and related documentation), (vi) all documents, records and files relating to, and tangible embodiments
of, all intellectual property described in clauses (i) through (v) above; and (vii) all licenses, agreements and other rights in any third
party product or any third party intellectual property described in clauses (i) through (v) above, other than any &ldquo;<B><U>off the
shelf</U></B>&rdquo; third party software or related intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Legal Requirement(s)</U></B>&rdquo; shall mean any federal, state, local, municipal, foreign or other law, statute,
legislation, constitution, principle of common law, resolution, ordinance, code, Order, edict, decree, proclamation, treaty, convention,
rule, regulation, permit, ruling, directive, pronouncement, requirement (licensing or otherwise), specification, determination, decision,
opinion or interpretation that is, has been or may in the future be issued, enacted, adopted, passed, approved, promulgated, made, implemented
or otherwise put into effect by or under the authority of any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Liability</U></B>&rdquo; shall mean any debt, obligation, duty or liability of any nature (including any unknown,
undisclosed, unmatured, unaccrued, unasserted, contingent, indirect, conditional, implied, vicarious, derivative, joint, several or secondary
liability), regardless of whether such debt, obligation, duty or liability would be required to be disclosed on a balance sheet prepared
in accordance with generally accepted accounting principles and regardless of whether such debt, obligation, duty or liability is immediately
due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Licensed Intellectual Property</U></B>&rdquo; means all Intellectual Property of any third party that is licensed
by Seller and expressly included in the list of the Purchased Assets on <B><U>Exhibit B</U></B> to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Order</U></B>&rdquo; shall mean any: (a) temporary, preliminary or permanent order, judgment, injunction, edict, decree,
ruling, pronouncement, determination, decision, opinion, verdict, sentence, stipulation, subpoena, writ or award that is or has been issued,
made, entered, rendered or otherwise put into effect by or under the authority of any court, administrative agency or other Governmental
Authority; or (b) Contract with any Governmental Authority that is or has been entered into in connection with any Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Owned Intellectual Property</U></B>&rdquo; means all Intellectual Property that is owned or purposed to be owned by
Seller and expressly included in the list of the Purchased Assets on <B><U>Exhibit B</U></B> to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Person</U></B>&rdquo; shall mean any individual, Entity or Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Proceeding</U></B>&rdquo; shall mean any material action, suit, litigation, arbitration, proceeding (including any
civil, criminal, administrative, investigative or appellate proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination
or investigation that is, has been or may in the future be commenced, brought, conducted or heard at law or in equity or before any Governmental
Authority or any arbitrator or arbitration panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Proxy Approval</U></B>&rdquo; means that Purchaser has filed a proxy statement with the SEC, all SEC comments to such
proxy statement (if any) have been cleared by Purchaser and such proxy statement has been mailed to all Stockholders of Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Proxy Statement</U></B>&rdquo; means the proxy statement to be filed by Purchaser with the SEC and sent to Purchaser&rsquo;s
stockholders in connection with the Stockholder Meeting, the form of which shall be subject to Sellers&rsquo; prior written approval (not
to be unreasonably delayed or withheld).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Purchased Assets</U></B>&rdquo; shall have the meaning specified in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Purchaser</U></B>&rdquo; shall have the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Representatives</U></B>&rdquo; shall mean officers, directors, employees, attorneys, accountants, advisors, agents,
distributors, licensees, shareholders, subsidiaries and lenders of a party. In addition, all Affiliates of Seller shall be deemed to be
&ldquo;<B><U>Representatives</U></B>&rdquo; of Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Securities Act</U></B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Seller</U></B>&rdquo; shall have the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Seller Intellectual Property</U></B>&rdquo; means all Owned Intellectual Property and all Licensed Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Seller Material Adverse Effect</U></B>&rdquo; means any event, occurrence, fact, condition or change that is, or could
reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the business, results of operations, condition
(financial or otherwise) or assets of the Purchased Assets and/or Seller, (b) the value of the Purchased Assets, or (c) the ability of
Seller to consummate the transactions contemplated hereby on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Stockholders Meeting</U></B>&rdquo; means the special meeting or annual meeting of the stockholders of Purchaser to
be held to consider the approval of the terms of this Agreement and the issuance of Purchaser Common Stock to Sellers upon conversion
of the Preferred Stock Shares and upon exercise of the Warrants in accordance with the rules and regulations of the Nasdaq and applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Software Assets</U></B>&rdquo; means all Software that forms a part of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Software</U></B>&rdquo; means computer software, programs, and databases in any form, including source code, object
code, operating systems and specifications, data, databases, database management code, tools, developers kits, utilities, graphical user
interfaces, menus, artwork, images, icons, forms and software engines, and all versions, updates, corrections, enhancements and modifications
thereof, and all related technical and functional documentation, developer notes, comments, and annotations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Tax Authority</U></B>&rdquo; means Governmental Authority responsible for the imposition, assessment or collection
of any Tax (domestic or foreign).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Tax</U></B>&rdquo; (and, with correlative meaning, &ldquo;<B><U>Taxes</U></B>&rdquo; and &ldquo;<B><U>Taxable</U></B>&rdquo;)
means any net income, alternative or add-on minimum tax, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits,
license, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, environmental or windfall profit tax,
custom, duty or other tax, governmental fee or other assessment or charge of any kind whatsoever, together with any interest or any penalty,
addition to tax or additional amount and any interest on such penalty, addition to tax or additional amount, imposed by any Tax Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Transaction Documents</U></B>&rdquo; shall mean this Agreement and all other agreements, certificates, instruments,
assignments, documents and writings delivered by Purchaser and/or Seller in connection with the Transaction, including, but not limited
to the exhibits hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Transaction</U></B>&rdquo; shall mean, collectively, the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>&ldquo;<B><U>Transfer Taxes</U></B>&rdquo; shall mean all federal, state, local or foreign sales, use, transfer, real property
transfer, mortgage recording, stamp duty, value-added or similar Taxes that may be imposed in connection with the transfer of Purchased
Assets, together with any interest, additions to Tax or penalties with respect thereto and any interest in respect of such additions to
Tax or penalties.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
II.</FONT><BR>
THE TRANSACTION; RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchased Assets.</B> Subject to the terms and conditions of this Agreement, at the Closing, Seller shall sell, transfer, convey,
assign and deliver to Purchaser, and Purchaser shall purchase from Seller, all of Seller&rsquo;s right, title and interest in all of the
Purchased Assets, and all Intellectual Property associated therewith. Purchaser agrees that Purchaser is receiving a copy of the Purchased
Assets from Seller and that Seller will retain the right to use the Purchased Assets, subject to the Exclusive Rights (as defined in <U>Section
11.5</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Assumed Liabilities.</B> Purchaser shall not assume any liabilities of Seller, except that Purchaser hereby assumes and agrees
to pay, perform, and discharge when due any and all Liabilities arising out of or relating to Purchaser&rsquo;s operation of the Purchased
Assets on and after the Closing (collectively, the &ldquo;<B><U>Assumed Liabilities</U></B>&rdquo;). Other than Assumed Liabilities, Purchaser
shall not assume and shall not be liable or responsible for any Liabilities of Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Excluded Assets.</B> Other than the Purchased Assets, Purchaser expressly understands and agrees that it is not purchasing or acquiring,
and Seller is not selling or assigning, any other assets or properties of Seller, and all such other assets and properties shall be excluded
from the Purchased Assets (collectively, the &ldquo;<B><U>Excluded Assets</U></B>&rdquo;). Excluded Assets include, by way of example
and not by way of limitation, all cash, bank and other accounts, intellectual property rights (other than those set out in the Intellectual
Property Assignment in the form attached hereto as&nbsp;<B><U>Exhibit D</U></B>), social media, websites, URLs and all other assets (other
than only the Purchased Assets) owned, licensed and/or operated by Seller. For the avoidance of doubt: (i)&nbsp;the Purchased Assets do
not constitute all or substantially all of the assets of Seller and (ii) Purchaser is not purchasing any goodwill related to the Purchased
Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Non-Assignable Assets.</B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding anything to the contrary in this Agreement, to the extent that the sale, assignment, transfer, conveyance or delivery,
or attempted sale, assignment, transfer, conveyance or delivery, to Purchaser of any Purchased Asset would result in a violation of applicable
law, or would require the consent, authorization, approval or waiver of a Person who is not a party to this Agreement or an Affiliate
of a party to this Agreement (including any Governmental Authority), and such consent, authorization, approval or waiver shall not have
been obtained prior to the Closing, this Agreement shall not constitute a sale, assignment, transfer, conveyance or delivery, or an attempted
sale, assignment, transfer, conveyance or delivery, thereof;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that, subject to the satisfaction
or waiver of the conditions contained in&nbsp; ARTICLE VIII, the Closing shall occur notwithstanding the foregoing without any adjustment
to the Purchase Price on account thereof. Following the Closing, Seller and Purchaser shall use commercially reasonable efforts, and shall
cooperate with each other, to obtain any such required consent, authorization, approval or waiver, or any release, substitution or amendment
required to novate all liabilities and obligations under any agreements or in connection with any liabilities that constitute Assumed
Liabilities or to obtain in writing the unconditional release of all parties to such arrangements, so that, in any case, Purchaser shall
be solely responsible for such liabilities and obligations from and after the Closing Date;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that neither Seller nor Purchaser shall be required to pay any consideration therefor. Once such consent, authorization, approval, waiver,
release, substitution or amendment is obtained, Seller shall sell, assign, transfer, convey and deliver to Purchaser the relevant Purchased
Asset to which such consent, authorization, approval, waiver, release, substitution or amendment relates for no additional consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>To the extent that any Purchased Asset or Assumed Liability cannot be transferred to Purchaser following the Closing pursuant to
this&nbsp;<U>Section 2.4</U>, Purchaser and Seller shall use commercially reasonable efforts to enter into such arrangements (such as
subleasing, sublicensing or subcontracting) to provide to the parties the economic and, to the extent permitted under applicable law,
operational equivalent of the transfer of such Purchased Asset or Assumed Liability to Purchaser as of the Closing and the performance
by Purchaser of its obligations with respect thereto. Purchaser shall, as agent or subcontractor for Seller pay, perform and discharge
fully the liabilities and obligations of Seller thereunder from and after the Closing Date. To the extent permitted under applicable law,
Seller shall, at Purchaser&rsquo;s expense, hold in trust for and pay to Purchaser promptly upon receipt thereof, such Purchased Asset
and all income, proceeds and other monies received by Seller to the extent related to such Purchased Asset in connection with the arrangements
under this&nbsp;<U>Section 2.4</U>. Seller shall be permitted to set off against such amounts all reasonable direct costs associated with
the retention and maintenance of such Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
III.</FONT><BR>
CONSIDERATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Consideration.</B> Subject to the terms and conditions of this Agreement and subject to the Closing having occurred, the full and
complete consideration for the Seller&rsquo;s full and complete sale, transfer, conveyance, assignment and delivery of all the Purchased
Assets to the Purchaser, shall be (a) 1,000,000 shares of Series B Convertible Preferred Stock of the Purchaser (the &ldquo;<B><U>Series
Preferred Stock</U></B>&rdquo;), with such rights and preferences as are set forth in the Designation (the &ldquo;<B><U>Preferred Stock
Shares</U></B>&rdquo;), issuable by the Purchaser to the Seller at the Closing in book-entry/non-certificate form; and (b) warrants to
purchase 3,000,000 shares of common stock of the Purchaser, evidenced by the Common Stock Purchase Warrant in the form of <B><U>Exhibit
E</U></B> hereto (the &ldquo;<B><U>Warrants</U></B>&rdquo;), which shall have an exercise price equal to the closing sale&rsquo;s price
of the Purchaser&rsquo;s common stock on the Nasdaq Capital Market on the Closing Date (collectively, (a) and (b), the &ldquo;<B><U>Purchase
Price</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Transfer Taxes; Prorations.</B> Notwithstanding any Legal Requirements to the contrary, Purchaser shall be responsible for and
shall pay any Transfer Taxes when due, and shall, at its own expense, file all necessary tax returns and other documentation with respect
to all such Transfer Taxes;&nbsp;<U>provided</U>, that, if required by any Legal Requirement, Seller will join in the execution of any
such tax returns and other documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Other Actions.</B>&nbsp;Purchaser and Seller agree that any Legal Requirements with respect to the transactions contemplated in
this Agreement shall be completed at the Closing and that Seller shall, and shall cause its respective Affiliates and representatives
at its own expense, to, provide any documents, invoices, bills of sales, assignment documents to transfer assets under Legal Requirements,
certifications, procure local notarizations, licenses and regulatory approvals and pay any applicable local taxes (other than in relation
to the transfer taxes as set forth in <U>Section&nbsp;3.2</U> above), dues, documentary stamps or fees related to, or required in connection
with the transactions contemplated in this Agreement, in each case with a view toward providing Purchaser with good, valid, marketable
and transferable title to all of the Purchased Assets, free and clear of any Encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
IV.</FONT><BR>
CLOSING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Closing.</B> Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement
(the &ldquo;<B><U>Closing</U></B>&rdquo;) shall take place remotely by exchange of documents and signatures (or their electronic counterparts)
on the second Business Day after all of the conditions to Closing set forth in ARTICLE VIII are either satisfied or waived (other than
conditions that, by their nature, are to be satisfied on the Closing Date), or on such other date as Seller and Purchaser may mutually
agree upon in writing. The date on which the Closing is to occur is herein referred to as the &ldquo;<B><U>Closing Date.</U></B>&rdquo;
The Closing shall be deemed effective as of 12:01 a.m., Eastern Standard Time, on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Closing Deliveries by Seller.&nbsp;</B>At the Closing, Seller shall deliver to Purchaser the Bill of Sale and the Intellectual
Property Assignment Agreement, each substantially in the form attached hereto as&nbsp;<B><U>Exhibit C</U></B>&nbsp;and&nbsp;<B><U>Exhibit
D</U></B>, respectively, as well as all source code relating to the Software Assets and the other Purchased Assets to the extent they
represent tangible assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Closing Deliveries by Purchaser.</B> At the Closing, Purchaser shall issue to Seller the Preferred Stock Shares and Warrants pursuant
to <U>Section 3.1</U> above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Closing Deliveries by Seller and Purchaser.</B> At the Closing, each of Purchaser and Seller shall deliver duly executed other
certificates, instruments or documents required pursuant to the provisions of this Agreement or otherwise necessary or appropriate for
Seller to transfer to Purchaser all of the Purchased Assets in accordance with the terms hereof and consummate the Transaction. Seller
shall deliver all of the Purchased Assets to such location as Purchaser shall designate to Seller at or prior to Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
V.</FONT><BR>
REPRESENTATIONS AND WARRANTIES OF SELLER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Seller hereby represents and
warrants to the Purchaser the following as of the date hereof, which shall be automatically deemed to be reconfirmed by the Seller at
Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Organization.</B> Seller is a limited liability company validly organized and existing, and in good standing, under the laws of
the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Authority.</B> Seller has all of the necessary power and authority to execute and deliver this Agreement and the other Transaction
Documents, to fully and completely perform its obligations hereunder, and to consummate the Transaction. The execution and delivery of
this Agreement and the other Transaction Documents and the consummation by Seller of the Transaction have been duly and validly authorized
by all requisite action and no other proceedings on the part of Seller are necessary to authorize this Agreement or to consummate the
Transaction. This Agreement and each of the other Transaction Documents has been duly and validly executed and delivered by Seller. This
Agreement constitutes, and at Closing the other Transaction Documents will constitute, the legal, valid and binding obligation of Seller,
enforceable against Seller in accordance with their respective terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Required Consents.</B> No Consents are required with respect to Seller&rsquo;s execution and delivery of this Agreement, the other
Transaction Documents, and the full and complete consummation of the Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Conflict.</B> The execution, delivery and performance of this Agreement and the other Transaction Documents by Seller do not
and will not: (i) require any consent by, approval of or notice to any Person or Governmental Authority other than as specifically referenced
herein; (ii) conflict with or violate any provision of any Legal Requirement or result in the breach of, or constitute a default under
any agreement or instrument to which it is a party or violate any judgment or order binding or imposed upon it; and (iii) require any
consent or approval of, or filing with or notice to any Governmental Authority or other Person under the provisions of any Legal Requirement
applicable to Seller or to the Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Litigation.</B> To Seller&rsquo;s knowledge, there is no Proceeding pending, threatened or reasonably foreseeable against or affecting
the Purchased Assets. Seller is not subject to any Order or any proposed Order that would prevent or materially delay the consummation
of the Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Employees.&nbsp;</B>There are no employees employed or workers contracted in respect of the Purchased Assets or the business
to which such Purchased Assets used as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchased Assets.&nbsp;</B>The Purchased Assets are sufficient to support the operation of a fully functional online blockchain
casino with the underlying blockchain technology and Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Brokers.</B> No broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in
connection with the Transaction based upon arrangements made, or alleged to have been made, by or on behalf of Seller. Seller shall be
fully responsible for, and shall indemnify Purchaser in connection with, any such fee arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Title.</B> Seller, solely and exclusively, has good, valid, marketable and transferable title to all of the Purchased Assets, in
each case free and clear of any Encumbrances. Seller, solely and exclusively, has the full right and power to sell, convey, assign, transfer
and deliver to Purchaser good, valid, marketable and transferable title to all of the Purchased Assets, in each case free and clear of
any and all Encumbrances. The Purchased Assets are not subject to, or potentially subject to, any preemptive right, right of first refusal
or other right or restriction. Upon Closing, Purchaser will be entitled to the continued and sole exclusive ownership, copyright, possession
and use of all Purchased Assets, subject to the Elray Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Intellectual Property.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller is not in any material violation of any license, sublicense or other agreement to which it is a party or otherwise bound
relating to any of the Seller Intellectual Property. Seller is not obligated to provide any consideration (whether financial or otherwise)
to any Person and no Person is otherwise entitled to any consideration, with respect to any exercise of rights by Seller in the Seller
Intellectual Property (other than licenses arising from the purchase of &ldquo;<B><U>off the shelf</U></B>&rdquo; or other standard products,
as set forth in <U>Schedule 5.10</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The use of the Seller Intellectual Property by Seller as currently used and as currently proposed to be used does not infringe
any other Person&rsquo;s Intellectual Property. No written claim (i) challenging the validity, enforceability, effectiveness or ownership
of any of the Seller Intellectual Property or (ii) to the effect that the use, reproduction, modification, manufacture, distribution,
licensing, sublicensing, sale, or any other exercise of rights in any Seller Intellectual Property by Seller infringes or has infringed
on any other Person&rsquo;s Intellectual Property has been received by Seller. To Seller&rsquo;s best knowledge, there is no unauthorized
use, infringement, or misappropriation of any of Owned Intellectual Property by any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller has taken commercially reasonable steps to protect the proprietary nature of the Seller Intellectual Property and to maintain
in confidence all trade secrets and confidential information owned or used by Seller. To Seller&rsquo;s best knowledge, no Person has
had access to the trade secrets and confidential information owned or used by Seller, other than Persons that (i) have entered into confidentiality
and non-disclosure agreements with respect to such trade secrets and confidential information, (ii) have duties of confidentiality to
Seller, under state or federal law (including fiduciary duties or professional duties), or (iii) are employees or service providers to
Seller. Seller has not notified any Person of, and to Seller&rsquo;s actual knowledge there is no basis for any notice to any Person with
respect to, (y) the unauthorized use or disclosure by such Person of the trade secrets and confidential information owned or used by Seller
thereto, including, but not limited to the Purchased Assets, or (z) the breach of any agreement between Seller and any Person relating
to the trade secrets and confidential information owned or used by Seller, including, but not limited to the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>At no time during the conception of or reduction to practice of any Owned Intellectual Property was any developer, inventor or
other contributor thereto operating under any grants from any Governmental Authority or private source, performing research sponsored
by any Governmental Authority or private source or subject to any employment agreement or invention assignment or nondisclosure agreement
or other obligation with any third party, in each case that would impair or limit Seller&rsquo;s right in such Owned Intellectual Property.
There exist no inventions by current or former employees or consultants of Seller made or otherwise conceived prior to their beginning
employment or consultation with Seller that have been or are intended to be incorporated into any of the Seller Intellectual Property,
other than any such inventions that have been validly and irrevocably assigned or licensed to Seller by written agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Neither the execution, delivery or performance of this Agreement, nor the consummation of the transactions contemplated hereunder,
will result in the loss or impairment of, or require the consent of any other person in respect of Seller&rsquo;s rights to own or use
any Seller Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Securities Representations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>Purchase for Own Account</I>. The Preferred Stock Shares and shares of common stock of the Purchaser issuable upon conversion
thereof (the &ldquo;<B><U>Conversion Shares</U></B>&rdquo;), Warrants and shares of common stock of the Purchaser issuable upon exercise
of the Warrants (the &ldquo;<B><U>Warrant Shares</U></B>&rdquo;, and together with the Preferred Stock Shares, Conversion Shares and Warrants,
the &ldquo;<B><U>Purchaser Securities</U></B>&rdquo;) to be issued to Seller hereunder will be acquired for investment for Seller&rsquo;s
own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within the meaning of the Securities
Act, and Seller has no present intention of selling, granting any participation in, or otherwise distributing the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>Disclosure of Information</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller has received or has had full access to all the information Seller considers necessary or appropriate to make an informed
investment decision with respect to the Preferred Stock Shares and Warrants to be issued to Seller hereunder. Seller has had an opportunity
to ask questions and receive answers from the Purchaser regarding the Purchaser and the Purchaser Securities, and all such questions,
if any, have been satisfactorily answered as of the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Without limiting or reducing in any way&nbsp;<U>Section 5.11(b)(i)</U>, above, the Seller acknowledges that it (A) is aware of,
has received and had an opportunity to review (x) the Purchaser&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2023
(the &ldquo;<B><U>Annual Report</U></B>&rdquo;); and (y) Purchaser&rsquo;s Quarterly Reports on Form 10-Q and current reports on Form
8-K filed with the Securities and Exchange Commission (the &ldquo;<B><U>SEC</U></B>&rdquo; or the &ldquo;<B><U>Commission</U></B>&rdquo;)
from January 1, 2024, to the date of this Agreement (which filings can be accessed by going to https://www.sec.gov/edgar/searchedgar/companysearch.html,
typing &ldquo;<B><U>180 Life Sciences Group</U></B>&rdquo; in the &ldquo;<B><U>Name, ticker symbol, or CIK</U></B>&rdquo; field, and clicking
the &ldquo;<B><U>Search</U></B>&rdquo; button)(such Annual Report, Quarterly Reports on Form 10-Q and current reports on Form 8-K (collectively,
the &ldquo;<B><U>SEC Reports</U></B>&rdquo;)), in each case (x) through (y), including, but not limited to, the audited and unaudited
financial statements, description of business, risk factors, results of operations, certain transactions and related business disclosures
described therein (collectively the &ldquo;<B><U>Disclosure Documents</U></B>&rdquo;) and an independent investigation made by it of Purchaser;
and (B) is not relying on any oral representation of Purchaser or any other person, nor any written representation or assurance from Purchaser;
in connection with Seller&rsquo;s acceptance of the Preferred Stock Shares and Warrants and investment decision in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>Illiquid Securities</I>. Seller realizes that the Purchaser Securities cannot readily be sold as they will be restricted securities
and therefore the Purchaser Securities must not be accepted unless such Seller has liquid assets sufficient to assure that holding such
Purchaser Securities indefinitely will cause no undue financial difficulties and such Seller can provide for current needs and possible
personal contingencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>Discussions with Advisors</I>. Seller has carefully considered and has, to the extent it believes such discussion necessary,
discussed with its professional, legal, tax and financial advisors, the suitability of an investment in the Preferred Stock Shares and
Warrants for its particular tax and financial situation and its advisers, if such advisors were deemed necessary, have determined that
the Preferred Stock Shares and Warrants are a suitable investment for it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>No General Solicitation</I>. Seller has not become aware of and has not been offered the Purchaser Securities by any form of
general solicitation or advertising, including, but not limited to, advertisements, articles, notices or other communications published
in any newspaper, magazine, or other similar media or television or radio broadcast or any seminar or meeting where, to such Seller&rsquo;s
knowledge, those individuals that have attended have been invited by any such or similar means of general solicitation or advertising.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>No Registration Rights</I>. Seller confirms and acknowledges that Purchaser is not under any obligation to register or seek
an exemption under any federal and/or state securities acts for any sale or transfer of the Purchaser Securities, and such Seller is solely
responsible for determining the status, in its hands, of the Purchaser Securities acquired hereunder and the availability, if required,
of exemptions from registration for purposes of sale or transfer of the Purchaser Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii) <I>Investment
Experience</I>. Seller understands that the acquisition of Purchaser Securities involves substantial risk. Seller acknowledges that
Seller can bear the economic risk of Seller&rsquo;s investment in the Purchaser Securities, and has sufficient knowledge and
experience in financial or business matters such that Seller is capable of evaluating the merits and risks of this investment in the
Purchaser Securities and protecting its own interests in connection with this investment. Seller hereby represents that it is an
&ldquo;<B><U>accredited investor,</U></B>&rdquo; as such term is defined under Rule 501(a) of Regulation D promulgated under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>Required Stockholder Approval</I>. Seller understands that the conversion of the Preferred Stock Shares and the issuance of
the Conversion Shares upon conversion thereof, and the exercise of the Warrants, and the issuance of the Warrant Shares upon exercise
thereof, will be subject to the approval of such issuances pursuant to the rules and requirements of the Nasdaq Capital Market in all
cases, as described in greater detail in the Designation and the Common Stock Purchase Warrant evidencing the Warrants, and such stockholder
approval may never be received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>Restricted Shares</I>. Seller understands that the Purchaser Securities are characterized as &ldquo;<B><U>restricted securities</U></B>&rdquo;
under the Securities Act inasmuch as they are being acquired from Purchaser in a transaction not involving a public offering and that,
under the Securities Act and applicable regulations thereunder, such securities may be resold without registration under the Securities
Act only in certain limited circumstances. In this connection, Seller represents that Seller is familiar with Rule 144 as promulgated
under the Securities Act and as presently in effect, and understands the resale limitations imposed thereby and by other applicable provisions
of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><I>Legend</I>. Seller acknowledges and understands that the certificates or book-entry statements evidencing the Purchaser Securities
will bear the legend set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><B>&ldquo;THE SECURITIES REPRESENTED
HEREBY [AND ISSUABLE UPON CONVERSION[EXERCISE] HEREOF] HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;),
OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT
BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD
OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT
THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Data Room; Information Supplied.</B> All copies of and originals of all information, documents, financial statements, agreements
and materials provided by the Seller (including its Representatives, and Affiliates) to the Purchaser, or its Affiliates or Representatives
as part of the due diligence process leading up to the parties entry into this Agreement were and remain accurate and complete in all
material respects when provided and as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Other Representations and Warranties.</B> Except for the representations and warranties contained in this Agreement, neither
Seller nor any other Person has made or makes any other express or implied representation or warranty, either written or oral, on behalf
of Seller, including any representation or warranty as to the accuracy or completeness of any information, documents or material regarding
Seller and/or the Purchased Assets furnished or made available to Purchaser and its Representatives in any form, any information, documents,
or material delivered to Purchaser on behalf of Seller for purposes of this Agreement or any management presentations made in expectation
of the transactions contemplated hereby, or as to the future revenue, profitability, or success of the Purchased Assets, or any representation
or warranty arising from statute or otherwise in law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
VI.</FONT><BR>
REPRESENTATIONS AND WARRANTIES OF PURCHASER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Purchaser hereby represents
and warrants to Seller the following as of the date hereof, which shall be automatically deemed to be reconfirmed by the Purchaser at
Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Organization.</B> Purchaser is a corporation registered, incorporated and in good standing in the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser Capitalization.</B> As of the date hereof and the Closing Date, the authorized capital stock of the Purchaser consists
of 100,000,000 shares of common stock, $0.0001 par value per share (&ldquo;<B><U>Common Stock</U></B>&rdquo;) and 5,000,000 shares of
preferred stock, $0.0001 par value per share, of which 1,000,000 shares have been designated as Series A Convertible Preferred Stock (of
which none are outstanding), of which one share of preferred stock has been designated as a Class C Special Voting Share, of which none
are outstanding, and one share of preferred stock has been designated as a Class K Special Voting Share, of which none are outstanding.
As of the date hereof the Purchaser has outstanding 1,026,930 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Listing and Maintenance Requirements.</B> The shares of Common Stock are registered pursuant to Section 12(b) of the Securities
Exchange Act of 1934, as amended (the &ldquo;<B><U>Exchange Act</U></B>&rdquo;), and the Purchaser has taken no action designed to, or
which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has
the Purchaser received any notification that the Commission is contemplating terminating such registration, except as set forth in the
SEC Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Authority.</B> Purchaser has all necessary power and authority to execute and deliver this Agreement and the other Transaction
Documents, to perform its obligations hereunder, and to consummate the Transaction. The execution and delivery of this Agreement and the
other Transaction Documents and the consummation by Purchaser of the Transaction have been duly and validly authorized by all requisite
action and no other proceeding on the part of Purchaser is necessary to authorize this Agreement and the other Transaction Documents or
to fully and completely consummate the Transaction. This Agreement has been, and at Closing the other Transaction Documents will be, duly
and validly executed and delivered by Purchaser. This Agreement constitutes, and at Closing the other Transaction Documents will constitute,
the legal, valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with their respective terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Required Consents.</B> No Consents are required with respect to Purchaser&rsquo;s execution and delivery of this Agreement, the
other Transaction Documents, and the full and complete consummation of the Transaction; provided that the approval of Purchaser&rsquo;s
stockholders is required for the conversion of the Preferred Stock Shares into shares of common stock of the Purchaser and exercise of
the Warrants into Warrant Shares, pursuant to the applicable rule and requirements of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Conflict.</B> The execution, delivery and performance of this Agreement and the other Transaction Documents by Purchaser do
not and will not: (i) require any consent by, approval of or notice to any Person or Governmental Authority other than as specifically
referenced herein; (ii) conflict with or violate any provision of any Legal Requirement or result in the breach of, or constitute a default
under any agreement or instrument to which it is a party or violate any judgment or order binding or imposed upon it; and (iii) require
any consent or approval of, or filing with or notice to any Governmental Authority or other Person under the provisions of any Legal Requirement
applicable to Seller or to the Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Independent Investigation.</B>&nbsp;Purchaser has conducted its own independent investigation, review and analysis of Seller and
the Purchased Assets, and acknowledges that it has been provided adequate access to the personnel, properties, assets, premises, books
and records and other documents and data of Seller for such purpose. Purchaser acknowledges and agrees that: (a) in making its decision
to enter into this Agreement and to consummate the transactions contemplated hereby, Purchaser has relied solely upon its own investigation
and the express representations and warranties of Seller set forth in ARTICLE V of this Agreement; and (b)&nbsp;neither Seller nor any
other Person has made any representation or warranty as to Seller, the Purchased Assets or this Agreement, except as expressly set forth
in ARTICLE V of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Litigation.</B> Purchaser is not subject to any Order or any proposed Order that would prevent or materially delay the consummation
of the Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Status of Purchased Assets.</B> Purchaser acknowledges that the Purchased Assets do not constitute a fully operational online blockchain
casino and a Front End of such casino would need to be built and integrated to the Purchased Assets, the cost of which build is not included
in the acquisition of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Brokers.</B> No broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in
connection with the Transaction based upon arrangements made, or alleged to have been made, by or on behalf of Purchaser. Purchaser shall
be fully responsible for, and shall indemnify Purchaser in connection with, any such fee arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
VII.</FONT><BR>
COVENANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Conduct of Purchased Assets Prior to the Closing.</B> From the date hereof until the Closing, except as otherwise provided in this
Agreement or consented to in writing by Purchaser (which consent shall not be unreasonably withheld or delayed), Seller shall (x) operate
the Purchased Assets in the ordinary course of business consistent with past practice; and (y) use reasonable best efforts to maintain
and preserve intact the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Access to Information.</B> From the date hereof until the Closing, Seller shall (a)&nbsp;afford Purchaser and its Representatives
full and free access to and the right to inspect all of the Purchased Assets and the books and records relating thereto; (b) furnish Purchaser
and its Representatives with such financial, operating and other data and information related to the Purchased Assets as Purchaser or
any of its Representatives may reasonably request; and (c)&nbsp;instruct the Representatives of Seller to cooperate with Purchaser in
its investigation of the Purchased Assets. Any investigation pursuant to this <U>Section 7.2</U> shall be conducted in such manner as
not to interfere unreasonably with the conduct of the Purchased Assets or any other businesses of Seller. No investigation by Purchaser
or other information received by Purchaser shall operate as a waiver or otherwise affect any representation, warranty or agreement given
or made by Seller in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Solicitation of Other Bids.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall not, and shall not authorize or permit any of its Affiliates or any of its or their Representatives to, directly or
indirectly, (i) encourage, solicit, initiate, facilitate or continue inquiries regarding an Acquisition Proposal; (ii) enter into discussions
or negotiations with, or provide any information to, any Person concerning a possible Acquisition Proposal; or (iii) enter into any agreements
or other instruments (whether or not binding) regarding an Acquisition Proposal. Seller shall immediately cease and cause to be terminated,
and shall cause its Affiliates and all of its and their Representatives to immediately cease and cause to be terminated, all existing
discussions or negotiations with any Persons conducted heretofore with respect to, or that could lead to, an Acquisition Proposal. For
purposes hereof, &ldquo;<B><U>Acquisition Proposal</U></B>&rdquo; means any inquiry, proposal or offer from any Person (other than Purchaser
or any of its Affiliates) relating to the direct or indirect disposition, whether by sale, merger or otherwise, of all or any portion
of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>In addition to the other obligations under this <U>Section 7.3</U>, Seller shall promptly (and in any event within three (3) Business
Days after receipt thereof by Seller or its Representatives) advise Purchaser orally and in writing of any Acquisition Proposal, any request
for information with respect to any Acquisition Proposal, or any inquiry with respect to or which could reasonably be expected to result
in an Acquisition Proposal, the material terms and conditions of such request, Acquisition Proposal or inquiry, and the identity of the
Person making the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller agrees that the rights and remedies for noncompliance with this <U>Section 7.3</U> shall include having such provision specifically
enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach shall cause
irreparable injury to Purchaser and that money damages would not provide an adequate remedy to Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notice of Certain Events.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>From the date hereof until the Closing, Seller shall promptly notify Purchaser in writing of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>any fact, circumstance, event or action the existence, occurrence or taking of which (A) has had, or could reasonably be expected
to have, individually or in the aggregate, a Seller Material Adverse Effect, (B) has resulted in, or could reasonably be expected to result
in, any representation or warranty made by Seller hereunder not being true and correct or (C) has resulted in, or could reasonably be
expected to result in, the failure of any of the conditions set forth in <U>Section 8.2</U> to be satisfied;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection
with the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>any notice or other communication from any Governmental Authority in connection with the transactions contemplated by this Agreement;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>any actions commenced or, to Seller&rsquo;s knowledge, threatened against, relating to or involving or otherwise affecting the
Purchased Assets that, if pending on the date of this Agreement, would have been required to have been disclosed pursuant to the terms
of this Agreement or that relates to the consummation of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser&rsquo;s receipt of information pursuant to this <U>Section 7.4</U> shall not operate as a waiver or otherwise affect
any representation, warranty or agreement given or made by Seller in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Confidentiality.</B> From and after the Closing, Seller shall, and shall cause its Affiliates to, hold, and shall use its reasonable
best efforts to cause its or their respective Representatives to hold, in confidence any and all information, whether written or oral,
concerning the Purchased Assets, except to the extent that Seller can show that such information (a) is generally available to and known
by the public through no fault of Seller, any of its Affiliates or their respective Representatives; or (b) is lawfully acquired by Seller,
any of its Affiliates or their respective Representatives from and after the Closing from sources which are not prohibited from disclosing
such information by a legal, contractual or fiduciary obligation. If Seller or any of its Affiliates or their respective Representatives
are compelled to disclose any information by judicial or administrative process or by other requirements of law, to the extent permitted
by law or Governmental Authority, Seller shall promptly notify Purchaser in writing and shall disclose only that portion of such information
which Seller is advised by its counsel in writing is legally required to be disclosed, provided that Seller shall use reasonable best
efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Closing Conditions.</B> From the date hereof until the Closing, each party hereto shall use reasonable best efforts to take such
actions as are necessary to expeditiously satisfy the closing conditions set forth in ARTICLE VIII hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Public Announcements.</B> The Purchaser shall have the sole authority to publicly disclose the terms of this Agreement and the
transactions contemplated herein, and the Seller shall not publicly disclose this Agreement or any terms hereof without the prior written
consent of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
VIII.</FONT><BR>
CONDITIONS TO CLOSING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Conditions to Obligations of All Parties.</B> The obligations of each party to consummate the transactions contemplated by this
Agreement shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 40.5pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Governmental Order which is in effect
and has the effect of making the transactions contemplated by this Agreement illegal, otherwise restraining or prohibiting consummation
of such transactions or causing any of the transactions contemplated hereunder to be rescinded following completion thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall have received all consents, authorizations, orders and approvals, in each case, in form and substance reasonably satisfactory
to Purchaser and Seller, and no such consent, authorization, order and approval shall have been revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Conditions to Obligations of Purchaser.</B> The obligations of Purchaser to consummate the transactions contemplated by this Agreement
shall be subject to the fulfillment or Purchaser&rsquo;s waiver, at or prior to the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The representations and warranties of Seller contained in&nbsp;ARTICLE V&nbsp;shall be true and correct in all respects as of the
Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters
only as of a specified date, which shall be true and correct in all respects as of that specified date), except where the failure of such
representations and warranties to be true and correct would not have a Seller Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by
this Agreement and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall have delivered to Purchaser duly executed counterparts to the Transaction Documents (other than this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall have received a certificate, dated the Closing Date and signed by a duly authorized officer of each Seller, that
each of the conditions set forth in&nbsp;<U>Section 8.2(a)</U>&nbsp;and&nbsp;<U>Section 8.2(b)</U>&nbsp;have been satisfied (the &ldquo;<B><U>Seller
Closing Certificate</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Seller certifying
that attached thereto are true and complete copies of all resolutions adopted by the board of directors or managers of Seller authorizing
the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions
contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection
with the transactions contemplated hereby and thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Seller certifying
the names and signatures of the officers of Seller authorized to sign this Agreement, the Transaction Documents and the other documents
to be delivered hereunder and thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall have received an opinion of Hempstead &amp; Co., LLC to the effect that, as of the date of such opinion and subject
to the assumptions, qualifications, limitations and such other factors deemed relevant by Hempstead &amp; Co., LLC, as set forth in such
opinion, the Purchaser Price to be paid by Purchaser is fair, from a financial point of view, to Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall have delivered Purchaser a detailed business plan using a Churn Model detailing expected net profits of the Purchased
Assets for the 24 months of operation following the Closing, which model will be based on industry standards (player acquisition costs,
and LTV of players) which will support the valuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Since the date of this Agreement, there shall not have occurred any Seller Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Conditions to Obligations of Seller.</B> The obligations of Seller to consummate the transactions contemplated by this Agreement
shall be subject to the fulfillment or Seller&rsquo; waiver, at or prior to the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The representations and warranties of Purchaser contained in&nbsp;ARTICLE VI&nbsp;shall be true and correct in all respects as
of the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address
matters only as of a specified date, which shall be true and correct in all respects as of that specified date), except where the failure
of such representations and warranties to be true and correct would not have a material adverse effect on Purchaser&rsquo;s ability to
consummate the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall have duly performed and complied in all material respects with all agreements, covenants and conditions required
by this Agreement and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall have received a certificate, dated the Closing Date and signed by a duly authorized officer of Purchaser, that each
of the conditions set forth in&nbsp;<U>Section&nbsp;8.3(a)</U>&nbsp;and&nbsp;<U>Section 8.3(b)</U>&nbsp;have been satisfied (the &ldquo;<B><U>Purchaser
Closing Certificate</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Purchaser certifying
that attached thereto are true and complete copies of all resolutions adopted by the board of directors of Purchaser authorizing the execution,
delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby
and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions
contemplated hereby and thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Purchaser certifying
the names and signatures of the officers of Purchaser authorized to sign this Agreement, the Transaction Documents and the other documents
to be delivered hereunder and thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall have filed a Listing of Additional Shares notice with Nasdaq disclosing the planned issuance of the Preferred Stock
Shares, Conversion Shares, Warrants and Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall have delivered to Seller a file stamped copy of the Designation as filed with the Secretary of State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall have delivered to Seller a signed copy of the Common Stock Purchase Warrant evidencing the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Preferred Stock Shares.</B> Within three (3) Business Days following the Closing, the Purchaser shall issue the Seller the Preferred
Stock Shares and shall provide the Seller a book entry statement showing the issuance thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
IX.</FONT><BR>
INDEMNIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Survival.</B>&nbsp;Subject to the limitations set forth in this Agreement, the representations and warranties (other than the Fundamental
Representations and Warranties (as defined below)) contained herein shall survive the Closing and shall remain in full force and effect
until the date that is one (1) year from the Closing Date. All Fundamental Representations and Warranties (as defined below) and all related
rights to indemnification shall survive the Closing indefinitely. &ldquo;<B><U>Fundamental Representations and Warranties</U></B>&rdquo;
means the applicable party&rsquo;s representations and warranties set forth in each of <U>Sections 5.1</U>, <U>5.2</U>, <U>5.8</U>, <U>5.9</U>,
<U>6.1</U>, <U>6.2</U>, <U>6.4</U> and <U>6.9</U> of this Agreement. None of the covenants or other agreements contained in this Agreement
shall survive the Closing Date other than those which by their terms contemplate performance after the Closing Date, and except for those
set forth under ARTICLE IX and ARTICLE XI and each such surviving covenant and agreement shall survive the Closing for the period contemplated
by its terms, or where no term is provided, three years. Notwithstanding the foregoing, any claims asserted in good faith with reasonable
specificity (to the extent known at such time) and in writing by notice from the non-breaching party to the breaching party prior to the
expiration date of the applicable survival period shall not thereafter be barred by the expiration of such survival period and such claims
shall survive until finally resolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Indemnification.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><B>Indemnification by Seller</B>. Seller shall indemnify, defend and hold harmless Purchaser and its Representatives from and against
any and all Damages, whether or not involving a third-party claim, including reasonable attorneys&rsquo; fees, arising out of, relating
to or resulting from (i) any breach of a representation or warranty of Seller contained in this Agreement or in any other Transaction
Document, (ii) any breach of a covenant of Seller contained in this Agreement or in any other Transaction Document and/or (iii) any liability
related to the Purchased Assets first arising prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Indemnification by Purchaser. Purchaser shall indemnify, defend and hold harmless Seller from and against any and all Damages,
whether or not involving a third-party claim, including reasonable attorneys&rsquo; fees, arising out of, relating to or resulting from
(i) any breach of a representation or warranty of Purchaser contained in this Agreement or in any other Transaction Document, (ii) any
breach of a covenant of Purchaser contained in this Agreement or in any other Transaction Document and/or (iii)&nbsp;any liability related
to the Purchased Assets first arising on or after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Indemnification Procedures.</B>&nbsp;<FONT STYLE="background-color: white">If any suit, action, proceeding (including any governmental
or regulatory investigation), claim or demand shall be brought or asserted against any Person in respect of which indemnification may
be sought pursuant to either <U>Sections 9.2(a)</U> or <U>(b)</U> above, such Person (the &ldquo;</FONT><B><U>Indemnified Person</U></B><FONT STYLE="background-color: white">&rdquo;)
shall promptly notify the Person against whom such indemnification may be sought (the &ldquo;</FONT><B><U>Indemnifying Person</U></B><FONT STYLE="background-color: white">&rdquo;)
in writing;</FONT>&nbsp;<U>provided</U>&nbsp;<FONT STYLE="background-color: white">that the failure to notify the Indemnifying Person
shall not relieve it from any liability that it may have under <U>Sections 9.2(a)</U> or <U>(b)</U> above except to the extent that it
has been materially prejudiced by such failure; and</FONT>&nbsp;<U>provided</U><FONT STYLE="background-color: white">,</FONT>&nbsp;<U>further</U><FONT STYLE="background-color: white">,
that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise
than under <U>Sections 9.2(a)</U> or <U>(b)</U> above. If any such proceeding shall be brought or asserted against an Indemnified Person,
the Indemnifying Person shall be entitled to participate in the defense thereof with counsel reasonably satisfactory to such Indemnified
Person;</FONT>&nbsp;<U>provided</U><FONT STYLE="background-color: white">,</FONT>&nbsp;<U>however</U><FONT STYLE="background-color: white">,
if the defendants in any such action include both the Indemnified Person and the Indemnifying Person and the Indemnified Person shall
have reasonably, based on advice of counsel, concluded that a conflict may arise between the positions of the Indemnifying Person and
the Indemnified Person in conducting the defense of any such action or that there may be legal defenses available to it and/or other Indemnified
Persons which are inconsistent with those available to the Indemnifying Person, the Indemnifying Person or Indemnifying Persons shall
have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on
behalf of such Indemnified Persons or Indemnified Persons (it being understood, however, that the Indemnifying Person shall not be liable
for the expenses of more than one separate counsel (together with local counsel (in each relevant jurisdiction)). If any proceeding is
settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified
Person against any loss, claim, damage, liability or expense by reason of such settlement or judgment. No Indemnifying Person shall, without
the written consent of the Indemnified Person, effect any settlement, compromise or consent to the entry of judgment in any pending or
threatened action, suit or proceeding in respect of which any Indemnified Person is or could have been a party and indemnity was or could
have been sought hereunder by such Indemnified Person, unless such settlement, compromise or consent (A) includes an unconditional release
of such Indemnified Person from all liability on claims that are the subject matter of such action, suit or proceeding and (B) does not
include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. The
remedies provided for in this ARTICLE IX are not exclusive and shall not limit any rights or remedies that may otherwise be available
to any Indemnified Person at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Certain Limitations.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Seller shall not be liable until the aggregate amount of all Damages in respect of indemnification exceeds $25,000. The aggregate
amount of all Damages for which Seller shall be liable shall not exceed the Purchase Price. In no event shall Seller be liable for any
punitive, incidental, consequential, special or indirect damages, including loss of future revenue or income, loss of business reputation
or opportunity relating to the breach or alleged breach of this Agreement, or diminution of value or any damages based on any type of
multiple.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall not be liable until the aggregate amount of all Damages in respect of indemnification exceeds $25,000. The aggregate
amount of all Damages for which Purchaser shall be liable shall not exceed the Purchase Price. In no event shall Purchaser be liable for
any punitive, incidental, consequential, special or indirect damages, including loss of future revenue or income, loss of business reputation
or opportunity relating to the breach or alleged breach of this Agreement, or diminution of value or any damages based on any type of
multiple.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
X.</FONT><BR>
TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Termination.</B> This Agreement may be terminated at any time prior to the Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>by the mutual written consent of Seller and Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>by Purchaser by written notice to Seller if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>(i) Purchaser is not then in material breach of any provision of this Agreement and there has been a material breach, inaccuracy
in or failure to perform any representation, warranty, covenant or agreement made by Seller pursuant to this Agreement that would give
rise to the failure of any of the conditions specified in&nbsp;ARTICLE VIII&nbsp;and such breach, inaccuracy or failure cannot be cured
by Seller by September 30, 2024 (the &ldquo;<B><U>Drop Dead Date</U></B>&rdquo;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>any of the conditions set forth in&nbsp;<U>Section 8.1</U>&nbsp;or&nbsp;<U>Section 8.2</U>&nbsp;shall not have been fulfilled by
the Drop Dead Date, unless such failure shall be due to the failure of Purchaser to perform or comply with any of the covenants, agreements
or conditions hereof to be performed or complied with by it prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>by Seller by written notice to Purchaser if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) &nbsp;Seller
is not then in material breach of any provision of this Agreement and there has been a material breach, inaccuracy in or failure to perform
any representation, warranty, covenant or agreement made by Purchaser pursuant to this Agreement that would give rise to the failure of
any of the conditions specified in&nbsp; ARTICLE VIII and such breach, inaccuracy or failure cannot be cured by Purchaser by the Drop
Dead Date; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) &nbsp;any
of the conditions set forth in&nbsp;<U>Section 8.1</U>&nbsp;or&nbsp;<U>Section 8.3</U>&nbsp;shall not have been fulfilled by the Drop
Dead Date, unless such failure shall be due to the failure of Seller to perform or comply with any of the covenants, agreements or conditions
hereof to be performed or complied with by it prior to the Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>by Purchaser or Seller in the event that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>there shall be any law that makes consummation of the transactions contemplated by this Agreement illegal or otherwise prohibited;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>any Governmental Authority shall have issued a Governmental Order restraining or enjoining the transactions contemplated by this
Agreement, and such Governmental Order shall have become final and non-appealable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>by either party, if there has been a breach of any material representation, warranty, covenant, agreement, or undertaking made
by the other party in this Agreement or the other Transaction Documents, which breach, if curable, is not cured within ten (10) calendar
days after delivery by the non-breaching party to the breaching party of written notice, which shall specify the nature of such breach
and the breaching party&rsquo;s intention to terminate this Agreement if such breach or failure is not cured (provided, however, that
if the cure reasonably requires more than ten (10) days to complete, then the breaching Party shall have an additional five (5) days,
provided it timely commences the cure and continues diligently prosecuting the cure to completion); provided further, however, that the
non-breaching Party shall be obligated to elect to terminate within ten (10) days of the end of the cure period (if applicable), or else
it shall be required to close regardless of such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Effect of Termination.</B> In the event of the termination of this Agreement in accordance with this Article, this Agreement shall
forthwith become void and there shall be no liability on the part of any party hereto except: (a) as set forth in this&nbsp;ARTICLE X
and&nbsp;ARTICLE IX&nbsp;hereof; and (b) that nothing herein shall relieve any party hereto from liability for any intentional breach
of any provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
XI.</FONT><BR>
POST-CLOSING OBLIGATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Assistance with Operations and Development.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Following the Closing, as part of the Consideration paid by the Purchaser to the Seller, the Seller will provide support and assistance
to the Purchaser in connection with the building and launching of a fully operational casino operation utilizing the Purchased Assets,
at no cost to the Purchaser for a period of six (6) months following the Closing, provided that such assistance shall not exceed 40 hours
per week without the prior written approval of the Seller (the &ldquo;<B><U>Post-Closing Assistance</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The Post-Closing Assistance will also require the Seller to assist the Purchaser with obtaining payment gateways and licensing
where required, acknowledging that Purchaser will require a Front End (the &ldquo;<B><U>Front-End Development</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Following the Closing, at the request of the Purchaser, the Seller and Purchaser shall negotiate in good faith to come to agreement
on an arrangement whereby Seller will, for an additional cost agreed to by Seller, help Purchaser complete the Front-End Development,
or at the request of the Purchaser, Seller shall introduce the Purchaser to a vendor that would sell such a Front End for one or more
casinos that will operate on the Purchased Assets at a cost to be agreed between such vendor and the Purchaser, in the Purchasers sole
discretion. The Purchaser has sole discretion to determine which, if any, vendor it retains for the Front-End Development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Proxy Statement and Stockholder Meeting.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>In connection with the Stockholders Meeting, as soon as reasonably practicable following the Closing, Purchaser shall prepare and
file with the SEC the Proxy Statement. Purchaser shall use its reasonable best efforts to: (i) cause the Proxy Statement to be mailed
to Purchaser&rsquo;s Stockholders as promptly as practicable following sign off from the SEC on such Proxy Statement, or no later than
the twentieth (20th) day after such preliminary Proxy Statement is filed with the SEC, in the event the SEC does not notify the Purchaser
of its intent to review such Proxy Statement, and (ii) ensure that the Proxy Statement complies in all material respects with the applicable
provisions of the Securities Act and Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser shall take all action necessary to duly call, give notice of, convene, and hold the Stockholders Meeting as soon as reasonably
practicable, and, in connection therewith, Purchaser shall mail the Proxy Statement to the holders of Purchaser Common Stock in advance
of such meeting. The Company shall use reasonable best efforts to: (a) solicit from the holders of Purchaser Common Stock proxies in favor
of Stockholder Approval; and (b) take all other actions necessary or advisable to secure Stockholder Approval. Purchaser shall keep Seller
updated with respect to proxy solicitation results as requested by Seller. Once the Stockholders Meeting has been called and noticed,
Purchaser and its Representatives shall not postpone or adjourn the Stockholders Meeting without the consent of Seller (other than: (i)
in order to obtain a quorum of its stockholders; or (ii) as reasonably determined by Purchaser to comply with applicable law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Public Announcements.</B> The Purchaser shall have the sole authority to publicly disclose the terms of this Agreement and the
transactions contemplated herein, and the Seller shall not publicly disclose this Agreement or any terms hereof without the prior written
consent of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Further Transfer of Purchased Assets.</B> Following the Closing, and in perpetuity the Seller shall never copy, sell, assign,
hypothecate, or otherwise transfer the Purchased Assets to any other party, without the prior written consent of the Purchaser, the Purchaser
shall be the sole owner of the Purchased Assets, subject to the Elray Rights, and the Seller shall use its commercially reasonable best
efforts to ensure that the Purchaser, subject to the Elray Rights, is the sole owner of, and has the sole rights to, the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Rights to Purchased Assets.</B> Seller confirms that no other copies of the Purchased Assets have been sold, or leased, to any
Person other than the Purchaser hereunder and that no Person shall be granted or transferred any future rights to the Purchased Assets
by or from the Seller, except that the Seller shall be authorized to retain and use the Purchased Assets for its own benefit and utilize
such assets to provide SAAS solutions and hosted casino solutions to third party companies. The obligations of the Seller set forth in
this <U>Section 11.5</U> shall survive in perpetuity. The rights of the Purchaser set forth in this <U>Section 11.5</U> shall be defined
as the &ldquo;<B><U>Exclusive Rights</U></B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
XII.</FONT><BR>
MISCELLANEOUS PROVISIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Amendments and Waivers.</B> This Agreement may not be amended, supplemented or modified, except by an agreement in writing signed
by each of the parties. Either party may waive compliance by the other party with any term or provision of this Agreement; provided that
such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No waiver shall be effective
unless it is in writing and is signed by the party asserted to have granted such waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notices.</B> All notices, approvals, consents, requests, and other communications hereunder shall be in writing and shall be delivered
(i) by personal delivery, or (ii) by international overnight courier service (which is mandatory with respect to any other Party not in
the sending Party&rsquo;s country), or (iii) by certified or registered mail, return receipt requested, or (iv) via facsimile transmission,
with confirmed receipt, or (v) via email, with no error/undeliverable message. Notice shall be effective upon receipt except for notice
via fax (as discussed above) or email, which shall be effective only when the recipient, by return or reply email or notice delivered
by other method provided for in this <U>Section 12.2</U>, acknowledges having received that email (with an automatic &ldquo;<B><U>read
receipt</U></B>&rdquo; or similar notice not constituting an acknowledgement of an email receipt for purposes of this <U>Section 12.2</U>,
but which acknowledgement of acceptance shall also include cases where recipient &lsquo;replies&rsquo; to such prior email, including
the body of the prior email in such &lsquo;reply&rsquo;). Such notices shall be sent to the applicable Party or Parties at the address
specified below, subject to notice of changes thereof from any Party with at least ten (10) Business Days&rsquo; notice to the other Parties.
Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was given shall be deemed
to be receipt of the notice as of the date of such rejection, refusal or inability to deliver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If to Seller:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 0.5in">Attn:</TD>
  <TD STYLE="width: 0.5in">Vincent Cai</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>General Manager</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Elray Resources Inc</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">3651 Lindell Rd, Ste D131</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Las Vegas NV 89103</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">legal@elraygaming.com</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If to Purchaser:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attn: Blair Jordan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interim Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3000 El Camino Real, Bldg.
4, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Palo Alto, California 94306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Email: bjordan@180lifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>With copy to (which shall not constitute notice):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Loev Law Firm, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Attn: David M. Loev and John S. Gillies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">6300 West Loop South, Suite 280</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Bellaire, Texas 77401</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Fax: +1 (713) 524-4122&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Email: dloev@loevlaw.com; and john@loevlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any party may alter its notice
address by notifying the other parties of such change of address in conformity with the provisions of this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Governing Law; Assignments Prohibited; Successors and Assigns; No Third-Party Beneficiaries.</B> This Agreement is to be construed
in accordance with and governed by the laws of the State of Delaware, without giving effect to any choice or conflict of law, rule or
regulation (whether of the State of Delaware or other jurisdiction) which would cause the application of any law, rule or regulation other
than of the State of Delaware. Seller shall not assign, or suffer or permit an assignment (by operation of law or otherwise) of, its rights
or obligations under or interest in this Agreement without the prior written consent of Purchaser. Any purported assignment or other disposition
by Seller, except as permitted herein, shall be null and void. Subject to the foregoing, this Agreement shall be binding upon and shall
inure to the benefit of the parties and their respective successors and permitted assigns. The terms and provisions of this Agreement
are intended solely for the benefit of each party hereto and their respective successors and permitted assigns, and the parties do not
intend to confer third-party beneficiary rights upon any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Limitation on Consequential Damages.</B> EXCEPT IN THE CASE OF FRAUD BY SELLER, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR
LOSS OF PROFITS, OR ANY OTHER INDIRECT OR SPECIAL, CONSEQUENTIAL, PUNITIVE OR INCIDENTAL DAMAGES, HOWEVER CAUSED, EVEN IF ADVISED OF THE
POSSIBILITY OF SUCH DAMAGE. THE PARTIES ACKNOWLEDGE THAT THESE LIMITATIONS ON POTENTIAL LIABILITIES WERE AN ESSENTIAL ELEMENT IN SETTING
CONSIDERATION UNDER THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Arm&rsquo;s Length Negotiations.</B> Each party herein expressly represents and warrants to all other parties hereto that (a) before
executing this Agreement, said party has fully informed itself of the terms, contents, conditions and effects of this Agreement; (b) said
party has relied solely and completely upon its own judgment in executing this Agreement; (c) said party has had the opportunity to seek
and has obtained the advice of its own legal, tax and business advisors before executing this Agreement; (d) said party has acted voluntarily
and of its own free will in executing this Agreement; and (e) this Agreement is the result of arm&rsquo;s length negotiations conducted
by and among the Parties and their respective counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Remedies.</B> The remedies provided in this Agreement shall be cumulative and in addition to all other remedies available under
this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Dispute Resolution.</B> The exclusive venue for all actions or disputes relating to this Agreement or to the Transaction shall
be the state or federal courts located in the State of Delaware, and the parties hereto hereby agree (i) to promptly and voluntarily submit
to the jurisdiction of such court and (ii) not to assert, by way of motion, as a defense, or otherwise in any such suit, action or proceeding
that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper
or that this Agreement or the subject matter hereof may not be enforced by such courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>JURY TRIAL WAIVER.</B> TO THE FULLEST EXTENT NOT PROHIBITED BY APPLICABLE LAW, WHICH CANNOT BE WAIVED, EACH OF THE PARTIES HEREBY
KNOWINGLY, VOLUNTARILY, INTENTIONALLY AND IRREVOCABLY WAIVES ANY AND ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE
OR DEFEND ANY RIGHT, POWER, REMEDY OR DEFENSE ARISING OUT OF OR RELATED TO THIS AGREEMENT, WHETHER SOUNDING IN TORT OR CONTRACT OR OTHERWISE,
OR WITH RESPECT TO ANY COURSE OR CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF ANY PARTY RELATING TO
THIS AGREEMENT; AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A JUDGE AND NOT BEFORE A JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Counterparts, Effect of Facsimile, Emailed and Photocopied Signatures.</B> This Agreement and any signed agreement or instrument
entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all
of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or
by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an &ldquo;<B><U>Electronic Delivery</U></B>&rdquo;)
shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal
effect as if it were the original signed version thereof delivered in person. At the request of any Party, each other Party shall re execute
the original form of this Agreement and deliver such form to all other Parties. No Party shall raise the use of Electronic Delivery to
deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic
Delivery as a defense to the formation of a contract, and each such Party forever waives any such defense, except to the extent such defense
relates to lack of authenticity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Severability; Entire Agreement.</B> If any provision of this Agreement, or the application of any such provision to any Person
or set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement,
and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful,
void or unenforceable, shall not be impaired or otherwise affected and shall continue to be valid and enforceable to the fullest extent
permitted by law. This Agreement contains the entire understanding between the parties hereto with respect to the subject matter hereof
and supersedes all prior and contemporaneous agreements and understandings, inducements or conditions, express or implied, oral or written,
between the parties. The parties intend that this Agreement be the several, complete and exclusive embodiment of their agreement, and
that any evidence, oral or written, of a prior or contemporaneous agreement that alters or modifies this Agreement shall not be admissible
in any proceeding concerning this Agreement. The express terms hereof control and supersede any course of performance and/or usage of
the trade inconsistent with any of the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Interpretation and Construction.</B> Unless otherwise indicated herein, with respect to any reference made in this Agreement to
a Section (or Article, Subsection, Paragraph, Subparagraph or Clause), exhibit or Schedule, such reference shall be to a section (or article,
subsection, paragraph, subparagraph or clause) of, or an exhibit or schedule to, this Agreement. The table of contents and any article,
section, subsection, paragraph or subparagraph headings contained in this Agreement are for reference purposes only and shall not affect
in any way the meaning or interpretation of this Agreement. Whenever the words &ldquo;<B><U>include,</U></B>&rdquo; &ldquo;<B><U>includes</U></B>&rdquo;
or &ldquo;<B><U>including</U></B>&rdquo; are used in this Agreement, they shall be deemed, as the context indicates, to be followed by
the words &ldquo;<B><U>but (is/are) not limited to.</U></B>&rdquo; Words used herein, regardless of the number and gender specifically
used, shall be deemed and construed to include any other number, singular or plural, and any other gender, masculine, feminine or neuter,
as the context indicates is appropriate. Where specific language is used to clarify or illustrate by example a general statement contained
herein, such specific language shall not be deemed to modify, limit or restrict the construction of the general statement which is being
clarified or illustrated. The construction of this Agreement shall not take into consideration the party who drafted or whose representative
drafted any portion of this Agreement, and no canon of construction shall be applied that resolves ambiguities against the drafter of
a document. The parties are sophisticated and have been represented by lawyers throughout this transaction who have carefully negotiated
the provisions hereof. As a consequence, the parties do not believe the presumption relating to the interpretation of contracts against
the drafter of any particular clause should be applied in this case and therefore waive its effects. All exhibits attached hereto are
hereby incorporated by reference into, and made a part of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Expenses of the Parties.</B> Whether or not the Transaction is consummated, all fees and expenses incurred in connection with the
Transaction including, but not limited to, all legal, accounting, financial, advisory, consulting and all other fees and expenses of third
parties incurred by a party in connection with the negotiation and effectuation of the terms and conditions of this Agreement and the
Transaction contemplated hereby, shall be the obligation of the respective party incurring such fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Further Assurances.</B> Each party agrees to furnish upon request to each other party such further information, to execute and
deliver to each other party such other documents and to do such other acts and things, all as another party may reasonably request for
the purpose of carrying out the intent of this Agreement and the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURES APPEAR ON FOLLOWING PAGE.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
each of the parties has caused this Agreement to be executed on its behalf by their respective officers thereunto duly authorized all
as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>&nbsp;&ldquo;<U>Purchaser</U>&rdquo;:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>180 Life Sciences Corp.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><I>/s/ Blair Jordan</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">Blair Jordan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Interim Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>&ldquo;<U>Seller</U>&rdquo;:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>Elray Resources, Inc.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><I>/s/ Anthony Goodman  &nbsp;</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">&nbsp;Anthony Goodman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">CEO</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Asset Purchase Agreement <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> of 29</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I><U>[See attached Form of Designation of Series
B Convertible Preferred Stock]</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>PURCHASED ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchased Assets include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><U>Source code:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><B>Back-End to support Blockchain casino operations.</B>&nbsp; A server/cloud server infrastructure, database,
and blockchain payment processing system specifically for casino game programming, fully secure and scalable.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><B>Blockchain to FIAT Seamless Exchange Technology:</B>&nbsp;Allows players to deposit and withdraw in
Crypto or blockchain currency and at the same time maintain the wallets as well as the gaming sessions where the player can only play
in FIAT. This is proprietary tech and not easily accessible. Games by third parties only operate in FIAT but Blockchain casinos only accept
Crypto hence the need for this advanced tech.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><B>Blockchain APIS&rsquo; for Payment Gateway Integration.</B>&nbsp;Integrates reliable FIAT to Blockchain
and Blockchain to FIAT payment gateways to facilitate deposits and withdrawals but to maintain Online Casino system operation blockchain
only. Support various payment methods, including credit cards, e-wallets, and multiple cryptocurrencies.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><B>Player Account Management.</B>&nbsp;Creates a system to manage player accounts securely, includes registration,
login, and player profile management, KYC and AML functionality.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><B>Loyalty Systems specific to blockchain users:</B>&nbsp;Is a CRM system that communicates with players
and creates loyalty and higher LTV</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><B>Affiliate Tracking System:</B>&nbsp;This system provides an ability to track incoming traffic and
                                                                registrations and allows casino to pay referral fees and royalties to agents or affiliates and understand where traffic originates
                                                                from And all Intellectual Property
and source code associated therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Purchased Assets will not
include Front-End Development.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BILL OF SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, Elray Resources, Inc., a Nevada corporation (&ldquo;<B><U>Seller</U></B>&rdquo;),
does hereby grant, bargain, transfer, sell, assign, convey and deliver to 180 Life Sciences Corp., a company incorporated in the State
of Delaware (&ldquo;<B><U>Purchaser</U></B>&rdquo;), all of its right, title, and interest in and to the Purchased Assets, as such term
is defined in the Asset Purchase Agreement, dated as of September 27, 2024 (the &ldquo;<B><U>Purchase Agreement</U></B>&rdquo;), by and
between Seller and Purchaser, to have and to hold the same unto Purchaser, its successors and assigns, forever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Seller for itself, its successors
and assignees, hereby covenants and agrees that, at any time and from time to time upon the written request of Purchaser, Seller will,
at its own expense do, execute, acknowledge, and deliver or cause to be done, executed, acknowledged, and delivered, all such further
acts, deeds, assignments, transfers, conveyances, powers of attorney, and assurances as may be reasonably required by Purchaser in order
to assign, transfer, set over, convey, assure, and confirm unto and vest in Purchaser, its successors and assigns, title to the assets
sold, conveyed, and transferred by this Bill of Sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, Seller
has duly executed this Bill of Sale as of September 27, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><U>SELLER</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">ELRAY RESOURCES, INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%; text-align: justify"><I>/s/ Anthony Goodman  &nbsp;</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">Anthony Goodman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">CEO</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT D</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I><U>[See attached]</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Intellectual Property Purchase Agreement<BR> D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This INTELLECTUAL PROPERTY
ASSIGNMENT AGREEMENT (&ldquo;<B><U>IP Assignment</U></B>&rdquo;), dated as of September 27, 2024, is made by Elray Resources, Inc., a
Nevada corporation (&ldquo;<B><U>Seller</U></B>&rdquo;), in favor of 180 Life Sciences Corp., a Delaware corporation (&ldquo;<B><U>Purchaser</U></B>&rdquo;),
the purchaser of certain assets of Seller pursuant to an Asset Purchase Agreement between Purchaser and Seller, dated as of September
27, 2024 (the &ldquo;<B><U>Asset Purchase Agreement</U></B>&rdquo;). Certain capitalized terms used herein but not otherwise defined have
the meanings given to such terms in the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, under the terms of
the Asset Purchase Agreement, Seller has conveyed, transferred, and assigned to Purchaser, among other assets, certain intellectual property
of Seller, and has agreed to execute and deliver this IP Assignment, for recording with the United States Patent and Trademark Office,
the United States Copyright Office, and corresponding entities or agencies in any applicable jurisdictions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW THEREFORE, Seller agrees
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<FONT STYLE="text-transform: uppercase"><B><U>Assignment</U>.
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller hereby irrevocably conveys,
transfers, and assigns to Purchaser all of Seller&rsquo;s right, title, and interest in and to the following (the &ldquo;<U>Assigned IP</U>&rdquo;):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) the unregistered trademarks
owned by the Seller relating to the Purchased Assets (the &ldquo;<B><U>Trademarks</U></B>&rdquo;), with the use of, and symbolized by,
the Trademarks, and the copyright owned by the Seller in connection with the Purchased Assets and associated content in the relevant recognized
assets (the &ldquo;<B><U>Copyrights,</U></B>&rdquo; and, together with the Trademarks, the &ldquo;<B><U>Intellectual Property</U></B>&rdquo;)
as set forth on&nbsp;<B><U>Exhibit B</U></B>&nbsp;to the Asset Purchase Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) all rights of any kind whatsoever
of Seller accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions,
and otherwise throughout the world;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) any and all royalties, fees,
income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) any and all claims and causes
of action with respect to any of the foregoing, whether accruing before, on, or after the date hereof, including all rights to and claims
for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation,
violation, misuse, breach, or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or
otherwise recover, any such damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Intellectual Property Purchase Agreement<BR> D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2</B>.&nbsp;<FONT STYLE="text-transform: uppercase"><B><U>Recordation
and Further Actions</U>. Seller hereby authorizes the Commissioner for Patents and the Commissioner for Trademarks in the United States
Patent and Trademark Office, the Register of Copyrights in the United States Copyright Office, and the officials of corresponding entities
or agencies in any applicable jurisdictions to record and register this IP Assignment upon request by Purchaser. Following the date hereof,
Seller shall take such steps and actions, and provide such cooperation and assistance to Purchaser and its successors, assigns, and legal
representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney,
or other documents, as may be necessary to effect, evidence, or perfect the assignment of the Assigned IP to Purchaser, or any assignee
or successor thereto.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3</B>.&nbsp;<FONT STYLE="text-transform: uppercase"><B><U>Terms
of the Asset Purchase Agreement</U>. The parties hereto acknowledge and agree that this IP Assignment is entered into pursuant to the
Asset Purchase Agreement, to which reference is made for a further statement of the rights and obligations of Seller and Purchaser with
respect to the Assigned IP. The representations, warranties, covenants, agreements, and indemnities contained in the Asset Purchase Agreement
shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict
or inconsistency between the terms of the Asset Purchase Agreement and the terms hereof, the terms of the Asset Purchase Agreement shall
govern.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4</B>.&nbsp;<FONT STYLE="text-transform: uppercase"><B><U>Counterparts</U>.
This IP Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed
one and the same agreement. A signed copy of this IP Assignment delivered by facsimile, e-mail, or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original signed copy of this IP Assignment.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5</B>.&nbsp;<FONT STYLE="text-transform: uppercase"><B><U>Successors
and Assigns</U>. This IP Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors
and assigns.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6</B>.&nbsp;<FONT STYLE="text-transform: uppercase"><B><U>Governing
Law</U>. This IP Assignment and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based upon,
arising out of, or relating to this IP Assignment and the transactions contemplated hereby shall be governed by, and construed in accordance
with, the laws of the United States and the State of DELAWARE, without giving effect to any choice or conflict of law provision or rule
(whether of the State of DELAWARE or any other jurisdiction).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Intellectual Property Purchase Agreement<BR> D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT>IN
WITNESS WHEREOF, Seller has duly executed and delivered this IP Assignment as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><U>SELLER</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">ELRAY RESOURCES, INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><I>/s/ Anthony Goodman  &nbsp;</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">Anthony Goodman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">CEO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><U>Address for Notices</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">ELRAY RESOURCES, INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Attention: Vincent Cai</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">E-mail: Legal@elraygaming.com</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Intellectual Property Purchase Agreement<BR> D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT E</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I><U>[See attached]</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock Purchase Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">E-1</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>ea021640301ex3-1_180life.htm
<DESCRIPTION>CERTIFICATE OF DESIGNATIONS OF 180 LIFE SCIENCES CORP. ESTABLISHING THE DESIGNATIONS, PREFERENCES, LIMITATIONS AND RELATIVE RIGHTS OF ITS SERIES B CONVERTIBLE PREFERRED STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit
3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt; width: 25%"><IMG SRC="ex3-1_001.jpg" ALT=""></TD>
    <TD STYLE="text-align: center; width: 75%">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATE OF DESIGNATIONS</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>OF <BR>
180 LIFE SCIENCES CORP. <BR>
ESTABLISHING THE DESIGNATIONS, PREFERENCES,
    <BR>
LIMITATIONS AND RELATIVE RIGHTS OF ITS <BR>
SERIES B CONVERTIBLE PREFERRED STOCK</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to <U>Section 151</U>
of Delaware General Corporation Law (&ldquo;<B><U>Delaware Law</U></B>&rdquo;)&nbsp;and the Certificate of Incorporation of 180 Life Sciences
Corp., a corporation organized and existing under Delaware Law (the &ldquo;<B><U>Corporation</U></B>&rdquo;), the Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>DOES HEREBY CERTIFY</B>
that pursuant to the authority conferred upon the Board of Directors by the Second Amended and Restated Certificate of Incorporation of
the Corporation, as amended (the &ldquo;<B><U>Certificate of Incorporation</U></B>&rdquo;), and pursuant to <U>Section&nbsp;151</U> of
Delaware Law, the Board of Directors, by unanimous written consent of all members of the Board of Directors on September 29, 2024, duly
adopted a resolution providing for the designation of a series of 1,000,000 shares of Series B Convertible Preferred Stock, which resolution
is and reads as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>RESOLVED</B>, that pursuant
to the authority expressly granted to and invested in the Board of Directors by the provisions of the Certificate of Incorporation of
the Corporation and <U>Section 151</U> of Delaware Law, a series of the preferred stock, par value $0.0001 per share, of the Corporation
be, and it hereby is, established; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>FURTHER RESOLVED</B>, that
the series of preferred stock of the Corporation be, and it hereby is, given the designation of &ldquo;<B><U>Series B Convertible Preferred
Stock</U></B>&rdquo;; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>FURTHER RESOLVED</B>, that
the Series B Convertible Preferred Stock shall consist of 1,000,000 shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>FURTHER RESOLVED</B>, that
the Series B Convertible Preferred Stock shall have the powers and preferences, and the relative, participating, optional and other rights,
and the qualifications, limitations, and restrictions thereon set forth in this Certificate of Designations (the &ldquo;<B><U>Designation</U></B>&rdquo;
or the &ldquo;<B><U>Certificate of Designations</U></B>&rdquo;)&nbsp;below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series B Convertible Preferred
Stock is sometimes referred to in this Certificate of Designations as the &ldquo;<B><U>Series B Preferred Stock</U></B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>CERTAIN CAPITALIZED TERMS
USED BELOW ARE DEFINED IN <U>SECTION 19</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.&nbsp;<U>Dividends</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1&nbsp;</FONT><U>Dividends
in General</U>. The Series B Convertible Preferred Stock shall not accrue any dividends and shall not participate in any dividends, except
as expressly set forth in <U>Section 1.2</U>, below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2&nbsp;</FONT><U>Dividends
on the Common Stock</U>. If the Corporation declares a dividend or makes a distribution of cash (or any other distribution treated as
a dividend under <U>Section 301</U> of the Code)&nbsp;on its Common Stock, each holder of Shares of Series B Preferred Stock shall be
entitled to participate in such dividend or distribution in an amount equal to the largest number of whole shares of Common Stock into
which all Shares of Series B Preferred Stock held of record by such holder are convertible pursuant to <U>Section&nbsp;3</U> herein as
of the record date for such dividend or distribution or, if there is no specified record date, as of the date of such dividend or distribution.
Notwithstanding the foregoing, Holders shall have no right of participation in connection with dividends or Distributions made to the
Common Stock stockholders consisting solely of shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.3&nbsp;</FONT><U>Non-Cash
Distributions</U>. Whenever a Distribution provided for in <U>Section 1.2</U> shall be payable in property other than cash, the value
of such Distribution shall be deemed to be the fair market value of such property as determined in good faith by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.4&nbsp;</FONT><U>Other
Distributions</U>. Subject to the terms of this Certificate of Designations, and to the fullest extent permitted by Delaware Law, the
Corporation shall be expressly permitted to redeem, repurchase or make distributions on the shares of its capital stock in all circumstances
other than where doing so would cause the Corporation to be unable to pay its debts as they become due in the usual course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.&nbsp;<U>Liquidation
Rights</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1&nbsp;</FONT><U>Liquidation
Preference</U>. In the event of any liquidation, dissolution or winding up of the Corporation, either voluntary or involuntary (each a
&ldquo;<B><U>Liquidation Event</U></B>&rdquo;), the Holders of Series B Preferred Stock shall be entitled to receive prior and in preference
to any Distribution of any of the assets of the Corporation to the holders of the Common Stock or the Junior Securities by reason of their
ownership of such stock, but after any required distribution to any holders of Series A Preferred Stock, an amount in cash per Share for
each Share of Series B Preferred Stock held by them equal to the greater of (x)&nbsp; one (1) times the Stated Value; and (y)&nbsp;the
total amount of consideration that would have been payable on such Share upon a Liquidation Event, had such Share been converted into
Common Stock pursuant to <U>Section 3</U>, below, immediately prior to such Liquidation Event (as applicable, the &ldquo;<B><U>Liquidation
Preference</U></B>&rdquo;). No Holder shall (i) be entitled to any payment in respect of its shares of Series B Preferred Stock in the
event of any Liquidation Event other than payment of the Liquidation Preference expressly provided for in this <U>Section 2.1</U>, or
(ii) have any further right or claim to any of the Corporation&rsquo;s remaining assets, including any right or claim to participate in
the receipt of any payment on Junior Stock in connection therewith (except as provided in (y) above). If upon a Liquidation Event, the
assets of the Corporation legally available for distribution to the Holders of the Series B Preferred Stock are insufficient to permit
the payment in cash to such Holders of the full Liquidation Preference, then the entire assets of the Corporation legally available for
distribution shall be distributed with equal priority and pro rata among the Holders of the Series B Preferred Stock in proportion to
the full amounts they would otherwise be entitled to receive pursuant to this <U>Section 2.1</U> and the Corporation shall not make or
agree to make any payments to the holders of Common Stock or Junior Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2&nbsp;</FONT><U>Remaining
Assets</U>. After the payment to the Holders of Series B Preferred Stock of the full preferential amounts specified above in <U>Section
2.1</U>, the entire remaining assets of the Corporation legally available for distribution by the Corporation shall be distributed to
the holders of the Junior Securities and then to the holders of Common Stock, pursuant to the terms of such securities, Delaware law,
and/or the governing documents of the Corporation, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3&nbsp;</FONT><U>Valuation
of Non-Cash Consideration</U>. If any assets of the Corporation distributed to stockholders in connection with any liquidation, dissolution,
or winding up of the Corporation are other than cash, then the value of such assets shall be their fair market value as determined in
good faith by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4&nbsp;</FONT><U>Notice</U>.
In the event of any Liquidation Event, the Corporation shall, within ten (10)&nbsp;days of the date the Board approves such action, or
no later than twenty (20)&nbsp;days of any stockholders&rsquo; meeting called to approve such action, or within twenty (20)&nbsp;days
of the commencement of any involuntary proceeding, whichever is earlier, give each Holder of Series B Preferred Stock written notice of
the proposed action. Such written notice shall describe the material terms and conditions of such proposed action, including a description
of the stock, cash and property to be received by the Holders of Shares upon consummation of the proposed action and the date of delivery
thereof. If any material change in the facts set forth in the initial notice shall occur, the Corporation shall promptly give written
notice to each Holder of Shares of such material change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5&nbsp;</FONT><U>Non-Liquidation
Events</U>. For the sake of clarity, the rights and obligations set forth in <U>Section 2.1</U> above shall only apply to actual liquidations,
winding ups and dissolutions of the Corporation, and shall not apply, to any other event or action, including, but not limited to, upon
any change of control, merger, consolidation, share exchange, or other similar event which does not result in the liquidation, winding
up or dissolution of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.&nbsp;<U>Conversion</U>.</B>
The Series B Preferred Stock shall have conversion rights as follows (the &ldquo;<B><U>Conversion Rights</U></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1&nbsp;</FONT><U>Holder
Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;</FONT><U>Conversion
Right</U>. Each Share of Series B Preferred Stock shall be convertible, at the option of the Holder thereof (a &ldquo;<B><U>Conversion</U></B>&rdquo;),
at any time following the Stockholder Approval Date, at the office of the Corporation or any Transfer Agent for the Series B Preferred
Stock, into that number of fully-paid, nonassessable shares of Common Stock as equals the number of shares of Series B Preferred Stock
Converted multiplied by the Conversion Rate (defined and discussed below in <U>Section 3.1(b)</U>)(such shares of Common Stock issuable
upon a Conversion, the &ldquo;<B><U>Conversion Shares</U></B>&rdquo;). In order to effectuate the Conversion under this <U>Section 3.1</U>,
the Holder must provide the Corporation a written notice of conversion in the form of <U>Exhibit&nbsp;A</U> hereto (the &ldquo;<B><U>Notice
of Conversion</U></B>&rdquo;). The Notice of Conversion must be dated no earlier than three (3) Business Days from the date the Notice
of Conversion is actually received by the Corporation. The &ldquo;<B><U>Conversion Date</U></B>&rdquo; means the date on which such Holder
complies with the procedures set forth in <U>Section 3.1(c)</U> (including the submission of the Notice of Conversion to the Corporation
of its election to convert) and <U>Section 3.1(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;</FONT><U>Conversion
Rate</U>. The &ldquo;<B><U>Conversion Rate</U></B>&rdquo; shall initially be 0.685, as equitably adjusted, as applicable pursuant to
<U>Section 4</U>; provided that if at any time after the Original Issue Date and prior to the Stockholder Approval Date, the Corporation
shall actually issue any additional shares of Common Stock of the Company (each a &ldquo;<B><U>Dilutive Issuance</U></B>&rdquo;), the
Conversion Rate shall be increased to a value equal to (x)(i) the Total Outstanding Shares on the date immediately following such Dilutive
Issuance, divided by (ii) One (1) minus the Conversion Percentage, minus (iii) the Total Outstanding Shares on the date immediately following
such Dilutive Issuance, divided by (y) the Original Series B Shares, rounded to the thousands place, as equitably adjusted, as applicable
pursuant to <U>Section 4</U> (each a &ldquo;<B><U>Dilutive Adjustment</U></B>&rdquo;); provided that in no event will the Conversion
Rate be greater than ten (10). The effect of any change in the Conversion Rate shall not be retroactive and shall only apply for Conversions
of Series B Preferred Stock following the date of any Dilutive Adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;</FONT><U>Mechanics
of Conversion</U>. In order to effect a Conversion, a Holder shall email a copy of the fully executed Notice of Conversion to the Corporation
(or in the discretion of the Corporation, with notice to the Holder, the Transfer Agent)(Attn: Blair Jordan, 3000 El Camino Real, Bldg.
4, Suite 200, Palo Alto, California 94306, Email: blair.jordan@highmontadvisors.com, or such other address as the Corporation shall notify
the Holders of at least ten (10)&nbsp;Business Days prior to the effective date of such change in record address, or any other Transfer
Agent authorized to serve as transfer agent and registrar of the Series B Preferred Stock, with a copy to (which shall not constitute
notice)&nbsp;The Loev Law Firm, PC, Attn: David M. Loev, Esq., 6300 West Loop South, Suite 280, Bellaire, Texas 77401, Fax: (713)&nbsp;524-4122,
Email: dloev@loevlaw.com). Upon receipt by the Corporation (or the Transfer Agent)&nbsp;of an emailed copy of a Notice of Conversion from
a Holder, the Corporation (or the Transfer Agent)&nbsp;shall promptly send, via email, a confirmation to such Holder stating that the
Notice of Conversion has been received, the date upon which the Corporation (or the Transfer Agent)&nbsp;expects to deliver the Common
Stock issuable upon such conversion and the name and telephone number of a contact person at the Corporation (or the Transfer Agent)&nbsp;regarding
the Conversion. The Holder shall surrender, or cause to be surrendered, the Preferred Stock Certificates being converted, duly endorsed,
to the Corporation (or the Transfer Agent)&nbsp;at the address listed above within three Business Days of delivering the fully executed
Notice of Conversion, if any. The Corporation (or the Transfer Agent)&nbsp;shall not be obligated to issue shares of Common Stock upon
a Conversion if the Shares so converted have been evidenced by a Preferred Stock Certificate, unless either (x)&nbsp;the Preferred Stock
Certificates; or (y)&nbsp;the Lost Certificate Materials described in <U>Section 12</U>, below have been previously received by the Corporation
or its Transfer Agent, in the event any Preferred Stock Certificates were issued in connection with the applicable Shares converted. In
the event the Holder has lost or misplaced the certificates evidencing the Preferred Stock, the Holder shall be required to provide the
Corporation or the Corporation&rsquo;s Transfer Agent (as applicable)&nbsp;with whatever reasonable documentation and fees each may require
to re-issue the Preferred Stock Certificates and shall be required to provide such re-issued Preferred Stock Certificates to the Corporation
(or the Transfer Agent)&nbsp;within three (3) Business Days of delivering the Notice of Conversion. Unless the Conversion Shares are covered
by a valid and effective registration under the Securities Act or the Notice of Conversion provided by the Holder includes a valid opinion
from an attorney stating that such shares of Common Stock issuable in connection with the Notice of Conversion can be issued free of restrictive
legend, which shall be determined by the Corporation (or the Transfer Agent)&nbsp;in its sole discretion, such shares shall be issued
as Restricted Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;</FONT><U>Delivery
of Common Stock upon Conversion</U>. Upon the receipt of a Notice of Conversion, the Corporation (itself, or through its Transfer Agent)&nbsp;shall,
no later than the third Business Day following the date of such receipt (subject to the surrender of the Preferred Stock Certificates
by the Holder within the period described in <U>Section 3.1(b)&nbsp;</U>or, in the case of lost, stolen or destroyed certificates, after
provision of the Lost Certificate Materials, to the extent the Shares so converted are evidenced by Preferred Stock Certificates)&nbsp;(the
&ldquo;<B><U>Delivery Period</U></B>&rdquo;), issue and deliver (i)&nbsp;(i.e., deposit with a nationally recognized overnight courier
service postage prepaid)&nbsp;to the Holder or its nominee (x a certificate representing, the Conversion Shares and (y a certificate representing,
the number of shares of Series B Preferred Stock not being converted, if any; or (ii)&nbsp;if the Shares are held in book-entry, non-certificated
format, notice and confirmation of the issuance in book-entry format of the Conversion Shares and the remaining number of Series B Preferred
Stock shares held by the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;</FONT><U>Failure
to Provide Preferred Stock Certificates</U>. In the event the Holder provides the Corporation with a Notice of Conversion, but fails to
provide the Corporation with the Preferred Stock Certificates or the Lost Certificate Materials (as defined in <U>Section 12</U> below),
to the extent such converted shares of Series B Preferred Stock were originally issued in certificated form, by the end of the Delivery
Period, the Notice of Conversion shall be considered void and the Corporation shall not be required to comply with such Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2&nbsp;</FONT><U>Fractional
Shares</U>. If any Conversion of Series B Preferred Stock would result in the issuance of a fractional share of Common Stock (aggregating
all shares of Series B Preferred Stock being converted pursuant to a given Notice of Conversion), then such fractional share shall be
rounded up to the nearest whole share of Common Stock. In the event multiple Conversions would result in the Holder being issued an unequitable
number of shares of Common Stock due to rounding, the Corporation reserves the right to keep an accounting of the fractional shares of
Common Stock due and aggregate multiple fractional shares into whole shares prior to issuance to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3 </FONT><U>Taxes</U>.
The Corporation shall not be required to pay any tax which may be payable in respect to any transfer involved in the issue and
delivery of shares of Common Stock upon Conversion in a name other than that in which the shares of the Series B Preferred Stock so
converted were registered, and no such issue or delivery shall be made unless and until the Person requesting such issue or delivery
has paid to the Corporation the amount of any such tax, or has established, to the satisfaction of the Corporation, that such tax
has been paid. The Corporation shall withhold from any payment due whatsoever in connection with the Series B Preferred Stock any
and all required withholdings and/or taxes the Corporation, in its sole discretion deems reasonable or necessary, absent an opinion
from Holder&rsquo;s accountant or legal counsel, acceptable to the Corporation in its sole determination, that such withholdings
and/or taxes are not required to be withheld by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4&nbsp;</FONT><U>No
Impairment</U>. The Corporation will not through any reorganization, transfer of assets, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder
by the Corporation but will at all times in good faith assist in the carrying out of all the provisions of this <U>Section 3</U> and in
the taking of all such action as may be necessary or appropriate in order to protect the Conversion rights of the Holders of Series B
Preferred Stock against impairment. Notwithstanding the foregoing, nothing in this Section shall prohibit the Corporation from amending
its Certificate of Incorporation, subject to the other terms of this Designation, with the requisite consent of its stockholders and the
Board, provided that such amendment will not prohibit the Corporation from having sufficient authorized shares of Common Stock to permit
conversion hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5&nbsp;</FONT><U>Reservation
of Stock Issuable Upon Conversion</U>. The Corporation shall at all times reserve and keep available out of its authorized but unissued
shares of Common Stock solely for the purpose of effecting the conversion of the shares of the Series B Preferred Stock, such number of
its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all then outstanding shares of the Series
B Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the
conversion of all then outstanding shares of the Series B Preferred Stock, the Corporation will use its commercially reasonable efforts
to take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common
Stock to such number of shares as shall be sufficient for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.6&nbsp;</FONT><U>Retirement
of Reacquired Shares</U>. Any shares of Series B Preferred Stock Converted shall be retired and canceled promptly after the acquisition
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7&nbsp;</FONT><U>Preferred
Share Register</U>. The Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation
as it may designate by notice to the holders of shares of Series B Preferred Stock), a register for Series B Preferred Stock, in which
the Corporation shall record the name and address of the Persons in whose name shares of Series B Preferred Stock have been issued, as
well as the name and address of each transferee. The Corporation may treat the person in whose name any of the Series B Preferred Stock
is registered on the register as the owner and holder thereof for all purposes, notwithstanding any notice to the contrary, but in all
events recognizing any properly made transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8&nbsp;</FONT><U>Cap
on Shares of Common Stock</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;</FONT>For
the sake of clarity and in an abundance of caution, no shares of Common Stock shall be issued in connection with the Conversion of any
shares of Series B Preferred Stock until Stockholder Approval has been received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;</FONT>Notwithstanding
any other term or condition of this Designations, in no event shall more shares of Common Stock than the Maximum Shares be issued upon
Conversion of the Original Series B Shares. In the event the Conversion of the Original Series B Shares would result in the issuance of
more shares of Common Stock than the Maximum Shares, such number of shares of Common Stock which equals the Original Series B Shares shall
be issued to the holder(s) thereof, and all Original Series B Shares then outstanding shall be automatically cancelled by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.&nbsp;<U>Adjustments
for Recapitalizations</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1&nbsp;</FONT><U>Equitable
Adjustments for Recapitalizations</U>. (a)&nbsp;The Stated Value (the &ldquo;<B><U>Preferred Stock Adjustable Provisions</U></B>&rdquo;);
(b)&nbsp;the Conversion Rate (the &ldquo;<B><U>Common Stock Adjustable Provisions</U></B>&rdquo;), and (c)&nbsp;any and all other terms,
conditions, amounts and provisions of this Designation which (i)&nbsp;pursuant to the terms of this Designation provide for equitable
adjustment in the event of a Recapitalization (the &ldquo;<B><U>Other Equitable Adjustable Provisions</U></B>&rdquo;); or (ii)&nbsp;the
Board of the Corporation determines in their reasonable good faith judgment is required to be equitably adjusted in connection with any
Recapitalizations, shall each be subject to equitable adjustment as provided in <U>Sections 4.2</U> through <U>4.3</U>, below, as determined
by the Board in their sole and reasonable discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2&nbsp;</FONT><U>Adjustments
for Subdivisions or Combinations of Common Stock</U>. In the event the outstanding shares of Common Stock shall be subdivided (by stock
split, by payment of a stock dividend or otherwise), into a greater number of shares of Common Stock, without a corresponding subdivision
of the Series B Preferred Stock, the applicable Common Stock Adjustable Provisions and the Other Equitable Adjustable Provisions (if any)&nbsp;in
effect immediately prior to such subdivision shall, concurrently with the effectiveness of such subdivision, be proportionately and equitably
adjusted, as determined by the reasonable good faith determination of the Board. In the event the outstanding shares of Common Stock shall
be combined (by reclassification or otherwise)&nbsp;into a lesser number of shares of Common Stock, without a corresponding combination
of the Series B Preferred Stock, the Common Stock Adjustable Provisions and the Other Equitable Adjustable Provisions (if any)&nbsp;in
effect immediately prior to such combination shall, concurrently with the effectiveness of such combination, be proportionately and equitably
adjusted, as determined by the reasonable good faith determination of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.3&nbsp;</FONT><U>Adjustments
for Subdivisions or Combinations of Series B Preferred Stock</U>. In the event the outstanding shares of Series B Preferred Stock shall
be subdivided (by stock split, by payment of a stock dividend or otherwise), into a greater number of shares of Series B Preferred Stock,
the applicable Common Stock Adjustable Provisions and the Other Equitable Adjustable Provisions (if any)&nbsp;in effect immediately prior
to such subdivision shall, concurrently with the effectiveness of such subdivision, be proportionately and equitably adjusted, as determined
by the reasonable good faith determination of the Board. In the event the outstanding shares of Series B Preferred Stock shall be combined
(by reclassification or otherwise)&nbsp;into a lesser number of shares of Series B Preferred Stock, the applicable Common Stock Adjustable
Provisions and the Other Equitable Adjustable Provisions (if any)&nbsp;in effect immediately prior to such combination shall, concurrently
with the effectiveness of such combination, be proportionately and equitably adjusted, as determined by the reasonable good faith determination
of the Board. Provided however that the result of any concurrent adjustment in the Common Stock (as provided under <U>Section 4.2</U>)&nbsp;and
any series of Series B Preferred Stock (as provided under <U>Section 4.3</U>)&nbsp;shall only be to affect the equitable adjustable provisions
hereof once.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4&nbsp;</FONT><U>Adjustments
for Reclassification, Exchange and Substitution</U>. If the Common Stock issuable upon Conversion of the Series B Preferred Stock shall
be changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification
or otherwise (other than a subdivision or combination of shares provided for above), then, in any such event, in lieu of the number of
shares of Common Stock which the holders would otherwise have been entitled to receive, each holder of such Series B Preferred Stock shall
have the right thereafter to convert such shares of Series B Preferred Stock into a number of shares of such other class or classes of
stock which a holder of the number of shares of Common Stock deliverable upon Conversion of such Series B Preferred Stock immediately
before that change would have been entitled to receive in such reorganization or reclassification, all subject to further adjustment as
provided herein with respect to such other shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.5&nbsp;</FONT><U>Other
Adjustments</U>. The Board of the Corporation shall also adjust equitably, and shall have the right to adjust equitably, any or all of
the Common Stock Adjustable Provisions, Preferred Stock Adjustable Provisions or Other Equitable Adjustable Provisions from time to time,
if the Board of the Corporation determines in their reasonable good faith judgment that such values and/or provisions are required to
be equitably adjusted in connection with any Corporation action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.6&nbsp;</FONT><U>Certificate
as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment pursuant to this <U>Section 4.6</U>, the Corporation at
its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder a notice
setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based. The
Corporation shall, upon the reasonable written request at any time of any Holder, furnish or cause to be furnished to such Holder a like
certificate setting forth (i)&nbsp;such adjustments and readjustments, and (ii)&nbsp;the number of shares of Common Stock and the amount,
if any, of other property which at the time would be received upon the conversion of the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.&nbsp;<U>Voting</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1&nbsp;</FONT><U>Voting
Prior to Stockholder Approval</U>. The Series B Preferred Stock shall not have any voting rights, including, but not limited to any series
voting rights, prior to Stockholder Approval, except as explicitly set forth in <U>Section 5.4</U> and under <U>Section 6</U>, below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2&nbsp;</FONT><U>Voting
After Stockholder Approval</U>. After Stockholder Approval, except as explicitly set forth in <U>Section 5.4</U> and under <U>Section
6</U>, below, each Holder of outstanding shares of Series B Preferred Stock shall be entitled to cast the number of votes in connection
with the Series B Preferred Stock shares held by such Holder equal to the number of whole shares of Common Stock into which the shares
of Series B Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on
such matter, and shall be entitled, notwithstanding any provision hereof, to notice of any stockholders&rsquo; meeting in accordance with
the bylaws of the Corporation. Fractional votes shall not, however, be permitted and any fractional voting rights available on an as-converted
to Common Stock basis (after aggregating all fractional shares into which shares of Series B Preferred Stock held by each holder could
be converted) shall be rounded down to the nearest whole share. Except as provided by law or by the other provisions of the Certificate
of Incorporation or this Designation, holders of Series Preferred Stock shall vote together with the holders of Common Stock as a single
class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3&nbsp;</FONT><U>No
Series Voting</U>. Except as provided in this Designation, following Stockholder Approval, Holders of Series B Preferred Stock shall vote
together with the holders of Common Stock as a single class. Other than as provided herein or required by law, there shall be no series
voting. The holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Designations that relates solely
to the terms of the Series B Preferred Stock, either separately or together as a class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4&nbsp;</FONT><U>Amendments
to This Designation</U>. This Designation may be amended with the consent of the Board of the Corporation and a Simple Majority, and no
amendment hereof shall require the vote or approval of any other stockholders of the Corporation, including, but not limited to, Common
Stock holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.&nbsp;<U>Protective
Provisions</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1&nbsp;</FONT>For
so long as any Series B Preferred Stock Shares are outstanding, the Corporation shall not, without first obtaining the approval (at a
meeting duly called or by written consent, as provided by law)&nbsp;of a Simple Majority:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;</FONT>Increase
or decrease (other than by redemption or conversion)&nbsp;the total number of authorized shares of Series B Preferred Stock of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;</FONT>Adopt
or authorize any new designation of any Preferred Stock or amend the Certificate of Incorporation of the Corporation in a manner which
(i)&nbsp;provides any holder of Common Stock or Preferred Stock any rights upon a liquidation of the Corporation which are prior and superior
to those of the Holders of the Series B Preferred Stock as set forth herein; or (ii) adversely affect the rights, preferences and privileges
of the Series B Preferred Stock (provided that no (1)&nbsp;increase in the number of authorized shares of Common Stock or Preferred Stock
of the Corporation; or (2)&nbsp;designation of a new series of preferred stock of the Corporation which has rights junior or pari passu
(except in the event of a Liquidation Event, in which case the rights of the Series B Preferred Stock shall be senior to all Junior Securities,
and junior to the Series A Preferred Stock) to the Series B Preferred Stock shall be deemed to adversely affect the rights, preferences
and privileges of the Series B Preferred Stock);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;</FONT>Effect
an exchange, or create a right of exchange, cancel, or create a right to cancel, of all or any part of the shares of another class of
shares into shares of Series B Preferred Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;</FONT>Alter
or change the rights, preferences or privileges of the shares of Series B Preferred Stock so as to affect adversely the shares of such
series; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;</FONT>Issue
any shares of Series A Preferred Stock or Series B Preferred Stock, other than the Original Series B Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
the number of authorized shares of the Common Stock or Preferred Stock of the Corporation (or any other designations of Preferred Stock
of the Corporation other than the Series B Preferred Stock) may be increased or decreased by the affirmative vote of the holders of a
majority in voting power of the capital stock of the Corporation entitled to vote thereon irrespective of the provisions of <U>Section
242(b)(2)</U> of Delaware Law, and no vote of the holders of any of the Common Stock or Series B Preferred Stock voting separately as
a class shall be required therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.&nbsp;<U>Redemption</U></B>.
The Shares shall not have any redemption rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.&nbsp;<U>Notices</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1&nbsp;</FONT><U>In
General</U>. Any notices required or permitted to be given under the terms hereof shall be sent by certified or registered mail (return
receipt requested)&nbsp;or delivered personally, by nationally recognized overnight carrier or by confirmed facsimile or email transmission,
and shall be effective, unless otherwise provided herein, three days after being placed in the mail, if mailed, or upon receipt or refusal
of receipt, if delivered personally or by nationally recognized overnight carrier or confirmed facsimile transmission, in each case addressed
to a party. The addresses for such communications are (i)&nbsp;if to the Corporation to, Blair Jordan, 3000 El Camino Real, Bldg. 4, Suite
200, Palo Alto, California 94306, Email: blair.jordan@highmontadvisors.com, or such other address as the Corporation shall notify the
Holders of at least ten (10)&nbsp;Business Days prior to the effective date of such change in record address, with a copy to (which shall
not constitute notice), The Loev Law Firm, PC, Attn: David M. Loev, 6300 West Loop South, Suite 280, Bellaire, Texas 77401, Fax: (713)&nbsp;524-4122,
Email: dloev@loevlaw.com, and (ii)&nbsp;if to any Holder to the address set forth in the records of the Corporation or its Transfer Agent,
as applicable, or such other address as may be designated in writing hereafter, in the same manner, by such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2
</FONT><U>Notices of Record Date</U>. In the event that the Corporation shall propose at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a) </FONT>to
effect any reclassification or recapitalization of its Common Stock outstanding involving a change in the Common Stock; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b) </FONT>to
voluntarily liquidate, wind up or dissolve;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">then, in connection with each
such event, the Corporation shall send to the Holders of the Series B Preferred Stock at least ten (10)&nbsp;Business Days&rsquo; prior
written notice of the date on which a record shall be taken for such Distribution (and specifying the date on which the holders of Common
Stock shall be entitled thereto and, if applicable, the amount and character of such Distribution)&nbsp;or for determining rights to vote
in respect of the matters referred to in (a)&nbsp;and (b)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such written notice shall
be given by first class mail (or express courier), postage prepaid, addressed to the holders of Series B Preferred Stock at the address
for each such Holder as shown on the books of the Corporation and shall be deemed given on the date such notice is mailed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The notice provisions set
forth in this section may be shortened or waived prospectively or retrospectively by the vote or written consent of the holders of a Simple
Majority, voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9. <U>No
Preemptive Rights</U></B>. No Holder shall have the right to purchase shares of capital stock of the Corporation sold or issued by the
Corporation except to the extent that such right may from time to time be set forth in a written agreement between the Corporation and
such stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10. <U>Reports</U></B>.
The Corporation shall mail to all holders of Series B Preferred Stock those reports, proxy statements and other materials that it mails
to all of its holders of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11. <U>Uncertificated
Shares</U>. </B>Unless otherwise requested in writing by a Holder to the Corporation, the shares of Series B Preferred Stock
and any shares of Common Stock issued upon conversion thereof shall be in uncertificated, book entry form as permitted by the bylaws
of the Corporation and Delaware law. Within a reasonable time after the issuance or transfer of uncertificated shares, the
Corporation shall send to the registered owner thereof an ownership notice setting forth such information regarding the securities
of the Corporation held by the Holder as is required by Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12. <U>Replacement
Preferred Stock Certificates</U></B>. In the event that a Holder requests certificated shares, and any Holder notifies the Corporation
that a Preferred Stock Certificate evidencing shares of Series B Preferred Stock has been lost, stolen, destroyed or mutilated, the Corporation
shall issue a replacement stock certificate evidencing the Series B Preferred Stock identical in tenor and date (or if such certificate
is being issued for shares not covered in a redemption or conversion, in the applicable tenor and date)&nbsp;to the original Preferred
Stock Certificate evidencing the Series B Preferred Stock, provided that the Holder executes and delivers to the Corporation and/or its
Transfer Agent, as applicable, an affidavit of lost stock certificate and an agreement reasonably satisfactory to the Corporation and
its Transfer Agent to indemnify the Corporation from any loss incurred by it in connection with such Series B Preferred Stock certificate,
and provides the Corporation and/or its Transfer Agent such other information, documents and if applicable, bonds and indemnities as the
Corporation or its Transfer Agent customarily requires for reissuances of stock certificates (collectively the &ldquo;<B><U>Lost Certificate
Materials</U></B>&rdquo;); provided, however, the Corporation shall not be obligated to re-issue replacement stock certificates if the
Holder contemporaneously requests the Corporation to convert or redeem the full number of shares evidenced by such lost, stolen, destroyed
or mutilated certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13. <U>No
Other Rights or Privileges</U></B>. Except as specifically set forth herein, the Holders of the Series B Preferred Stock shall have no
other rights, privileges or preferences with respect to the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14. <U>Construction</U></B>.
When used in this Designation, unless a contrary intention appears: (i)&nbsp;a term has the meaning assigned to it; (ii)&nbsp;&ldquo;<B><U>or</U></B>&rdquo;
is not exclusive; (iii)&nbsp;&ldquo;<B><U>including</U></B>&rdquo; means including without limitation; (iv)&nbsp;words in the singular
include the plural and words in the plural include the singular, and words importing the masculine gender include the feminine and neuter
genders; (v)&nbsp;any agreement, instrument or statute defined or referred to herein or in any instrument or certificate delivered in
connection herewith means such agreement, instrument or statute as from time to time amended, modified or supplemented and includes (in
the case of agreements or instruments)&nbsp;references to all attachments thereto and instruments incorporated therein; (vi)&nbsp;the
words &ldquo;<B><U>hereof</U></B>&rdquo;, &ldquo;<B><U>herein</U></B>&rdquo; and &ldquo;<B><U>hereunder</U></B>&rdquo; and words of similar
import when used in this Designation shall refer to this Designation as a whole and not to any particular provision hereof; (vii)&nbsp;references
contained herein to Article, Section, Schedule and Exhibit, as applicable, are references to Articles, Sections, Schedules and Exhibits
in this Designation unless otherwise specified; (viii)&nbsp;references to &ldquo;<B><U>dollars</U></B>&rdquo;, &ldquo;<B><U>Dollars</U></B>&rdquo;
or &ldquo;<B><U>$</U></B>&rdquo; in this Designation means United States dollars; (ix)&nbsp;reference to a particular statute, regulation
or law means such statute, regulation or law as amended or otherwise modified from time to time; (x)&nbsp;any definition of or reference
to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document
as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications
set forth herein); (xi)&nbsp;unless otherwise stated in this Designation, in the computation of a period of time from a specified date
to a later specified date, the word &ldquo;<B><U>from</U></B>&rdquo; means &ldquo;<B><U>from and including</U></B>&rdquo; and the words
&ldquo;<B><U>to</U></B>&rdquo; and &ldquo;<B><U>until</U></B>&rdquo; each mean &ldquo;<B><U>to but excluding</U></B>&rdquo;; (xii)&nbsp;references
to &ldquo;<B><U>days</U></B>&rdquo; means calendar days; and (xiii)&nbsp;the paragraph and section headings contained in this Designation
are for convenience only, and shall in no manner affect the interpretation of any of the provisions of this Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15. <U>Record
Holders</U></B>. To the fullest extent permitted by applicable law, the Corporation may deem and treat the record holder of any share
of Series B Preferred Stock as the absolute owner of such share of Series B Preferred Stock for the purpose of making any payment and
settling any conversion or redemption of such share of Series B Preferred Stock and for all other purposes under this Certificate of Designations,
and the Corporation shall not be affected by any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16. <U>Severability</U></B>.
If any term of this Certificate of Designations is invalid, unlawful or incapable of being enforced by reason of any rule of law or public
policy, all other terms set forth herein that can be given effect without the invalid, unlawful or unenforceable term will, nevertheless,
remain in full force and effect, and no term herein set forth will be deemed dependent upon any other such term unless expressed stated
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17. <U>Withholding</U></B>.
All payments and distributions (or deemed distributions) on the shares of Series B Preferred Stock (and any share of Common Stock issued
upon the conversion of any share of Series B Preferred Stock) shall be subject to withholding and backup withholding of taxes to the extent
required by applicable law, subject to applicable exemptions, and amounts withheld, if any, shall be treated as received by the Holders
to the extent timely paid by the Corporation or the Transfer Agent to the appropriate taxing authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>18. <U>Miscellaneous</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.1 </FONT><U>Further
Assurances</U>. Each Holder hereby covenants that, in consideration for receiving shares of Series B Preferred Stock, that he, she or
it will, whenever and as reasonably requested by the Corporation, do, execute, acknowledge and deliver any and all such other and further
acts, deeds, confirmations, agreements and documents as the Corporation or its Transfer Agent may reasonably require in order to complete,
insure and perfect any of the terms, conditions or provisions of this Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.2 </FONT><U>Technical,
Corrective, Administrative or Similar Changes</U>. The Corporation may, by any means authorized by law and without any vote of the Holders
of shares of the Series B Preferred Stock, make technical, corrective, administrative or similar changes in this Designation that do not,
individually or in the aggregate, adversely affect the rights or preferences of the Holders of shares of the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.3 </FONT><U>Waiver/Amendment</U>.
Notwithstanding any provision in this Designation to the contrary, any provision contained herein and any right of the holders of Series
B Preferred Stock granted hereunder may be waived and/or amended as to all shares of Series B Preferred Stock (and the Holders thereof)&nbsp;upon
the written consent of a Simple Majority, together with the approval of the Board of the Corporation, as described in <U>Section 5.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.4 </FONT><U>Interpretation</U>.
Whenever possible, each provision of this Designation shall be interpreted in a manner as to be effective and valid under applicable law
and public policy. If any provision set forth herein is held to be invalid, unlawful or incapable of being enforced by reason of any rule
of law or public policy, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating
or otherwise adversely affecting the remaining provisions of this Designation. No provision herein set forth shall be deemed dependent
upon any other provision unless so expressed herein. If a court of competent jurisdiction should determine that a provision of this Designation
would be valid or enforceable if a period of time were extended or shortened, then such court may make such change as shall be necessary
to render the provision in question effective and valid under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.5 </FONT><U>No
Other Rights</U>. Except as may otherwise be required by law, the shares of the Series B Preferred Stock shall not have any powers, Designation,
preferences or other special rights, other than those specifically set forth in this Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>19. <U>Definitions</U>.</B>
In addition to other terms defined throughout this Designation, the following terms have the following meanings when used herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.1 </FONT>&ldquo;<B><U>Asset
Purchase Agreement</U></B>&rdquo; means that certain Asset Purchase Agreement entered into on September 29, 2024, by and between the Corporation
and Elray Resources, Inc., as amended, modified and restated from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.2 </FONT>&ldquo;<B><U>Board</U></B>&rdquo;
means the Board of Directors of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.3 </FONT>&ldquo;<B><U>Business
Day</U></B>&rdquo; means any day except Saturday, Sunday or any day on which banks are authorized by law to be closed in the city in which
the Corporation has its principal place of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.4 </FONT>&ldquo;<B><U>Closing</U></B>&rdquo;
means the Closing as defined in the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.5 </FONT>&ldquo;<B><U>Code</U></B>&rdquo;
means the U.S. Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.6 </FONT>&ldquo;<B><U>Common
Stock</U></B>&rdquo; means the common stock, $0.0001 par value per share of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.7 </FONT>&ldquo;<B><U>Conversion
Percentage</U></B>&rdquo; means 40%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.8 </FONT>&ldquo;<B><U>Distribution</U></B>&rdquo;
means the transfer of cash or other property without consideration whether by way of dividend or otherwise (other than dividends on Common
Stock payable in Common Stock), or the purchase or redemption of shares of the Corporation for cash or property other than&nbsp;repurchases
of Common Stock (or securities convertible into Common Stock)&nbsp;approved by the Corporation&rsquo;s Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.9 </FONT>&ldquo;<B><U>Exchange
Act</U></B>&rdquo; means the Securities Exchange Act of 1934, as amended (and any successor thereto)&nbsp;and the rules and regulations
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.10 </FONT>&ldquo;<B><U>Junior
Securities</U></B>&rdquo; means each other class of capital stock and series of Preferred Stock of the Corporation, other than the Common
Stock, if any outstanding from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.11 </FONT>&ldquo;<B><U>Holder</U></B>&rdquo;
means the Person in which the Series B Preferred Stock is registered on the books of the Corporation, which shall initially be the Persons
subscribing to purchase shares of Series B Preferred Stock in the Private Offering, and shall thereafter, be permitted and legal assigns
which the Corporation is notified of by the Holder and has consented to such transfer in writing, which consent shall not be unreasonably
withheld, conditioned or delayed, which the Holder has provided a valid legal opinion in connection therewith to the Corporation and to
whom such Series B Preferred Stock Shares are legally transferred, provided that no transfer of such Series B Preferred Stock shall be
allowed, authorized or effective, unless transferred in accordance with, and such transfer is allowed pursuant to, applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.12 </FONT>&ldquo;<B><U>Maximum
Shares</U></B>&rdquo; means 10,000,000 shares of Common Stock, as equitably adjusted, as applicable pursuant to <U>Section 4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.13 </FONT>&ldquo;<B><U>Original
Issue Date</U></B>&rdquo; means the date on which the Original Series B Shares were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.14 </FONT>&ldquo;<B><U>Original
Series B Shares</U></B>&rdquo; mean those 1,000,000 shares of Series B Preferred Stock issued to the initial Holder thereof upon the Closing
of the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.15 </FONT>&ldquo;<B><U>Preferred
Stock</U></B>&rdquo; means all shares of the Corporation&rsquo;s issued and outstanding preferred stock, including, but not limited to,
the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.16 </FONT>&ldquo;<B><U>Person</U></B>&rdquo;
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.17 </FONT>&ldquo;<B><U>Preferred
Stock Certificates</U></B>&rdquo; means the stock certificate(s)&nbsp;issued by the Corporation representing the applicable Series B Preferred
Stock shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.18 </FONT>&ldquo;<B><U>Recapitalization</U></B>&rdquo;
means any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event
described in <U>Sections 4.2 through 4.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.19 </FONT>&ldquo;<B><U>Restricted
Shares</U></B>&rdquo; means shares of the Corporation&rsquo;s Common Stock which are restricted from being transferred by the Holder thereof
unless the transfer is effected in compliance with the Securities Act and applicable state securities laws (including investment suitability
standards, which shares shall bear the following restrictive legend (or one substantially similar)):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><B><I>The securities represented by
this certificate have not been registered under the Securities Act of 1933 or any state securities act. The securities have been acquired
for investment and may not be sold, transferred, pledged or hypothecated unless (i)&nbsp;they shall have been registered under the Securities
Act of 1933 and any applicable state securities act, or (ii)&nbsp;the corporation shall have been furnished with an opinion of counsel,
satisfactory to counsel for the corporation, that registration is not required under any such acts</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.20 </FONT>&ldquo;<B><U>Securities
Act</U></B>&rdquo; means the Securities Act of 1933, as amended (and any successor thereto)&nbsp;and the rules and regulations promulgated
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.21 </FONT>&ldquo;<B><U>Securities
and Exchange Commission</U></B>&rdquo; or &ldquo;<B><U>SEC</U></B>&rdquo; means the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.22 </FONT>&ldquo;<B><U>Series
A Preferred Stock</U></B>&rdquo; means the Corporation&rsquo;s Series A Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.23 </FONT>&ldquo;<B><U>Shares</U></B>&rdquo;
shall mean issued and outstanding shares of Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.24 </FONT>&ldquo;<B><U>Simple
Majority</U></B>&rdquo; means the holders of at least a majority of the then issued and outstanding shares of Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.25 </FONT>&ldquo;<B><U>Stated
Value</U></B>&rdquo; means $17.30 per share, as equitably adjusted, as applicable pursuant to <U>Section 4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.26 </FONT>&ldquo;<B><U>Stockholder
Approval</U></B>&rdquo; means (i)&nbsp;the approval by the stockholders of the Corporation, as required pursuant to applicable rules and
regulations of Nasdaq, of the issuance of shares of Common Stock issuable upon conversion of the Series B Preferred Stock; and (ii)&nbsp;such
other matters as may be required to be approved by the shareholders pursuant to the rules and regulations of Nasdaq or the SEC in order
to allow for the conversion of the Series B Preferred Stock into Common Stock pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.27 </FONT>&ldquo;<B><U>Stockholder
Approval Date</U></B>&rdquo; means the date that Stockholder Approval has been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.28 </FONT>&ldquo;<B><U>Total
Outstanding Shares</U></B>&rdquo; means the total number of outstanding shares of Common Stock of the Corporation then outstanding on
any date of determination, as set forth in the records of the transfer agent for the Common Stock, without factoring in any shares of
Common Stock issuable upon exercise of outstanding warrants or options or upon conversion of any convertible securities, including, but
not limited to any shares of Common Stock issuable upon conversion of the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.29 </FONT>&ldquo;<B><U>Transfer
Agent</U></B>&rdquo; means initially, the Corporation, which will be serving as its own transfer agent for the Series B Preferred Stock,
but at the option of the Corporation from time to time, may also mean any transfer agent which the Corporation may use for its Series
B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW THEREFORE BE IT RESOLVED</B>,
that the Designation is hereby approved, affirmed, confirmed, and ratified; and it is further</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>RESOLVED</B>, that each
officer of the Corporation be and hereby is authorized, empowered and directed to execute and deliver, in the name of and on behalf of
the Corporation, any and all documents, and to perform any and all acts necessary to reflect the Board of Directors approval and ratification
of the resolutions set forth above; and it is further</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>RESOLVED</B>, that in addition
to and without limiting the foregoing, each officer of the Corporation and the Corporation&rsquo;s attorney be and hereby is authorized
to take, or cause to be taken, such further action, and to execute and deliver, or cause to be delivered, for and in the name and on behalf
of the Corporation, all such instruments and documents as he may deem appropriate in order to effect the purpose or intent of the foregoing
resolutions (as conclusively evidenced by the taking of such action or the execution and delivery of such instruments, as the case may
be)&nbsp;and all action heretofore taken by such officer in connection with the subject of the foregoing recitals and resolutions be,
and it hereby is approved, ratified and confirmed in all respects as the act and deed of the Corporation; and it is further</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>RESOLVED</B>, that this
Designation may be executed in several counterparts, each of which is an original; that it shall not be necessary in making proof of this
Designation or any counterpart hereof to produce or account for any of the other parts hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page left intentionally blank. Signature
page follows.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, <FONT STYLE="font-weight: normal">the
Corporation has unanimously approved and caused this &ldquo;</FONT><U>Certificate of Designations of 180 Life Sciences Corp. Establishing
the Designations, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock,</U><FONT STYLE="font-weight: normal">&rdquo;
to be duly executed and approved this 30th day of September 2024.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><B><U>180 Life Sciences Corp.</U></B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><I>/s/ Blair Jordan</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Its:</TD>
    <TD>Interim CEO</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 12%">Printed Name:</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 28%">Blair Jordan</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">180 Life Sciences Corp.: Series B Convertible Preferred Stock Designation</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page 18</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NOTICE OF CONVERSION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Notice of Conversion is executed by the undersigned
holder (the &ldquo;<B><U>Holder</U></B>&rdquo;)&nbsp;in connection with the conversion of shares of the Series B Convertible Preferred
Stock of 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<B><U>Corporation</U></B>&rdquo;), pursuant to the terms and conditions
of that certain Certificate of Designations of 180 Life Sciences Corp. Establishing the Designations, Preferences, Limitations and Relative
Rights of Its Series B Convertible Preferred Stock (the &ldquo;<B><U>Designation</U></B>&rdquo;), approved by the Board of Directors of
the Corporation on September 29, 2024. Capitalized terms used herein and not otherwise defined shall have the respective meanings set
forth in the Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conversion</U>: </B>In accordance with and
pursuant to such Designation, the Holder hereby elects to convert the number of shares of Series B Convertible Preferred Stock indicated
below into shares of Common Stock of the Corporation as of the date specified below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date of Conversion: <U>__________________________</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Preferred Shares Held by Holder:
    <U>______________________________</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount Being Converted Hereby: <U>__________________________________________</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conversion Rate: <U>__________________________________________</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Stock Shares Due:<U>&nbsp;______________________________________</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preferred Shares of this Series Held After
Conversion: <U>__________________________________________</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Delivery of Shares</U>:</B> Pursuant to
this Notice of Conversion, the Corporation shall deliver the applicable number of shares of Common Stock (the &ldquo;<B><U>Shares</U></B>&rdquo;)&nbsp;issuable
in accordance with the terms of the Designation. If Shares are to be issued in the name of a person other than the Holder, the Holder
will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested
by the Corporation in accordance therewith. No fee will be charged to the Holder for any conversion, except for such transfer taxes,
if any. The Holder acknowledges and confirms that the Shares issued pursuant to this Notice of Conversion will, to the extent not previously
registered by the Corporation under the Securities Act, be Restricted Shares, unless the Shares are covered by a valid and effective
registration under the Securities Act or this Notice of Conversion includes a valid opinion from an attorney stating that such Shares
can be issued free of restrictive legend, which shall be determined by the Corporation in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If stock certificates are to be issued, they shall
be issued in the following name and to the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Authority</U>:</B> Any individual executing
this Notice of Conversion on behalf of an entity has authority to act on behalf of such entity and has been duly and properly authorized
to sign this Notice of Conversion on behalf of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1.5pt solid; text-align: justify"><I>(Print Name of Holder)</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">By/Sign:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 30%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Print Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Print Title:</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>ea021640301ex4-1_180life.htm
<DESCRIPTION>COMMON STOCK PURCHASE WARRANT TO PURCHASE 3,000,000 SHARES OF COMMON STOCK DATED SEPTEMBER 30, 2024, GRANTED BY 180 LIFE SCIENCES CORP. TO ELRAY RESOURCES, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THIS WARRANT NOR ANY OF THE SECURITIES
ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED AND SUCH SECURITIES MAY NOT BE TRANSFERRED
UNLESS COVERED BY AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT. THE ISSUER
OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED
TRANSFER OR RESALE IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant No.: <B>180-LIFE-2024-1</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares: <B>3,000,000 </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Date: <B>September 30, 2024</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>180 LIFE SCIENCES CORP.<BR>
COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Issuance</U>.
For value received, the receipt of which is hereby acknowledged by 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<B><U>Company</U></B>&rdquo;),
<B>Elray Resources, Inc.</B>, a Nevada corporation or its registered assigns (the &ldquo;<B><U>Holder</U></B>&rdquo;), is hereby granted
the right to purchase, at any time following the Stockholder Approval Date, and until the close of business on September 30<B>, </B>2031
(the &ldquo;<B><U>Expiration Date</U></B>&rdquo;), <B>Three Million (3,000,000)</B>, subject to adjustment upon certain events as described
in greater detail below, fully paid and nonassessable shares of the Company&rsquo;s Common Stock, par value $0.0001 per share (the &ldquo;<B><U>Common
Stock</U></B>&rdquo;). This Common Stock Purchase Warrant (this &ldquo;<B><U>Warrant</U></B>&rdquo;) is being issued to the Holder as
partial consideration for the purchase of the Purchased Assets (as defined in the APA), pursuant to the terms of that certain Asset Purchase
Agreement entered into between the Company and Holder on or around September 29, 2024 (the &ldquo;<B><U>APA</U></B>&rdquo;). For the purposes
of this Warrant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;</FONT>&ldquo;<B><U>Stockholder
Approval</U></B>&rdquo; means (i)&nbsp;the approval by the stockholders of the Company, as required pursuant to applicable rules and regulations
of Nasdaq, of the issuance of shares of Common Stock upon exercise this Warrant; and (ii)&nbsp;such other matters as may be required to
be approved by the shareholders pursuant to the rules and regulations of Nasdaq or the Securities and Exchange Commission in order to
allow for the exercise of this Warrant into Common Stock pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;</FONT>&ldquo;<B><U>Stockholder
Approval Date</U></B>&rdquo; means the date that Stockholder Approval has been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the sake of clarity and
in an abundance of caution, no shares of Common Stock shall be issued upon conversion hereof and no conversion hereof shall be made until
Stockholder Approval has been received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>2.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1&nbsp;The
exercise price per share of Common Stock shall be <B>$1.68 </B>per share (the &ldquo;<B><U>Exercise Price</U></B>&rdquo;)(subject to adjustment
upon certain events as described in greater detail below). The Exercise Price shall be payable in cash in immediately available funds,
or at the option of the Holder, via a cashless exercise, as discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2&nbsp;This
Warrant may be exercised at the Holder&rsquo;s election, to the extent the Exercise Price is greater than the Fair Market Value (defined
below), in whole or in part, at such time by means of a &ldquo;<B><U>cashless exercise</U></B>&rdquo; in which the Holder shall be entitled
to receive a number of shares of Common Stock upon exercise hereof (&ldquo;<B><U>Warrant Shares</U></B>&rdquo;) equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(A) = The Fair Market
Value on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a &ldquo;<B><U>cashless
exercise</U></B>,&rdquo; as set forth in the applicable Notice of Exercise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(B) = The Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(X) = The number of
Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Fair Market Value</U></B>&rdquo;
means, as of any particular date (i) the closing sales price per share of the Common Stock for such date on the Trading Market on which
the Common Stock is at the time be listed, provided the Trading Market is a national securities exchange, (ii) if there have been no sales
of the Common Stock on such national securities exchange Trading Market on any such date, the average of the highest bid and lowest asked
prices for the Common Stock on the Trading Market at the end of such date, (iii) if on any such day the Common Stock is not listed on
a national securities exchange, the closing sales price of the Common Stock as quoted on the Pink Open Market, the OTCQB or the OTCQX
for such date, (iv) if there have been no sales of the Common Stock on the Pink Open Market, the OTCQB or the OTCQX on such date, the
average of the highest bid and lowest asked prices for the Common Stock quoted on the Pink Open Market, the OTCQB or the OTCQX at the
end of such date or (v) if at any time the Common Stock is not listed on any domestic securities exchange or quoted on the Pink Open Market,
the OTCQB or the OTCQX, the fair market value per share as determined in good faith by the Board of Directors of the Company; provided,
with respect to clause (v) the Holder is entitled to object to the fair market value per share determined by the Board of Directors and
require, at the Company&rsquo;s sole expense, such determination to be made by a nationally recognized investment banking, accounting
or valuation firm that is reasonably acceptable to the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Trading Day</U></B>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Trading Market</U></B>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: on
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange,
the Pink Open Market, the OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act (as defined
below), the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares
being issued may be tacked on to the holding period of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;180 Life Sciences Corp.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock Purchase Warrant 180-LIFE-2024-1</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 7</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Procedure
for Exercise</U>. Upon surrender of this Warrant with the annexed Notice of Exercise Form duly executed, together with payment in cash
of the aggregate Exercise Price for the shares of Common Stock purchased, the Holder shall be entitled to receive a certificate or certificates
for the shares of Common Stock so purchased. This Warrant may be exercised in whole or in part. On any such partial exercise, provided
the Holder has surrendered the original Warrant, the Company will issue and deliver to the order of the Holder a new Warrant of like tenor,
in the name of the Holder, for the whole number of shares of Common Stock for which such Warrant may still be exercised. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional Shares or scrip representing fractional Warrant Shares shall be issued upon the exercise
of this Warrant, but in lieu of such fractional Warrant Shares the Company shall issue an additional share of Common Stock to the Holder
or pay the Holder the fair market value of such fractional share, as determined in the reasonable discretion of the Board of Directors
of the Company, in the Company&rsquo;s sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Reservation
of Shares</U>. The Company hereby agrees that at all times during the term of this Warrant there shall be reserved for issuance upon exercise
of this Warrant such number of Warrant Shares as shall be required for issuance upon exercise hereof. Any shares issuable upon exercise
of this Warrant will be duly and validly issued, fully paid, non-assessable and free of all liens and charges and not subject to any preemptive
rights and rights of first refusal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Mutilation
or Loss of Warrant</U>. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this
Warrant, and (in the case of loss, theft or destruction) receipt of reasonably satisfactory indemnification, and (in the case of mutilation)
upon surrender and cancellation of this Warrant, the Company will execute and deliver a new warrant of like tenor and date and any such
lost, stolen, destroyed or mutilated Warrant shall thereupon become void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>No
Rights as Shareholder</U>. The Holder shall not, by virtue hereof, be entitled to any rights of a shareholder of the Company, either at
law or in equity, and the rights of the Holder are limited to those expressed in this Warrant and are not enforceable against the Company
except to the extent set forth herein.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>8.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Effect
of Certain Transactions</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.1&nbsp;<U>Adjustments
for Stock Splits, Stock Dividends Etc</U>. If the number of outstanding shares of Common Stock of the Company are increased or decreased
by a stock split, reverse stock split, stock dividend, stock combination, recapitalization or the like, the Exercise Price and the number
of shares purchasable pursuant to this Warrant shall be adjusted proportionately so that the ratio of (i) the aggregate number of shares
purchasable by exercise of this Warrant to (ii) the total number of shares outstanding immediately following such stock split, reverse
stock split, stock dividend, stock combination, recapitalization or the like shall remain unchanged, and the aggregate purchase price
of shares issuable pursuant to this Warrant shall remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;180 Life Sciences Corp.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock Purchase Warrant 180-LIFE-2024-1</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 7</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2&nbsp;<U>Fundamental
Transactions</U>. If at any time the Company plans to sell all or substantially all of its assets, or engage in a merger or consolidation
of the Company in which the Company will not survive (other than a merger or consolidation with or into a wholly- or partially-owned subsidiary
of the Company)(each a &ldquo;<B><U>Fundamental Transaction</U></B>&rdquo;), the Company will give the Holder of this Warrant advance
written notice at least thirty (30) days prior to the planned closing of the Fundamental Transaction. If this Warrant or any part thereof
is not exercised by the Holder prior to the date of the closing of the Fundamental Transaction, this Warrant or any unexercised portion
thereof, shall expire and terminate effective upon such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Transfer
to Comply with the Securities Act</U>. This Warrant and the Warrant Shares have not been registered under the Securities Act of 1933,
as amended, (the &ldquo;<B><U>Securities Act</U></B>&rdquo;) and has been issued to the Holder for investment and not with a view to the
distribution of either this Warrant or the Warrant Shares. Neither this Warrant nor any of the Warrant Shares or any other security issued
or upon exercise of this Warrant may be sold, transferred, pledged or hypothecated in the absence of an effective registration statement
under the Securities Act relating to such security or an opinion of counsel satisfactory to the Company that registration is not required
under the Securities Act. Each certificate for this Warrant, the Warrant Shares and any other security issued or issuable upon exercise
of this Warrant shall contain a legend in form and substance satisfactory to counsel for the Company, setting forth the restrictions on
transfer contained in this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally or sent by certified,
registered or express mail, postage pre-paid. Any such notice shall be deemed given when so delivered personally, or if mailed, two days
after the date of deposit in the United States mails, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">180 Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attn: Blair Jordan<BR>
3000 El Camino Real, Bldg. 4, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Palo Alto, California 94306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: blair.jordan@highmontadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Holder, to its address appearing on the Company&rsquo;
records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any party may designate another
address or person for receipt of notices hereunder by written notice given at least five (5) business days prior to the date such change
will be effective, given to the other parties in accordance with this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Supplements
and Amendments; Whole Agreement</U>. This Warrant may be amended or supplemented only by an instrument in writing signed by the Company
and the Holder hereof. This Warrant contains the full understanding of the parties hereto with respect to the subject matter hereof, and
there are no representations, warranties, agreements or understandings other than expressly contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;180 Life Sciences Corp.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock Purchase Warrant 180-LIFE-2024-1</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 7</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. This Warrant shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed
by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State.
Any action brought by either party against the other concerning the transactions contemplated by this Warrant shall be brought only in
the state courts of the County of Dover, Delaware or in the federal courts located in the County of Dover, Delaware. The parties to this
Warrant hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense
based on lack of jurisdiction or venue or based upon <I>forum non conveniens</I>. Each party hereby irrevocably waives personal service
of process and consents to process being served in any suit, action or proceeding in connection with this Warrant by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Warrant may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original,
and all such counterparts shall together constitute but one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Descriptive
Headings</U>. Descriptive headings of the several Sections of this Warrant are inserted for convenience only and shall not control or
affect the meaning or construction of any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Assignability</U>.
This Warrant or any part hereof may only be hereafter assigned by the Holder to an affiliate thereof executing documents reasonably required
by the Company, subject to applicable law. Any such assignment shall be binding on the Company and shall inure to the benefit of any such
assignee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16.&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
By acceptance hereof, the Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant have restrictions upon
their resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>[Remainder of the page intentionally
left blank; signature page follows.]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;180 Life Sciences Corp.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock Purchase Warrant 180-LIFE-2024-1</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 7</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Company has executed this Warrant as of the Warrant Date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>COMPANY:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>180 Life Sciences Corp.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/ Blair Jordan</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:&nbsp;</TD>
  <TD>Blair Jordan</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Interim CEO</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;180 Life Sciences Corp.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock Purchase Warrant 180-LIFE-2024-1</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 7</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF EXERCISE OF WARRANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby elects
to purchase, pursuant to the provisions of the Common Stock Purchase Warrant 180-LIFE-2024-1 issued by 180 Life Sciences Corp., a Delaware
corporation (the <B>&ldquo;<U>Company</U></B>&rdquo;) and held by the undersigned, _________ shares of Common Stock of the Company. Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[ ] in lawful money of the
United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[ ] the cancellation of such
number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2.2, to exercise this Warrant with respect
to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby represents
and warrants that the undersigned is acquiring such Shares for his own account for investment purposes only, and not for resale or with
a view to distribution of such Warrant Shares or any part thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Date: ________, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">WARRANTHOLDER: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Signature:___________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Print Name:___________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:___________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Address:___________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name in which Shares should be registered:___________________________</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ea021640301ex99-1_180life.htm
<DESCRIPTION>PRESS RELEASE DATED OCTOBER 3, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>180 Life Sciences Corp. &ndash; Corporate Updates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Announcing Acquisition of Advanced Gaming Technology
Platform, Positive Progress on <BR>
Legacy CBD Formulation, and Strengthened Balance Sheet </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Palo Alto, CA, October 3, 2024</B> &ndash;
180 Life Sciences Corp. (NASDAQ: ATNF) (the &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>180</B>&rdquo;) is pleased to provide a corporate
update covering several key initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>CORPORATE UPDATE HIGHLIGHTS:</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><U>Company shifts
                                            focus and enters global iGaming market </U>- completes a significant technology acquisition</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><U>Expected Compliance
                                            with Nasdaq Listing Rule 5550(b)(1)</U> &ndash; Company expects to meet Nasdaq continued
                                            listing requirement which requires maintenance of stockholders&rsquo; equity of at least
                                            $2.5 million</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><U>Positive Study Results on CBD Pill Forms</U> - 180 achieves
promising study results showing faster absorption and improved bioavailability for its new CBD pill formulation</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><U>Strengthened Balance Sheet</U> &ndash; Company enhances its
financial position by settling meaningful legacy liabilities at substantial discounts, improving its flexibility for future growth while
at the same time resolving certain legacy litigation matters</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We believe that this acquisition is a pivotal
moment for the Company,&rdquo; said Blair Jordan, Interim CEO of 180, who continued, &ldquo;We believe this transaction not only satisfies
Nasdaq&rsquo;s minimum stockholder equity requirements for continued listing, but also sets the stage for the Company&rsquo;s entry into
the dynamic and fast-growing global iGaming industry. Our new Gaming Technology Platform offers a competitive edge with its seamless integration
of blockchain and FIAT technologies, providing a unique solution in the marketplace.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>ACQUISITION OF IGAMING TECHNOLOGY PLATFORM:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is thrilled to announce the acquisition
of a comprehensive intellectual property package, consisting of a complete &ldquo;back-end&rdquo; technology solution for online casino
operations (collectively, the &ldquo;Gaming Technology Platform&rdquo;). The acquisition,marks the beginning of a strategic shift toward
the rapidly expanding iGaming industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Gaming Technology Platform includes advanced
components designed to support online casinos using blockchain technology. These components are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><B>Blockchain Casino Operations Back-End</B>: A robust infrastructure designed to support casino game
programming through secure and scalable server/cloud solutions, database management, and blockchain payment processing.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><B>Blockchain to FIAT Seamless Exchange Technology</B>: A proprietary system allowing players to deposit
and withdraw using cryptocurrency while maintaining FIAT-based wallets and gaming sessions. We believe that this cutting-edge technology
offers a significant competitive advantage in the growing blockchain casino market.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><B>Blockchain API Technology</B>: A sophisticated application program interface (API) that facilitates
reliable FIAT-to-blockchain and blockchain-to-FIAT payment gateways, supporting credit cards, e-wallets, and multiple cryptocurrencies
while enabling blockchain-exclusive online casino operations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><B>Player Account Management</B>: A secure system for managing player accounts, including registration,
login, and player profiles, alongside know-your-client (KYC) and anti-money laundering (AML) compliance features.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><B>Loyalty Systems for Blockchain Users</B>: A customer relationship management system designed to foster
player loyalty and enhance the lifetime value of each customer by catering to blockchain users.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><B>Affiliate Tracking System</B>: A tool to monitor traffic, registrations, and referral sources, allowing
for scalable growth through affiliate partnerships and the distribution of referral fees and royalties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued 1 million shares of a new series
of Series B Convertible Preferred Stock (convertible into 40% of the Company&rsquo;s then outstanding shares of common stock upon stockholder
approval for such issuance) and warrants to purchase 3 million shares of common stock of the Company upon stockholder approval in consideration
for the acquisition of the Gaming Technology Platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With this acquisition, 180 plans to undertake
a rebranding and preparation phase, positioning itself to enter the global iGaming market. According to a report by Statista, the global
online gaming sector is estimated to reach $97 billion in 2024 and is projected to grow to nearly $133 billion by 2029.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Management believes the purchase of the Gaming Technology Platform positions the Company to capitalize on this significant market opportunity
and create value for shareholders. In particular, the Gaming Technology Platform purchased by 180 uses blockchain technology, which we
believe is rapidly emerging as the preferred technology platform for customers due to the high levels of transparency, fraud reduction
and ease of access offered to clients. To become fully operational, the Company will be embarking on the acquisition or development of
a &ldquo;front-end&rdquo; customer interface.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional information regarding the terms
of the acquisition is described in greater detail in the Current Report on Form 8-K which the Company filed today with the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>NASDAQ MINIMUM SHAREHOLDERS EQUITY REQUIREMENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that the acquisition of the
Gaming Technology Platform enables the Company to satisfy Nasdaq&rsquo;s continued listing stockholder equity requirement as of September
30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify"><I>https://www.statista.com/outlook/amo/online-gambling/worldwide</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq has provided the Company until October
15, 2024 to complete all public filings which will demonstrate the Company&rsquo;s compliance with Nasdaq&rsquo;s stockholder equity requirements.
While the Company believes the acquisition has cured the Company&rsquo;s prior stockholder equity non-compliance, the Company hasn&rsquo;t
yet received official word from Nasdaq regarding such compliance, and Nasdaq could require additional information or continue to deem
us in non-compliance, which could result in the delisting of our common stock and warrants at the end of the extended compliance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>POSITIVE CBD PILL FORM STUDY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to its new gaming focus, 180 plans
to retain its current portfolio of biotechnology intellectual property. The Company is actively exploring opportunities to maximize the
value of its biotechnology assets through various corporate transactions, including joint ventures, partnerships, and outright sales.
Management remains committed to optimizing the value of all assets for the benefit of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company would like to highlight its most recent
study results, involving the Company&rsquo;s Synthetic CBD analogs (&ldquo;<B>SCAs</B>&rdquo;), which are man-made derivatives of cannabidiol
(&ldquo;<B>CBD</B>&rdquo;). 180 aims to develop SCAs that are safe, non-psychoactive and formulated to improve efficacy and bioavailability
&ndash; a real alternative to unregulated CBD. 180 previously announced results from a study comparing two new pill forms of CBD with
the U.S. Food and Drug Administration (FDA)-approved liquid CBD drug, Epidiolex. The study involved 12 participants and found that one
of the pill forms absorbed CBD faster and reached higher levels in the body than Epidiolex, while the other pill form was similar to Epidiolex.
Both pill forms were well-tolerated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CBD, which in certain studies has been found to
be beneficial for conditions such as epilepsy, inflammation, PTSD, and pain, is typically taken as a liquid, which can lead to inconsistent
absorption. The new pill forms, developed with &ldquo;ProNanoLipospheres&rdquo; technology, aim to solve this issue by improving uptake.
These results suggest that solid CBD pills could offer a more reliable and convenient option for patients, with potential highly commercial
benefits in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>STRENGTHENED BALANCE SHEET</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to completing the acquisition of the
Technology Gaming Package and advancing the Company&rsquo;s SCA program, management of the Company has also been successful in settling
a variety of legacy debts and litigation matters. The debt settlements have helped de-leverage 180&rsquo;s balance sheet through highly
favorable, low-cost settlements. In addition, the Company has successfully resolved certain longstanding legacy litigation in a manner
that we believe is highly advantageous, marking a significant milestone in our ongoing efforts to strengthen our position. We believe
that this favorable resolution removes a major overhang, allowing the Company to focus fully on its core operations and strategic growth
initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About 180 Life Sciences Corp.</B> is a publicly-traded
company that focuses on developing new technologies across multiple sectors. With its current portfolio of inflammation focused intellectual
property and its recent acquisition of the Gaming Technology Platform, the Company believes it is positioned for growth in both the biotech
and iGaming industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-Looking Statements:</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release includes &ldquo;forward-looking
statements&rdquo;, including information about management&rsquo;s view of the Company&rsquo;s future expectations, plans and prospects,
within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act
of 1995 (the &ldquo;Act&rdquo;). Words such as &ldquo;expect,&rdquo; &ldquo;estimate,&rdquo; &ldquo;project,&rdquo; &ldquo;budget,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo;
&ldquo;should,&rdquo; &ldquo;believes,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue&rdquo; and similar expressions
are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties
that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without
limitation, the ability of the Company to maintain the continued listing of the Company&rsquo;s securities on The Nasdaq Stock Market,
including that the Company is not currently in compliance with Nasdaq&rsquo;s continued listing standards, and is subject to delisting;
the ability of the Company to build out a front end for the Gaming Technology Platform, and the costs and timing associated therewith;
the ability of the Company to generate revenue from the Gaming Technology Platform, including timing and cos thereof; our need for significant
additional funding, the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; the review and
evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of
strategic transactions; the outcome of potential future strategic transactions and the terms thereof; our ability to commercialize our
drug candidates, if proven successful for treatment in trials; risks regarding whether the administrative processes required for the
issuance of patents will be completed in a timely manner or at all; risks regarding the outcome of pharmaceutical studies, the timing
and costs thereof, and the ability to obtain sufficient participants; the timing of, outcome of, and results of, clinical trials statements
regarding the timing of marketing authorization application (MAA) submissions to the UK Medicines and Healthcare products Regulatory
Agency (MHRA) and New Drug Application submissions (NDA) to the U.S. Food and Drug Administration (FDA), our ability to obtain approval
and acceptance thereof, the willingness of MHRA to review such MAA and the FDA to review such NDA, and our ability to address outstanding
comments and questions from the MHRA and FDA; statements about the ability of our clinical trials to demonstrate safety and efficacy
of our product candidates, and other positive results; the uncertainties associated with the clinical development and regulatory approval
of 180 Life Sciences&rsquo; drug candidates, including potential delays in the enrollment and completion of clinical trials, the costs
thereof, closures of such trials prior to enrolling sufficient participants in connection therewith, issues raised by the FDA, the MHRA
and the European Medicines Agency (EMA); the ability of the Company to persuade regulators that chosen endpoints do not require further
validation; timing and costs to complete required studies and trials, and timing to obtain governmental approvals; 180 Life Sciences&rsquo;
reliance on third parties to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies;
the ability to come to mutually agreeable terms with such third parties and partners, and the terms of such agreements; estimates of
patient populations for 180 Life Sciences planned products; 180 Life Sciences&rsquo; ability to fully comply with numerous federal, state
and local laws and regulatory requirements, as well as rules and regulations outside the United States; current negative operating cash
flows and a need for additional funding to finance our operating plans; the terms of any further financing, which may be highly dilutive
and may include onerous terms, increases in interest rates which may make borrowing more expensive and increased inflation which may
negatively affect costs, expenses and returns; statements relating to expectations regarding future agreements relating to the supply
of materials and license and commercialization of products; the availability and cost of materials required for trials; challenges and
uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory
approvals; uncertainty of commercial success; the inherent risks in early stage drug development including demonstrating efficacy; development
time/cost and the regulatory approval process; our ability to attract and retain key personnel; changing market and economic conditions;
competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable
laws and regulations, including global health care reforms; expectations with respect to future performance, growth and anticipated acquisitions;
expectations regarding the capitalization, resources and ownership structure of the Company; the ability of the Company to execute its
plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets
for the Company&rsquo;s potential drug products; the outcome of current litigation involving the Company; potential future litigation
involving the Company or the validity or enforceability of the intellectual property of the Company or lawsuits alleging that we have
violated the intellectual property of others; global economic conditions; geopolitical events and regulatory changes; the expectations,
development plans and anticipated timelines for the Company&rsquo;s drug candidates, pipeline and programs, including collaborations
with third parties; and the effect of changing interest rates and inflation, economic downturns and recessions, declines in economic
activity or global conflicts. These risk factors and others are included from time to time in documents the Company files with the Securities
and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, and including the Annual Report on
Form 10-K for the year ended December 31, 2023, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and future SEC
filings. These reports and filings are available at www.sec.gov and are available for download, free of charge, soon after such reports
are filed with or furnished to the SEC, on the &ldquo;Investors&rdquo;, &ldquo;SEC Filings&rdquo;, &ldquo;All SEC Filings&rdquo; page
of our website at www.180lifesciences.com. All subsequent written and oral forward-looking statements concerning the Company, the results
of the Company&rsquo;s clinical trial results and studies or other matters and attributable to the Company or any person acting on its
behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance
upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this
press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance
or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake
or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any
change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as otherwise
provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Blair Jordan<BR>
Interim Chief Executive Officer<BR>
Email address: bjordan@180lifesciences.com</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex3-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G ,\# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>atnf-20240929.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /aw5s7xRiXgen8uLYXBcWauDGcPtwJF9OYkhuWp0bekajy8rYVyRNyeAJYv24eUH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ATNF="http://180lifesciences.com/20240929" elementFormDefault="qualified" targetNamespace="http://180lifesciences.com/20240929">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://180lifesciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240929_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240929_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240929_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>atnf-20240929_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20240929.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240929.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240929.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>atnf-20240929_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20240929.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20240929.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>atnf-20240929_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20240929.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240929.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240929.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45741594474800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 29,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES CORP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg. 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,%=:)(=@($AXNO^F+X=$G!/@'@+<@GO_1P7E#=5T,I)B1Z0Y&]3,1G&I133
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MDF)SRRC,%W,"_+X60K_MF'=HY2O0R;]02P,$%     @ PT-#6>#T.HFJ @
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M?P%02P$"% ,4    " ##0T-9!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,-#0UFT&@AL[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( ,-#0UF97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ PT-#6;88Z0O6!   #A4  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( ,-#0UG@]#J)J@(  # ,   -              "  1D-  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ PT-#69>*NQS     $P(   L
M ( ![@\  %]R96QS+RYR96QS4$L! A0#%     @ PT-#6:K$(A8S 0  (@(
M  \              ( !UQ   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M ,-#0UDD'INBK0   /@!   :              "  3<2  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,-#0UEED'F2&0$  ,\#   3
M              "  1P3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  &84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0216403-8k_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180lifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20240929.xsd</File>
    <File>atnf-20240929_def.xml</File>
    <File>atnf-20240929_lab.xml</File>
    <File>atnf-20240929_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0216403-8k_180life.htm">ea0216403-8k_180life.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0216403-8k_180life.htm": {
   "nsprefix": "ATNF",
   "nsuri": "http://180lifesciences.com/20240929",
   "dts": {
    "schema": {
     "local": [
      "atnf-20240929.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20240929_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20240929_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20240929_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0216403-8k_180life.htm"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 28
   },
   "report": {
    "R1": {
     "role": "http://180lifesciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0216403-8k_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0216403-8k_180life.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "auth_ref": []
    },
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20240929",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20240929",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001213900-24-084859-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-084859-xbrl.zip
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M_0_>['/(!\WNP#0[E4Z3J=1T-PS)=,_N"Z782J)"D2A)AN3?K^2/8,>ZML.
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M*,&-@8TU?('HE 5X^QO>E9%^8-H"UFV(0=H=);8QLAM!-DCL9L2O[E@.;5M
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MZOQR S#;N/0P=$%Q IB#+TE*O5]2)O<D2>0S&IAV=R@VL6M:8,,F+TUE4,2
M]D!F5 3*0\+!YN)1SL[%-*EG92MZG_ T;+?Q4XJ#1<ATV),B%89DG">2*H^&
M=##44+JF![!J<F/(@B+&[@UD1<N1TON'Y(+.>R%2ZOP 8MBTXY&+ H2C[JP+
M#:'V"<9EG$8XT5XNQ3;SYY4.K6M 0+LF) UA4*! [D!8=$#!C KQ"LQ_".;]
M<*DH_<#2L&I'I90%"(KIK0L3J?<"R?F&\YIK>,2!I:XPZ3);< +I@@"EPUSC
M>20MKX'B:02ZH%F</<LU#C<;R_-'=HDK-B!S!1/F_B!8 $R9#&@9DCJDA5Y:
MOOB5@&9R80E8'5/FE@"[R3H%=4U )%B- 33LM&J=CQ<BSD7/Q'%R1>=D^P=Y
M!NO5T+EE K!9A\(0!42%W1F 12Y&2HV$W L8=SQ>8?X\B:..H:(I=(L&9+3.
MAJD*" [ &D!'KD:3JW.?(\D4;Z_F M1X$>LU>AV4@'JWL'38KC,#B -"I]TA
M0) (0O4HGR!=T8CQ-:L\[G#.-J(#?#YG<WB&TA'E%JI>5:BCU1H2$&!]? *8
MU4)?Z6=2$)-KJU4!2);@A;BS^5R<J#3_YSJFY BLOU7KEJX6NW6F+,* 2(+=
M ?SDRE?%!R1CT"T-!9KQ'E4=^X=FW!>:<=#0C%\"S?2)!0+-\1Y5/?8/S7%?
M:(Z#AN;X1="(AO?:UYR+C[=\RIYL#V>#2B_(-*U:@=G)PL.EX:T+%AD@YS,R
MQ"<F:F)UR^\X>XQI!$^9(;D78 #35FH,;7CHV UV\5-.B(LXKWV-GI1W?DD*
MF9]>IF[2WL5H37B0U(UU=BY:[1.).Y9F./EOO&Z]$+>+O>!A-6R%I*8,#Q6;
MO2Y@= P203XNK'-<Y0\:UJ5DQGYGOS;;;)4_,5=W!@&!S5$SN86^>Z)%KIM9
M,LH)!GJ$^FYGC6PQ5;9Q95\83=PTU&AA];T6&A]?9)EQ+[F[9Q1^0* I<=72
MD+FBM<W]0;0X8,IL=25#2N?I;KS,^I7:N^_*/F<CNVFG',B+'4&TKNFF,4P7
M^QVWYF<>9^+(,L_,AN:_\MB>&P1TKEJYU6;1XE91$*W?YJR1$4AK45WL&(L)
M2^(HSF*Z?"\N/GF,;;6RB5P! 1LL:&@J@D !M-7(Y%(*4:%T#,$=)Q)"(AI"
M+0*4R1[Y[6)A'>W;Q*Z@Z#9<P $K@X"DTYX)BP@81I4(I$.0BO&+S56:;@C?
M"QY+B">$0/, 2 U]B#A!)CNATH$^V9J0:"/&Q^>C\6P:9XTD=':)LS$),%>.
M2,;^(-@ 3)DLJ'TR(^'1^,?93ZB(<MS\-VS*L4SH/WE>S5@"9)^RJEQ!T&*Q
MX, B"0(%V)=)PPU#N11IK8_L5#6SENH8^UT!8+55-'UM9Q"-;G/4^/+7VMI3
MEW^QC>Z%*0(L2+#+7'?]-I-F]U_5!(% B['&14DN1876QX*$W9"U[)X$++U-
M I8=DX!EB). 9=])P-+;)* XK$X1(OJEVUD2+S&0G+!5[1J*%LLF'Q9I4*C
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M7W!R92YX;6S5G=]WVC84Q]]WSOX'CST3?J3=EJQ93TK##F=MDP76;GOI$;8
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M1A3:PSGA_$VJK<LZ..P<&$)IUV$%<*E&%-HW<ZJF=KS[5<DG,]OLH0U1]Q2
MTJ_#.M^@9IPH+)^W\J]W%09#4&(-?F5$'?A[U6*]'26.W;J0]65?)$1Y\(?L
MH0&HQP96O^(3A^#6S*C:G75ESCCW0VLXJDM!PX&;"$/5XUR(=]ZJ$+P.[]E!
MP=<AY2U3B+,!+1US%O>Y),'Y_9X9%'0=\ML2?2B<WQ#QH-*%B5=W2L:4NN<Z
M>GO^ 3(L8 70V-0A\SV*"<X=B><W7VY>AIF:[*\ 6/^"]R6"Y: QJD-2#"&
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MC=,6?CAF7I>>. JC 7M<><VZGH^H[L6 ]XD _'6!^[#8&XS\A <B',7^A,6
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M^47>3I(#TM0Z-FAJ=UUBEC'."0,$HNM)*5-*?<+(8 H26B"]:+4N<+$C:77
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M9$*27%X*'.V]JO.> F3(IB2#\[TN9KU%=-,5J=0(<QTU4UX8I-(B2!$W\GB
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MV:F**&X\8I[=0G%9AC(-8=4O#_""F@Y_$@KQ=0_1 )US]09<-D'2Q^J]= P
M0*F,3&C;<3R2WEVXMWV0A7S5-]Q] /?!<7$ FK1'.'-,)9'615%]])(T29#N
M=>P/ZG4PS +K(H\F,@4 O:4K&#\<:9 *V[),+>(U(MKG46CZUVHA=5ZKHMN-
M+'(/\4@6IC:]42GI#/A/U3DPVK=\E.C>@UF\J'!&T(*HLRI*(!QK4*JX(*:J
M/2>1U^M1C?\N!V"I]'\!&CAE2L@\-#NFA&NG$@'%2JK(;OFWG\7$Y?V2WA5M
MAS69.6G[#2?GATP;7>8[AJ]<7<RNB$]M*_1MN71M_]C)=*E8^-W&JBT![&X
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ME=:5EB"MH8CB*7><G1Z$-143+QE1 0(V"I2%GA([KKFN%6*&P3X'O#-)<SE
M](5[%0A%Y55A]6"%-'9O.D.M_-':UDQ*O7_,^B:A(T=AA$V^*^Q-&)*3.#5U
M_7J!()>SPQ0<[#6J&GN3LYJ@XBN@Q*G]CW@?^K6HVG"^AV',N^AUC-IAIB"[
M):,-!->Y<KI>=F.[I8, <\V_);-K9IF=>:U^N *S3-,3D!R2S+MOX$>/4-HY
M1P/R  >Q7ZZRH]F00:#(H%%8')P8"*_X1>I84X 7-T/8@:6TYGWX7GPEOQ@%
M*I<!5U=V!JJT;MJ*IBTF(;4@DJF\44B=C[GTB'3X"(L/4.DS%?YC1VB@E\0C
M'Y[VX&&-+,D),&99!2_@IB_[(A;INISLNMABZU)%"]0PF1 @PAQUJJ8"\;(I
M8N<P+COBU,8RFRE&][SP8S&6Y;X#6E@K"$94F!W)(#;A.O4:-MV5Q8[Q,5E(
M6,8EQ[E<31.\(L,XPE'"?&.0*-/KD1G>P>%CV=,7[4BURKNR[(ZC(8?QTMCB
MGCRX$HW45&PLVK&'?#Y9TF(]'H^K -IJ+[S61FO8,J<*5E1,G5/U8B&SRU&I
MQUIF.,((VV$H;Y]:R6RVH(-,XJ'@JG]:/DHJ2)MX3%(&(C-3N]AQ9@[-."!&
M>8BFU+W'!-64IVF)@JNZ<97]A9$F5+%"YSMS;R"%R+:OJ!RI0:</D+$I--4M
MI-,;MP%OC(:X!7(F8X"-Y&FJWO,<5JG8J=)JO$".+_>:K9:&F)+9BI+GY!-4
M'5)2;9FE64VXG(X7@9J+CN^.K'RG:#"8Z/K5)LX^ELS)-$O@<5K(6K;4N']W
MAG813ML8QM+D\M2XF[Z&)VF1Z:V)YWA:'__:GM;MA^QI_0F0].+XQ4GK\OWY
MX<7W6<*W%U;G+.;,TIME/*D),XD7%@CEB[(B0B#C<%W, B6AR97*D Y%D9%O
M5 Z2J:8M;='G?E?%6<KV+^H!9/4C##2EX=+VB_?#7+_%"<V< ZOK[DZ;G;_9
MMKZ)$[QX)0MXQZ<\,X5N\B)/#HR$DMFS4G,!ES"9G8Z/#MG%_O'AR?[A!=L_
M/3^KKN83+LUW,=D+L[Z_C[%OV>CSR6ZAV]ZLJ%&:<?6V\U?OK3#U]M;C=;RR
MO8B]@L%XD*EKM\*&<U:AK=K\\ +UV,9"3VW^<=N&Z'+7 ]T:^M"LWSI@%C3W
MBV,KX,8EZH>%Z''+B^1) B5@OP\J MP+<$>05^D4HW#1:3_'4?2C\NU;Q<1I
M(7'.:AY_76X^+6>CW;NBI3I;N%S!MCLMCM/;!;*XC1FVX(E"I_JO+75F%OF-
M[KJ,$)]HB?W&O7G"C@_HEX^UQ\\_FLS\F-9&KXE7-_6K]T>C\:?6N_/WZZV7
M[_\Y]\?]V&ML3?CD]/7GJ^-VB[^*FY>MX5%X%;SX%+__E)RWZ\%1ZQ_WB/N?
MOYQ_.;M>_[0YOAHWSE]<;OVSWQ\U/W5ZFU'T*GDM-M[!#=P/]\?CRT;WY,W^
MZ,C=^.S>!-&'>MR>[+]X]_Y%J_EV_7W_K?LB>%GCS[^,W@^?>V].SO^^?+__
M^<_#3\='CP>]K89[=;%]<K"UT1B].XG=S</QR8OU"_YEN[G_UW#]^'W0./VS
MGUS]\[CW8O3/R["Q\[^]_M'E^.*JNW/^X6;\]M5.,/FK]?>7R?X_;]M_G@Q>
M?19G)Y]/^R\&1V[[^9>S;GW[[\W/GOO/]N>=H_J79/.F_7YG<Q*[G=,_F]<G
M6R?;K^,7KT[<T5_#T_W)>/VJ=7KU_/SU1?=H//EPXH_/W]:.;H:=F^.CUUNM
M][W7UU_ZW=>G7;ZS'7Z^>G]S>/7F^.6!/_C?M]WZG\'?QY_^^GO#];YT=B[?
MU38^))[W^CHXJ+==O]MY)D]GO1VZ$_S93P;^WO\'4$L#!!0    ( ,-#0UGD
M1*98I)0  .0/!  <    96$P,C$V-# S,#%E>#(M,5\Q.#!L:69E+FAT;>R]
M:U/C5K<N^ITJ_H-.SEZKH$I-H"]).IU%E0%WXKUHZ(U)\KZUZWR0K6FCM"PY
MND![_?HS;O,B60;30<: =ZW]IK%E:6K.,<<<EV<\XY??+C^='FYO_?);MW,"
M__7P__URV;L\[1[^\CW_%[[]7K[^Y>C\Y-]>__+?I]W_^FZ4)L7/WL'^M/ N
MHXG*O3-UXUVDDR#Q^0/?ZZLL&GT'/X2??M:_*]37XE401^/D9R^+QE?%!V\2
M9.,(_MS_[K#[R]'AUZMH$!7>Z[V#7[X_@G%\KMW!N?P_DT$^_0"_D7\T7B\C
M_>FND3H#@4OW/WCN4(<J*53VW2$\J]/O=R^]S[]?'/_6Z7>]SJ\7W>ZG[MGE
MK4^_<YZ6??H2;_I@SSH)"A7"3Z:%F@Q4YKU^[WNO]U^_]9_?JQ[-O" )O<XD
M3<9>-\Z"F7>A\K3,AGBK7C+<6]%+_]([#'+X21RK[)?O>X?/;ZIAGI_?2QW\
MM.^=1B/E]8>12D!HO.,TFZY6:#Z#M%X%^>/*#3SM_WGUROL8J3C\V?L<C-4'
MN.7?)4X*/-E[]4H.FE].>G]45?JK(IW^[/TP-4?"JT%:%.E$/AND6:@R\]E1
M' R_> =[[V" >1I'(0QH_HR8%N:4@ '^\CT\M.'Y@TP%7UX-U"C-8)!3&O02
M8[KO$YV)^1YGAB=C?GT&:1Q^\R(569#D\"(PQ'(Z5=D0)*)Y_>PH'W$0EYVC
MTZYW_M$[/C^[A%.T_\CCJ4T*#^^X>WK:_]PY[IW]^E_?[7]'?W_NG)SHO^^]
MNVZBL+C"2_?_PPCV,(WC8)J# .I_?4>"\\OEA7[ M<J*:!C$>M @G/!SV ?C
M+"V3$&^19F!7C0<[K_??^J_?_.2_?O=N]SLM@)<G,,WX)F?_]=UKD-Z/,.?N
MX%^-@DD4SWZ^:_AT;1[]C^*WO662V6*ZN.P=PS3V]G@<)]V/O;/>9>_\K,^J
M \>!%N>),] &>]$HGA6-^Z ^.OB?BV]<DS^OHD(]\$)8:5W-!#8][Q],R6UB
MNG#PSM[YCX>3A.\.#_8.]FZ=1WGL3P_[V!,UBI*HB-(DO_WQ*YR)MB1^-0)I
MGK?95>NE_+7VO_RMZUU>=,[ZG6,\ CYX%]WCWF7G=+W/@A\V9\':G04/J?5>
M+]+_#_@,[:"%7B?/57%OC?^0[_O#T]'RC:OUNO75@C4J)[!6IU$PB&(XH]6S
M6+ UV&EO6E^[[M=A7(:;C?8 B_6V]<4Z2Y-7L$[P!L$@5FNP9#\^R:VV,897
M8VG] PM8F\#'YV?]WDGWHH,&\%J;O3\]H-G;LF?RW$1U):KNS0K,WN,TR:-0
M90&&.5:FU[]#V7V":KQQD=JW=B]) ZC,NPR^JOR#]SE+><$>]21^J"5\K,W5
MOJ5[7ES!HG6&SV:I-D;3VIU$CVHT_:%MIM/S?N_LUXVUM-D'S]HB>[L*BRQ.
M\R@9;XZ+!UFO]HTS62_O1,41S$L$/Q[,!"3V'!;QL79:^^99\\H9I-9S6+PU
MV('MQRAOVX&$''U62[I)W:]=$O0Q;7!M@E]T/U]T^]VS2XI;]KW.V8GW9^?B
MHG-VV>OV$<37[YZ>=B_6VD9_WV8B?[-/'GN?K$3/OEN!C7Z>C8,D^I_5!DT;
MQO'^Z>R5QI5: 5"@+*[2+"IFSV&9UF!OM6^57ZB_RRA3H8>I"7B#1PV</O4-
MM@J  "[4*(Z&Q7-8J#788N]:7[/3J(C&F\/K'Z[3#ZO86]W)-$YGZG'A;0?[
MSV=W_?BBD*0/MG*/M<E^:GVYCK+TB\J>QRJMP?YZWSX:(BIB]2R6Z[$VU<%^
MZXO4@U''L1H691 C7F4*,_*H/MASVF,'[4<X^FI89H2K]R[4-%/HB06/CF,Y
M>$+U;\TKUW[$XR0H K@TG7SP>@D&66G9O'XYG<:1"A]U^=X^HSW8?B0$S']&
MD-5V(.6T_@RR+$@>N_#EP59T$ZU?NVC]HV:U>DNGM339TWIGMG"C;%);SW>S
MK$3;_O""4EM/Z61I7*KV+3T#:_&.@VE4P+L\HV5;@\W6OH5W&N4%(I?0H/L4
M1/ *29 ,E2<YL,ECI[^>_"9L/_^U%@GFY[3KVD]_K56&^<EOL96DP=8AQ7SP
MKF&EX#_(0G=X%PWN;4RYYLM;R!E??_#.I^3]_XQ#[BLJ*OO@_1'$Y0JY&W%2
MEF/1:^+$<H>SWS <3>VA"@/9]3KC3-%!Z/UR='%8X6G4L_/!NYQ-81).TQN5
MT6 ^>&?!1/$L@O3 W$05@D?]2_SF27!/+A:H9T>"N' OM\6I]L.BG+"^>SOL
M<KTD5%,%_P.BW4NN5?ZMF(S6N.::]-U3.IG:SQVO!Y#FP19J#:R_]M/'_2(H
MRMQ+1]Y: 36>^F9;04YY'9 :3W.K;:*Y:UY)_X=#/_1']ZQ#7-OKG,YXMZFF
M?\Y[827*],?5\!N%Y;!H.NZ]SUF49C E7G&EO#4HNW^BATOCRJZ@LF<X5'F.
MR^? 7)[%\CW6;EP)HJ6?QM$P8B0+[DI&N!Q%X>/:=<^&P?7'E=3\P%0H7+UC
MF)4@2KSN]:/'T9\VE^N/*\A[8! ]PGA3!*_QR FKITGCVKAP[2= -,$%&C/?
MUH]B+=?NL7;:*DJ !G#*>9TD@?<=KD$>_VENMXVKMOYA"X<V^83;1GF7YT^"
M$! WQ2:&\7PWQDHTZT\KBF'PL8_>[CD<+9QSHB1&)XZ]ST'VZ(4 3_.$:5S1
M%7 &WK:B:\%6=O"$Z,H:%W$%](&W+>+C\S\>/!M*C)]6$-+XG*F1RA 4V"_2
MX1>O?Q5DCZM17S^A*N.-/?)T2JMZ_Q*+O7=VTOUTUOO8.U[_5B>X&3;E4\]W
M0ZQ$H[Y?@:W>+[/KZ#J(-R?'/UBF]@UP!%].DF@$D_#8:<,'6ZTUV%_M&]VU
MA4-JD:$*R\>VU9XV+\7[59!T2Z;P-)I$:\ DTKABJRKF>+.IVUBZ;F-3N'&_
M]7N\PHW'=&JT3W/9O?C4.WL"_LSK3<ORM?,U6BNDV5_D>.C;MU-A=*FR291\
MDX';UE2@W#]A0PE6LGW?I#L:*4:L_H,%?-!%>_,D/91-#&;-T0/_TMB!S^?]
MRU<"&?#.CTY[OS+;TWH?X6\V\('GO#-6<Z <K" F"9Y9E!=$+',3%5?>^53Z
M/3.3X(FZ5G$Z15]M<\H\T**N@/PI2[_./"QF92\;5Y)2EU=I##Z?]TFIXI'K
M65X_;6H36,;VXYGKAA1]L#5;AUVXDNXG'\N,2EA,D_8UJRQ_2KMP8Y@\H9";
M@?Y^ZO4Q;-DYZY[_WO<^7YS_T>NOO_G^D!7,FZVQ=EMC-6?,ZU68[V 4A&08
M"/$W-KE]W"/E:5>ZPJJU;Y^?48WD\UBF==AG[9OBOZ8P'0G6V9T&-Q_0<H.W
MX7T'SM95- !9#3]X_9(*S].,MB,/A*_-/WA@#UY>15GX"B'Y,^]()6H4#:,@
M>V1X_NNG71T+Z]^^+6^1"1[\'W&#8K(9JV6]DV 2C)_)$J[#;FZ_V+F33?XS
MR_\NTP^Y=ZJ2<7$%/QZ#4EX#[,G3+J"%Y6N_Y/E"353XV$KSV=0TP9*U7_1\
M$N73LD#R\CR-RT=/6C[Y3=8^?>7__OWBW][E1:]SZOW9Z?W1O7@6"[8.NZU]
M&LMC>&48]Q3L3+C*8@8^!L,<#)E8P8>3 /X;DM?X^2HMTF$ZC928K'UX^:!X
M=.#LD]^E*^"]["N8A& 0(6G+!Z\+%FGFX"L?=?D>JDIT'?;L"KHJ]FC+9DK<
M#-R8Z&<463E\]//R:1?\XOJM )KU=:K +:0*7R0-7(/"^^>U!=N/\NAT72?/
MRPPQ$6NY>HV%"/CKG[U!&H=+(<$= +NW?TLZI GS3RD2':L_.OPVT'H%BLZ#
M7V;<_PBTOB [=NMJ'L&^IO!>SN^Z_#[ZAJ?I2?UGF_7_/3[N'G_\V+!'9=)_
M_(^%R]HQ;[GHQ^_?U'[]5YD7T6C&53Q<?$7T?R<J)S-2LQX<_+3OG48CY?6'
M$99IY'"\9=,]KYL7P2".\BN,KJ+B='_H>UQ\3S_PW0(A.B O5 Q_78-?&8VO
M"GI,#_Z#P@+W/\(#E"9M$"NO5L7_K4MYN[ <+9Z_QCFK@P':6_L% SZ^YX"/
MHC@F#HL@5NU,X<D]1]383=R)T"_2GM]2 -6D-I?1C;>7?+W=E'PM7_+UQ&N^
M'E36%I4</K1 =_K][J5IINMU?KWH=C]USRXKQ_\*M],#/TM4B7P84=L=N'#O
M791\=WAY%>7>(F'>WMHI\/O_C$/,)L!@?_G]T'S[R_>_'^*P_S.C;W<]N'(2
MA,H+A 9H6JC) .S-U^]][_7^Z[>^-YC1N19,4C@,NW$6S"AD"@_&5^DEPSW?
M"^ EKX,P -LGFZ:,UH6!5,; %$/U ?AT\P4',=[X!,[3FR!3[JV]ZIT- U7]
MYGNVTRC&D6#U)KE7YA)C2M+"2]&XOHE@ D,UBA+X!OY64>)=!7"$X]$_40$F
M67,OGZHAV!)P29IYYN N4@^N-F0E>^W*P^KV%TSK1?>X=]DY[>M9?>[;"@;P
MYV_=BVZ'D&!X.Q18+[T!FV][:P0[B,1F&*N 4)-!,O-B$%=X\C16X1B'@!VR
M0%I\$!U0[X5*M+@$>9J 33GS4-WG2@5H_PWC()K KS)C*A:8C?>F[*?C+_$A
M)*1>-QF6DP'[@# >E,V &P. I5K@<Q*9/UH]\1&\([,IZ,N@*(+AE<AYD?K>
MS54TO/+RJP",*!%Q,)-@H%$RC$O4#/!%/QT5M FE%<$.J O9,-M; Q6G-[L[
MZ/9@F[]K%<]\VCJ-F]2:E=6]^@$G]S&6O=4==2^!,WIL>RL$AP/D!-7+5*OX
M499.1"A9:XJ .M?F\ G^U]S)I^73X9]Z1PG0I/@YZT62;<L1!Q> T*=9<24J
ML675MH:+<W;^)]P-5^CC^467URB"<PUF*8]"*4K1DXO[>IRBPY@I;!@0\XS2
M$5*2(Y"I*6[]I-!^).PHV,ZXTWV8^6MLIBR@N2DL=82!.W@4TE"8<XDW%AS8
M?Y?!<+:]A1?GY0A!.W!NSG PO*%QL^)/\/0>?DG2&])0(9[F> ?1,+[[AZ@$
M+QB3JLOAE6+8V?G/SV[AJ^><8SNNST'WC\)F->>H.K\DW-^*AQ5#9WNK9\*0
M1^C%GG0_]LYZ4@7Y&&_TJ(J"JN(>+,CJ(;,+S>T)'K&&0?_H$*QMV/NLH74C
M(%;>VGI5<:YN<!^C54I^@#']?511=!S B3)-35J@>@VK,MSWH,JTR=Q@#(/O
MP8>#?@Y9^)06 @__ +?2P^D-_E^<[L?3(-\TAIU@MPVYJ/IVH/WC"&S-FD5%
M)JKW665@>=+"Y8XQ*1\75T'AA6 ]# NP^$ \8/SR%YFP:3F^ BM!X5>3E*0*
M)4*%#!'UZ2PLLC2&84=\6F5H!N(YX]/]P-]*L+YOF$[ @=174&&G#R<7G%0\
ME#WO4H2Y:C;*#^KOML/6J<1G<1CXW"";R7YHN@</JWXG/$$K5R\<[YSOS)-*
M)V@*!E6>@_##E"R:3S$4IAA+PMW+W^!5PP"<4OJ2/W/,"A",8&Q+)J?4CHBW
MKEY<M.$5K:I>,9H2\%O@ZZMHBM=>IUA="=MV6&81G_Q@"1SCVP4\!N,)/YR=
M]W2W[6 %VW9!2$9<L;K*K6M<2AX$$_0BG;U 3ARZ=V6LV))4DBKRM..WO<5F
M'D9>X%,LUH!]0;Y% 2]"QPK\=R,%ASO#]J7@J,SAW,YS[R28TTQ69X>!UMN@
ML!-8\%W8_'V$0]$W&?X%:HO_O1/1U_17(M[ ($B^H'Q$";QO06#'')P'4.A!
M65RE&<;'.$[Q=QEE[";$P0T*PP##%"DZC2)W5,--S;1@$D$BDRC8",OA3MB^
ML.B^2B<-A_TBK6&"EI&.#ED[[2W;:9O5.]Q1*UN]S<(]Y!B6H:]\]\$[GY+*
M^QF'(I/X\A*<E/V[+<O90=3F<#[#>; POXG'P.OWSSG+^61WQLYH!2H-B\X6
M6;"HR<AZ":;3++T.8@QRTO6^AZ%3S8F,29-L$K'WY-U0N3#9-&*92,;/&+D8
M])QY7/V(PAW$7D>>L+O1B(<[XY6L._F-=RV\#2L-Y1=:!G(,B*>F!XVO(]X^
MAPN0_HGS:!0B9P>8H@V325202@,)H4N+@"Q;R<=QC8"WHSWB&_!V"Y60@YO!
M(]$ETM^IKQB/IRQ;-)G&<-;N6E<:/L3\<*S&E P;1#2>C7P=[ERU+U]2OGJK
M>(4V08EYV#2'QX3T.TS2_%5F,_A;#6-PK]!SN<;#WL?K0'2F4W"DRR0J9HC?
MDU(%%"_,Q^+/8.RACRYW$8L _U6&8_X7HA'@2XRW4KXWB/$VE\%7^$Q5O7$<
M& H0?@$_' ZQ" :_H;]!_D!\Z4>H[L+K*$^S&?Z]BV.Y@J52N%]@Q+6;TF<@
M\5%RK6"I> _MXET4([ZKVV$CM8?@,K<OM18DVNS*HWW?"B)U>ZLM2*JOO7X$
M87LU\  &D"I@@^VMCG[SC<P=[OS5OLP)'HO6=;'0&7P)XP;<R+"!N6!NF1+6
M*:*NANETM@@V .*6EX._,'8M.:CN5]!.N2-A#CX$!<C-#8%WA /=F&H@(%]6
M(" 6-72'M890)HUD\KVKV10CCMI$UZ?1! [.,9VQDDJ8<4H(CB$XT.RS0$8P
ME(@G8Y&5]"7^2:@G^P,Y;Z=&>0D4"B7/2:G (1J@:5@@0F((MXRC(9YR],0L
M!96DC4S&4*#2&F61-1OIB>81%F/%@S=([:E&:LL@,CW <_3RR4;]BGF<*<^)
M&>HH H,5(8%ECE[.%*W>*2E<NL2G9!*9&]M;YAEV%L!$4&ANP(91:"&#,:K"
MB%])?1TJ_3B5J^Q:UB,V*IZN#Z*,K\??9B,GA105E0R!3YFLM 15[=Z"C I\
M5[8JFN;$*@T"A,YT"M&)2U-TF+3)KF^A1!Q7SHLL,J.RILGV5LVTJ5S)MY3<
ME?Q.RYV_Z/+"(39T?V"27 R;F_O]]I;<(%-#%4T+_7L87SI!?&@&*RJ9$O)N
M&N^B1U%:(XPN9 QM\[6NJ*NO*AN"(P2CR>9>189?P T&)1L0E2R?>=I&NX)V
MC5>A76&#S25N:HJU ERN2GN2)J]@AXVBPKT*=@]H!(7^*FHI66#9])C!:_H4
M_BN.3/5'?Z6PGSU0C+C=0+YR3-^(5B85EX+Z@*'4_9:YN^H+X3=T3[ "J/6H
M?+X1.1"Y2?LB]S&#"[TN8F47F7N@>S(^7T;!$+3_[[U=;<O=J$$>%>1PYAK3
M"P(XSH*)5Q:PT/^C'0QC]8%1SVA1Q^?FYX3D@]#G^,A7<.;"01;/G&<CY @O
M31-RQ(=!'B4I&YHW:1F'.N,H]R+I\ZY WT[)R!@'H'GC=#! [UP_1SO2+C8B
MG^6%FFQ$\' G:5\$&V.OMRO!G\$EV.5 ;^'8;T/K#9/%,-3'X'S,>'MK<="8
M(/ED=N+E8(Y-Y"(X32=B/G%@V8?S&RZ\BJI/IRM"ZU)SA!K-I4R-(SBPY=/K
M((O$O/V[Q/2W^3'()#C-AI"M'KZ&D98*;+PQ G[I'S":I(*[D3J<ZR"*R4P>
MS$R,DT&_?,-BID]Z=QE@D]JO,T3XY24\"1TTO/24HE 7O-?P%Q\(*3#8%2.6
MGX)7&D@04>_/1]KU4S9;;:G<XP^;-./2:<;7FS3CT]L$.^FJSQNM@98Y<+0V
MGV9@N$33@.+\GIC #/&\44&,6%0\;R*.#Z@,[I]FE!% 0P-^@NZ[O4$8L0]G
M7<J_P,7,PR8/]P.IV9'">I'8/#M.A_B7N2V!LQ5:4^:68_/6'\!+'N[R:H_=
MN8!KX1C*HU>53^<."IT4JUKXE=^$T77$9VE>#NP?H4)?0O(>8ZPP@3D9P,V"
MTO<HTG.%N%8X!F4^S8F,[2$B>*U!2MF2B%B#^&$TA?RC3/X1X0RX]3'7"N'#
MXR"1 Q3S@F@Y#-*0#CAVO-@F9!^KS)SE( <Y">)=F/UP%Z8Y+J0Q&<V:O2_^
M!._)YZ':)<#N=126."!^B+Y$N^9D%F"J):'@"D9,M[>TV\[Q /AK6/)+Q&@_
MQ/)&?\'L\[L&X21*Q+# ;\#,*.$J%#K&^&*L#?TNA#2C#1U\I1@('-+9("JR
MZC)G#"K>WMJD?6K::=J^=FHD>UB Y<3JO" 94Z:%T.'F+XRS@?M$ZQTEF&T)
M#.<6_!.&%!#(WJ(@))!7"042,A0>@HG!A!- )A4^Q7)4CL"27>G\[6;%)?$-
MQFPYY/KF*=J#()&[7$P835!5<NL7-$PS1:AWVHE87$*WQ5)8^@=:\K%8R5+;
MQI^##D5<*3+Z@<I-QY*O)ZL3;H. @2@I)<%5_1-6^17J)=^H+:RA561C8W8"
M! '<"_/ 3+U27P/=F5"/>>0+4A;7) LPYYM]R3&NG5W#RWKR)WWEA0@40*T]
M3LUG28#BL^/45YH20 ,C *>%_ >5,;ZV3.S?%"/EF(^^&8YV<>"%KH%W!F&-
M$OUXJ],K@CY/PW+#/&<W-S=[.:Q(D:7#+^R.[\$#>+.F&8-KX$2$HX%SAO@<
MJ6",!=)!4C&8Z;I!V13P/K]?G.;LW.<IZCF/*D6TO]ZXSA3BC/4R!V$PU>61
M6 2;1=>.Y, X!_.KJ 7/%;2JWZ;%(%$W6)8945E'(D%RN@^7HX \B$#<I+#X
M='R2DL5(&IS!>HO<LJ8RSNE,4FX/.;AK&MOV%HM?KL#A+$S9[BA"Q8=S/M"0
M<E>-.'("%P8YIQ."#"M%X0:A[:GF>U@M^NHJO2&;!([.@/;?9)KFD8P?M&4Y
M J509H+'HHK5D%D!\9_HQW,V40VODNAOW)<@##"7(6ZQX97"<0U1(O "D-#Q
M3/Z-U>=>&!2!=LA1Y+, R]'@7Z,XO<%<% K3(,;P(P@81J\H*ZG+U[72@*,A
MG9!CBU6RN 3P!U;+YV02#MD4"AE/4=>Z9AY9!6=?J$&9-XV#Q!3IPIS HH'D
M[_#BF* :3PI&(BC$YDR_O!K\[R#(E5Y]V $@36$Z9!M)HL [UR*/^@M:-] :
M(?]N%&&9!_V:PG8263.'BIJ X4*9I!QM ]'?C>D=F.LA&$V<KQW&6)"4TW&B
M:XKH#0>@^+ED"H8F8Y-@#NY>[0CRZ-@4DXT0<2R<<F\<P)YIF=$T!W?GY98?
MI._FI?#FE2,;;$ZND<JO5#RJG]7N.$R0E))8O$J-8]L86X<[?[=O;,T%LG;R
MW3O2+]_@>L7!#5]>%ACJ,S8\>S:VAL8XEC'EXJ1FD'Z=&59Q=!9@Y^OP9*A,
M/EFAPT@HM0SQ8*@WXT"'+@OD#YG1\\26PQ!H&5MGP89!$5%;QF1X2 'A-=_/
M=NGS=:2= C4[O&G%I3 A2% Y%1V*8RML4V<::B15CND4'!AVH*(J32P5E4:P
MME=![@T4ASDGP<Q B4IR1P?*1$55 H<)_B,(TRG]8XIIS%#'@>F3+(6S:!S0
MUQ@JI60WP_,P25$)I4Y+U.=@I2@FFKY7++6U(.?!DMNIK0U]G^<O$]S\<1/<
M7#JX^>:E!S<?6_CO?9IE*SC-M(]WQQ$6J@$H<!<N'Y8<][%>XJVQOC)!HQ[5
M-NA =KQ1C9;)A"ZG?V(&JY1_PA[(2-&RWSUF;)'4LCO8'CP]!3OO>^ V!UF4
MEFBPB^=&02\$"Z!??4V(!LP\*[Q!D,T0A"3CWZ5C+<C"F"#Y(Q./((Z 92:
M\\D#98M8N7K5O"_";0)O$,346AI,/]CG<&J!H8?G!QJH0S2M;>-I 6&@VSM$
M&!;RQED,MSGZM0W_CT8?@8D\(7<9C$N8F+!4$BV988AF8UX>HJ77_H8D7R;T
M[AG4:R9\E2WI^A-B&VFG"=G39AJ!R^7Z5)-BZ==,V36ZK;<1>2U@?6.(KLOQ
MLA&EPYVB?5$B&W^9'%6A)A@$I,@_N)@16ML<]$?;/DBXV(D<!EN$@A4NR5!
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MJ3I* [$RZJ[LAJVJQ)@5:!C'(SE.2AI; MOU&U!WAI*@^FS_N@-J:.TXAWG
M?)4-TBYGSC/IU+Q[4'T>K0H^](7;NH1D:<DQ[\5Q]'<9A9684\\VXP3#+H;?
MYA;<V.3QZ"Z_<'6(7@SWZPZ%R7QF@E*Z"@.$(W<"/N),43=LM?@ADS)G52/'
MQY3[L,:XL4F!.CZ@O)5T'JG6,9+ 2^(.>[ 2:SK\?GNK\;&X&J"U(F+ 8N8B
M:K="*,6P5 [<.XSP.:"B],'L#@L//@T>1_M#*^_$]&7%HI&(VFWP[N7NUFB#
MP>D5/62OC">Z#Z[;C$^5>6Z[%G?"ZRB',Z>R&5"PA@%6&2&,4<=%C)&:UQLY
M1RBJ<:1 T;$DA.8Q-I8"1[-\K T\9%=S86V^IL;"-E'X*"MP@0R3C]R\C K-
M_T?)*5?)BI6S6#UO;QG]3#%C' 7%4<LXR!J>G4=%&1B*)KR<1J-P-)%TT=7C
M\S"HH?DC[:L+1% A%Q=VJ:<]*20<RQPCF,"7MXY5/<H=O?08R4YKV^4L]7Y5
M"4$T^RG8O%%A@[EU#.5 80=JX]_IO2+?(5A@-*)-M%#O"T9$>BIN;XWET;GS
M:#)D0NJ>R6CY.RQ4?:TV0$G0J9L50S.=RF5,-X'3*;VI.-.17W&$D\&<ZB:?
M!@2QF03CX'] DFW" ;8)3#AL()#\*""'2\5*4SK! 0LG)M5=!R&8VH4VXF!@
ML-'(IILH16[X#9Z0OH'CUI,X%2!]BNW DC""PZ;$AE@6'Q$4@LFP(4C8-U%A
MV]EQ+Q1WX '3)2TQ[R]^Q[5FJ,&6NU!C3%SQO'-Y:&7'"1\O*\GY6(N;(J7]
M8.%=#N*) BOX''8H<J6^H(&&B=0)^V?V9QJF#<_[/M7P[=P)30P+"WG6B4%#
M?S^7N:U'T%WC"8;,!=0,D'8[2^KCPR3S8!@E%RQ'Q'F9A A&7OPTFRNU:50=
MWP^N ]@$NGS(:?[H4T;9S(HD#S)WB7!PTS+#,BC3+F_9&7CA&VFI\/X/F_#^
M\N']UYOP_M/: G"61+L>NNC&K-W>ZGZ=8@^5!-LE.YJ?=!95UCJ..FFU/)J/
M$U5\V^LT9O?$='RBF)NY]=PY8EJ9<" W$! ?'#[I!!$@&+";A[XU."(+]3Y:
MAX[';NMIR$E19@KP3I52:Q/FFZ"5DXG3Y79.C="!FY*W@-K[&M1'8% @$[BO
M!*?P+6S#E[G!+X@4<!MU*F2C7(ET5XVH$BOGXLQYQIO* ZSY/$?OKQ,FF"Q)
MMK<JD<E@.(0S*6)@+=XKS?QZK#G0\Z&0P3OW**I!$10\\"ZHV'K_ 'MVPWM?
M<%M5HE7%=YJ4,5? &RY-E /SYIWAQMEJ,4IGR)7)%\:8%:Q!1YA2[]8$%I"W
M1)"64""(H>.8+GOC\VBV&M)/0[PLV[);F^P"[_RFI[A75)Y@\7OF 3J86&--
M<7E[&1XNM\_G>CIE(.LZ0>!T<I9A-+>[1U\OCHG%C'L>>S9]@/T3B'&4C%$P
M&+6..Y'V2#I(PE-)Z$6>=W/.ZW=7UU2NJE52==+HM7(K D15RR^-C2D3A1Q
MW)J#DJ<O?4M&7]O;D":0K=&B=VW"YA,C4\A>0,R*7-T)@E71[(TA\[D&H);A
MN*J401"#?$*1. G%XQ,'BH"2!B%:2?N0I+NI-&%L0$.!?J:QGA2W<=N3^[>,
M@UQ2RZN<F>,E9\TAW2-8PIV0?S"3O &F$VX$F5#QLIH>21A2Y""DYI4Z/:CC
M/\,H&Y:3O!!ZJI[TS[8GL^FV63]]K15!4A0% @2FP_/@[5N<9>>PO&L^<HUI
MY7$RC80O&5-7A)0&UM(KR+QI<NU"3 5JF:#3?\Y<6\YK X+>G-RNFFA-2YRJ
ML4K"BFJHF-/S"ZT/;*=I(1FV:?KE%8R9V\A+UKQ^5C0I&*ER,69Z3"-RV'8&
M*DYO'JY+$T__0@!N2\M]R_.08(O5Z>5O7:_?/?[]HD?-PTQOL>[)]M9OW8ON
MT;^]_XL-QGK]_N^=H].N]_OG\S/O^/SLC^Y%OW=^]G^[_^I>'/?ZW?_/P\O/
M/\)_.W]TO;/S2^^HVSV#._[:ZU_"5R?>[V<GW0NO]L3.\26V+#MX_^:-[W7@
M[T]=N.S$V\'K9)!PC2E_V-XZOVB^TVGG3^I^=MR]N.STSF ..Y?=_AY>UJ\^
M\@+^_/WH?W?AT9?G,,+^Y47OF)NIP<M=7G3.^A^[%YVCWFGO\M_47PVNZ<#+
MXS\_=?Z-;[>]==0UE^+;P;#@JO/3$Z_[K^/NYTM\F<_=BT^]R\O*N^,+XWWH
MWY\_G_:.:5YIM/77\;W/OU_ Q)_)0'$J+ZCM&SX.IO[39_QC>^L2)__CQ?DG
M4-RP-/W+\XN^U__M_'<8#HRS\R>^\^5OG4M\[+_I'>#CB^[_^;V'8X>;'W4[
M/+Z/O;/.V7&O<^I=]/K_33-Z^5NO+_>%U;GT/L+#.V?PR4D7KN[!N.%%>^<@
M,GAQ[U.7)IUD!EZ:;E!; AR /!WO=/X9;H,O!:MW_OM9OWL*-\?'?**I@L6"
MZ3D[AEO R_<_PA2>7_P;1^T\1O[J?OP(ZXHSTL%Y_K?W^>+\\WD?7U(62U8*
MUY->"Q[Y"9:![O]G[_*WRBKA'>Y:I3T1SI7WJ6T#JK_T<Y<*1OZX"48N'XQ\
M\X*#D>LL[A46SG8ZW9T$10 _2B<?W#(@KU^BP4HN*S:!IO9@4R$.0C,IS2)X
M%4QE"HMJA6XHM,V>FO&%EMN(T4::@#+7B)QZ#TN'=0C#>&ZUZ+6.4W9&B&E%
M&VVW3AV340(8?VDOPD]J]R'J0]TKCB"T)5:GP1+1?J#&<GD.5EM (RFGIMP.
M\]6*B+BS&=?2UU"W!+C@$ <R8B%@JLP":0YH&F#IJ(8AY)3:G!RSS8F=''%7
M9)2FIS?\:NVJD]O?&.TT4 /5>$ZN6ZTRV86\<&(0-DCW*\+?#(P]:_C)C?D)
M@<@"BO5&R7PA/9?BF[!^4H&16B(S0R"!E5YYA800'Z[KYG$3-X!,931(P<B5
M_QJ/2G0D"&XR1.WDI<ZQ-=$#%]^7XAL2""1)'\Z$;IX$G>D>N5Z_67.X?7EL
MU9>9%4EQ-]%#>:,R2P@1PO<(3=:86;6K16,-VD075>"P_%N&Z!-'B1FD[=)8
M>4@#X?U<)GJ^Z22S\B8!TRMZ57&B=\( Q5?4#4&E0]'M7 O84(T@QGIQ1B7Q
M^5$OI!+I8;)T9$!K/M.[<%'B0B)R&6U5%FAJK#"XI+6$!RAJW"<8#@INUI!=
M>^U;=/?NVZ,;'+OCWSK]E]:FV^[(N52>M"-TBEL-C4[;+;H=9?22NW3_L+(N
MW1745>!I!J2(Z T99Z5"O\J-U-23VU!XZQ;<)RHF3.4:ZK#6%Z\=U\0NE>3^
M*@O9:=J--JOGF,2Z_LDP=@XEE;B L82 Y'G!X?F#_7U_G___ LH3W_M?^WOP
M]0%Z 4AU!3[#E+O9P,FZ,U?+IY.-C95*[^8?MKTU-=GANQ](R#I620?U>SE-
MMB41R@DN7 I,/4A:N2 H7STEO8,CX1LG:<)MRM*RT/MAUWDP?LUO#Q_5!N_T
MO*Z,(8 E"\#,./;ZV*055N>/E% ;_=I;X<-!85>?S@[@/WGN?R_SW/I+[VUO
M-8MA5:#PT<ZO<&%>_^"_?[-(HEZB"FG'B3N%?:Q3HI\"8JHAA(/37S:W#9#M
M:E1  =PG6Y\-%?2"KK4^>+TSV&WBSC&5P!UF(#MX_^8MH16""<.^Y\N"W9_,
M<S#-$UU85N\D]21%S#(NV'JDEV09AA&COV,17!%69GVAXDIIV%58_GPT;AC*
M:S%9E52O#C^XDV4SK)573YCJI-K0-7/+RF?"[CP4W+/.O3DEU)'KT="(G-%1
MJMH=GH]-@= KK[>S8+"4K;9]B=NMG;;BABFT;FNAC*)];!EKN)\6Q;$,O2C(
M(),/<E3,=-%:LN'X]I;39![I69FQD'%_!E&?.Z2#FCC<D!:R_+M=?JN=T=UQ
MS18W0]?\F,W=T/4+5*@2!VXGN_ENP^[970J3IF'5M)8-P@Z(19&AIGA0#LVX
M03U(+;+MT<Q(,1/SK-8DF,7"(DW]D*67PWECU$!P#Z[3<P.>4K:W>.XKC])'
MN!#Z%,;*N^OYDG3W:>[8V].3)P(7NBO+$VGF8FX<MH-[_FU#L3<0(@ I**1!
M,7!$-VVWE2#N\CB=5)S6V57,T! \F)!..TU3$64ZGHPL2Z@\7Z3N:Z=CNL&$
M'C,=J6WBJ3\00T(NJU-OS7.4+*MU_#M5CC4;F&;,33DT$;8Z-_E@DPX6R>Y
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MVD1A/Q>FZ*EM-?9ON0$6Y9:Y98YMDY..X ;<9X>4@&6BQ2Z<KEY8D.N1^:]
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M]C/Z_X7Z[K WDF[%$5:?2I=CZGR@Z"#9L6<*7C=VR%2WM^B<&)>@#M,,.RN
M_5E(;<.NSX<2ZCX8K(U^H<-(33.8(5O[S>XQJ/L0)J:[N&G]60]!30(\$Y 1
MG.[H]LM1$:EX-[KSWO!YX+/A&\$B>L$@Q0ZA;A?$"@K1V//P&S/Y6!U&U^I
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MM9BY)&-$+(5<FI5+S_&,P20W+':4,+K04\E?*?^QE!AL;SD)66.>-CS&&<U
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M_8.#A.5:J :\_O9650;<MQB8QDQ<U<,%"Y7%J4L=S92<J5CKGSJ3+4PW.[
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MY]_<"553\^J.J-S[3DO!'#M,MJAERJ",8E-M% =EPL8),=P@0>C,]G_%"L
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M$^O8%"HMIC$XI)V-,6KJ:^XRQ-F. "\QG]8.N=59ZGUD( =CA4;,V%9WN5D
M%P5/N'L2..U3591,3%N7#D2(4"].G\("/L7GQD@">S6;HD8;$EZ_@G\L]( :
M@P!"BN: H?Q;\AV+1,FO&Z<&"F V57J3\*0T)GX,W9T<\=TX Z/Z@EC>%FP5
M[6(0-B<;,IEQ[13?WK+'^+SE:T=_Z].C?/XMQ# *G*],YSF_\15?VFY;)IWS
MTR:=LWPZY^T+3N<\#9&G ^9=*P?,A6EKV7RFV-9/HRC35**)L!'CB1&I?)'R
M]5SNU#BDXX.83+'!8,K\>2X!NF<:DCJQ7<.VRKJ:GUXG(A\C5I>+MO2IE)%#
M,#,D7N8]FT9*V-W4:2>JX_::]5ZK]CJMH%AT_\,!?PXGTTA-]&FN*PY%GG-4
M^'"#1(V8REH #-@;48 $<HAJ?$6_T^GC-)8637.5DK\D6 C['==L9J$@T(;D
MDL(ZL8<J^,YJ1(7?RD'(840*SB>GW ]%D!CGJVT**Y8%/T%SJ-;.\H:VM8MO
M/U"Z(^OVEAR&E1Q=US"YL@37TG-K>"BN/UBNAI;[U.L?=T]/.V?=\]_[WN>+
M\S]Z_9>)EGO=%EH.CN^0BU*YYR\B]?.%/%!2\8QM@PGECI KYI5FU3=)0RJM
M-FIK,*,$I0O/U3U4T;H7(A%+/BC4\J@INDXA!3W\!@<G05S*\#=4.YCZ6VHH
MRR32BVK>/U3Q4Z+WZ"FNSZISC: # OTM6LF((,_!Q)BJN!YH\AW'(\70^4 X
M('79 -&A5YZ$O2P(!TTL+U*5'%%4W9DS<J1RF3K]_L(@KGMJ@.ZE4T^?2,Y;
MK:%.:G_CM),]/*,HG^R4#HL*?N ;X%SN:Y\R]W5L41P^;;I,)F4B9*>Y8V<8
MB:BMO',N444-[A[,- V0NA[-$>K9P,4VOHGA#1CCG24:N4AU8]008IB6643'
M8D;M.G:DMU/N89\H;B95CZ%:R>:J#>Z&R.FC7 CT/U=*;+!70I'-=O60>$Q#
MD%:F8>#F5=@: RTFC)#C?!48 <W44$73PH9FY1[7N]YUA.3MPSR:8!J/;"ZA
M>\=NC=SGA2Q&N*?<AG\LOU7\(+H2:5ZS+,V^Q_FG^2,W>X*!Z3%M5LH>S.]4
MKYRF=I1. VZ6ANTM'N57[N\>Y<,R1T.,.N;LD@:143A%397[IPE&577=#SPH
M G,7DU[4>('FB*8/@Z]T+\\\W)62@5ZSB0)K,6QFJW=-H=>Z@[I%-"FRIKFG
M);SOM8:=\F-W1/.B/9IBF>NP:BV!EX8M['FF:J82Z4A<Q\",G6JJ8%<445&*
M_+M#F4BD!C[EQ^LEP/>9EMDTS96-83:]&,Q)6>B.#0TW'N)2.C!: I+II@-@
M[ZK<T^ O61-X7Q)X7 PXP'233]U-B*--LMZ&Z9?WS2 -#6.$<QVN#/W6N;/>
M5KM[7A^_$K5C9<?M=.%$XGFSIKQKT6,2=R((0]C<N6F(3BB9.+VI!(Y,]LSC
M)&?.*:YT9'M.?7:.WX)\K,(6:!UIDN*3P'8_M40^]A"7P>UM;UVHOY3IS,-?
M9FI4Y@'WJJ'ET96,46+Z7:5:ZK&.AQ+P9M"A?E?;JB,QKX8=-S!1F+A*%MLO
M4'Z>2L-8P&25Y&>!\3%TZW9:KTP/WC>#IGTV/\R7=B(O$SI[OPF=+1\Z>[<)
MG:V+R)/!V1M9$M"?J:WC\Z+EN>P<G78]],H_=TY.>F>__M=W^]_1W_W/G6/]
MMQ8PWH/#-(Z#:0XRIO_%IO5RP[N)PN(*+]W_C^\.<007^O;7:$(.@UB/%H2V
M.OQ8C8KO2 Q_N3S1OY+[B6!TBB*!=;H\N?VR/^#$QMUZ'/S_[5U;<]K(MGZG
MBO_0-4]Q'<6)DTPRDSD[-1C+";,)^ ".)[5K/P@AL&:$Q):0'>]??]:M6RTA
M?$N,G9AY\ 20U!=UK[5Z7;XOM"\VLP__A#^#K^F?_2S]U?L@!ELT4A^]&#9.
MNLFF)5 49'!&0 .C$_L;;%ZU^[B@>O_XZ<5/[UZ^_GE/=7%'@V8>P!E@"+KV
M8._EWD9:[X*2_Q3,X&_OD_KEU[WG+S?2+,&]_![@6YC!:36>[<)YL=3R,]J+
MF]GV]V$C?(]M7I$P=]>CV[BB,Z[U'T;7U2\04A-H1(:I^H/0!>ZC%QTT.,.Y
M:I^&P52Y7PB+XRQ0_>D43B.;Q9:4+NW]\AQ$\S100S]D&)%VDB[NY5CS\OGS
MY\J-0$?/,1HU")!P9S^:S. X^0J>GH>@-EX\?WX??3ORHD2U(G0-M^%ZL+CC
MT%._OGKY_/5]=,=%]\);-?Z+EO+O\!*A3T$FKY US?>_E4%.==Z=L"MP0:?N
M)[:CK>1CTD?Z'1!DG>]-D%VI=3 FVDV",]7USN$LELX===3>7/,L/0^\LW"B
M/NYR3]"A_4=R&JOAKGH?1N@RVUR'7H.L4">8"]U-DH4:)CDF:XN$^.7;28@K
M.[(/)BWHE ">$GP!$_/-FU?/]S;7_*'WY:WZGSWUY,W>RQWU\XM73U_MO7BQ
MZ=4ITF@2P;KX'?]$WCG*(,X=_PL6B?WM=[8W;V)D&,@>8D2/L.P&$S5T,$'[
M+\<74C>C$RV+"*CDPC"C-!>DH#=;;N0R!807#K6SEEW.Y0(7C#"R__*QN2<I
M8'@W6=L,UXAO#&3P;U2H/HLY\GY4P'BB4Q_K(9*4 _)\6?8;QHM'F%'SE!WM
M^Y2WXX=>&@;UX?HPDSHS4G%ICJ[L&G L;&1&72L"RK#1BL2<I3BV#P+XVD-)
MI7-H9R%%@X2"6T*#_FE"H0).V(I"!O:"6QV5YIAEFF(4:)9'7'X!"IFYU=<U
M5[C_2\3JXL#G,N*BTDX"'AH;3'!83=/*:ID>BN$7+U[;^.YJ!KMD)7-8?SKE
M /\"RR*6%*,RKU4]&5N ,3()I?3E'4HCH%)"2B!BWD8K-XJCP10YP-AHMJP!
M<[Q60G.1%Z](QF" C'(%K.Z:>9Z$V2+)0F:2M K();J)!8@T7#OAOX!'RR.&
M&T7\- Q1E9*/T=$\2R@EO Z&#1\P#CF$3(%5$_3&I2M8@Q0ODZRU<LJ(SJ4.
M4QVOQK-15MY01=]Y[)*2Q@4'=,&J,&P5A?FX(JDL$8.GF!L=79C2;:M7E-!2
M0E^[5=^*]' ]Q$FBZ<^Q#UQY$W,&/ H';G)LA(-A$Y?I--GPS&'^&*7[W51)
M%-3?6'+;MDE?-3$M2VGWS[9[-%*=GAI]<%6[-715_U =#EK'!VK_LQJZW:X[
M<%3/[<#O W74&HS@VP^M;E?MNZK;(??[J$]W]^F2P_Z@V>CVAT-\T-&@?]@9
M#1W5'ZA6[[-<TND== 9N>X3?#H_<=J?5A7-HOS=T_^_8[8WHX]%QKS/J?'+Q
MFDZOW3F 'UI===#ZV'KOP@,_]$_<3_"L=NMXZ!XX"C[T5.=0M0X^=> +;!S:
M(H2[86>_T^U O^&[X7'[@SQDESJ-(^JX0]5J_[/7/^FZ!^]A/!]:(_QQB"/\
MV!DQ)I[J]]11?\0=I*'C4_'>$W?@PO"4.QS*KV[7_0C_Q'D=NJ-1I_>^V< !
MPC &]#1UW(-_0B,=:/K]P*7+']L&N$;T]>7S;?3U^M'7U]OHZP-?\B3S[Z9P
MH97.38Y;-XAG8$WW!.4'S0>1]V5+($16<ZP!SB*+)(G5OP!^<^&:J9/6FE_L
M"$JYPJ)M7CC-1O"E0&0N4W=G"*8H38/5QA"&82SL,F!W!M'4!M7EA,4E)RQ:
M%#W8-S;R:TRBWZBV&YMJ-HJV"(36&$B,)\UX0_"1;!%=@/!7/IGIS.!U0X$V
M_)WJ<$X]MHQLHG,J&@_^9M1OO(B+G87?'8O+.8M)-TXQ-K!%O2_41\.E3F7H
M:)7Q)%_6L<E*QSP?+;BS),KC)1S/$## 8U!JW>P4;F<<HTL'387SP4[55)::
M/2Y<IU..M0XC7H>QM0[I5>;8*3+G"1USGFB8RLM,9TS<A$7RV+0DB8S7=U/K
MA"EEUHD=7R-_4Z1DKI[QS.'(S^=T?#T+=$FMAOXJRPSS4._,"XGO@<^24E)C
MLTDL];$4E^)_J#;WB<E.5)Z:!#ZN5O0I<8*@KQFJR(< W7AF3HYA_%<>\](A
M 3#]AK7_W]'2>7,G2^< CN48IL",#"ZS*A918$J1SH(X#Q@7SB"C$-_8A&\G
MT>RQN%GAU2MHQ6Q6"#F ZX)G]I&D:AI,*#4%<\A!KD6)3Q  85SO2ED]RHI"
M$UP[*A$AW"2N.!.TH[@D23$G%<Y9!M+7=@D5;D_L4 $*1+R(B91'4-[TN4?)
MMO.$,S2IKF,23 .0=97Z\I#/S/38#/:&H[%FN+ $074EAU>R:==?A&)[G"8Y
MIMW38S$'F)!H*'=XBE@<!4&"O$=1SI<_-9S#YP7!)J7Z 75\'SJ?=^XMEU+6
MB+-05/4$:!KX[ 8L9O+157?3'O[E3O;P'\>#SVHTP /K20O.V@/9PGR</SR&
ML_]PI-P_\<RK>OT1'N<_P&%ZY))SH'5TU.VTR0/0;9TXZN1#!P[7[58/+]UW
M^9EX-&_!UWP>-\?M#W!DWO_<;."A&T['W<^.^M3O'L,9?]#!#YT>';3[O5:W
M"RWU#E1G,' _];&YS_SD(7D4\"?T1@PZ[S^,L.LM&1%TD,8'1W"ZKDW'[OX
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M_OMY=G8.G+]))Q=975;U)MAMY*\F[L1.:Y 8F)YK\%:B289 #KY1SB'%1N7
MXIM6%#.T9@,!QZ>(UR>HD73W7"HJ94:)<>OP/,U6#@?LW1%XN/^1@+VN+B@$
MWI@=3_DI@A8ZP^A^6MV4W"G'*32$@DI,7\MK,!+09 U0DPEFR;*1?;TI]07!
M:[[.*MCF]_N)XO,^2(%1JE\WZ0DXJ?K?FXEZ"N>N_L#JJC=E.5<G):S'GO:/
M<-JO=(YG"6S^5%_!RIX]V]W:3M3K].JYVGBV_5B^_&1G]]'N]LY.,AP("4QR
M^,S?\1]Y>HE'#NSU-W3OF"SF2(;-AOC*6@0KQ<G(_?B"Z8F]8&G\/J$# ZN@
M_6NP\I=:T<-:%R#.+H#(Z>,,>%I,87MMG8;GEE (ELELFSV&5&3;G>$Y;"95
M QB_2>(8/;G!^-0_:N+Z"K/M*=-6HJY>R8C#0V)O&W^%B=]-RT1OBW3&4@Q4
M"CT_Q]H*YU.D#6A U&$Z-A:9B&]TY8G"94@KCC:%8I5%<,!2ZP7<C8).$1/D
MN5Z.@M;V+V;SVC+4JS#$S:8< ^/J9(A.!>\#2X(?+>+CRHN011O6E6<$ LGA
M1Y.H0/ZUD!NYD+@MN X$1)Q>J 0<^!!OT$>2LB@H$D45]"O2UGO4<PE(!JX^
MX5K\0EUZ52RN.D93N?>8-<MTV7DD:E'DN"=2V&7+>"+G""J^=Y OD S\.AY@
M7<"__&K27R5R7]O4BDF[2-F'U_'+>RI8 NBWR_V9E%N%#K]PSQ,CKED!1:FQ
ME"(ON: ?SF$22^\BXG)&H.R\W7943OCZ\.<\=S7REAPW!8M9LYKT=+[68__[
M<EJ&##MRJ&E?15)RI3H,:S&<0SPLNRVK]H[92IA6="0L3I(SI=5? ONDQ!RN
M8Z,M,,F,J4TTF6I<1TK9&K9TC:YRI1\QB=_(&)RNWK,^XI%FO,GRP?H4N=X;
M&G"*KB>^RRUBW %$*]^FEI$B-,.8%1>:@DYT,\$6S@2AV^I#1D-I_."(]G-8
M]\:-.=NH3+/&6)!%)-D/A&G"WRWG64$[0W$&+!=L&E C]74H/%>)&?5=G.C\
MQFE!?@$^QRGN..%\".@C&O"Y/B-Q[^M<A#I@<QH_5F_)&%0%T2L\/3X)5N=<
M%C0U @D[EFDAG=%3]\W(6R%>L+N.%ZSC!7<B7K"[CA=\OYSFD]U)DXX[Z<!F
MN\9TZHY_Z3?3D<&O[8T*KX@-"V)%Y].$17)5+L[.(TJI;P@DG51M\N=FU230
M.GI\CZ(&\3PWZA#:Q=IBQKVQ3$LB)<13$*P.I-&@S,I)K][.*25FTW][2=A8
M_.8X9<P35'P3S'?.-6FB$Y2CY37Z#+PI)!P8&0XL)K\M(.^U)A+K0V(DFCY[
MB!(S?4MHV5[(8C9(B6[W;B%2PN@ [$DW^F$"+A-K[6]D9KAL4V^"B:OG99TU
MQJ/$'-AD:Y1GW*>%:X6P !V!8S+<%'1D(07"VQB40+,(4Y&,S>6[&)680D6)
MZA&HL%?H'O"V#UZ%'<+J+$Q_[5%0"9IAV8MLZ7Q,6I-8O2VCGZUHMB$SLUNA
M;8O'1] 30%BCLOSP"*9075,:UB-O?J"E84Y/VB3&]2JY^LXS)!252=PE'%#Q
MV\ZA&]L49@VFHLTMOS>;S&R,AYTA!W7?U,=/9NJZP]1?IUF^$+ORO1B%R^YT
M! ''NS!B)74]W7)+X]P?\\:G,(^:@L!]N6C6_EEJI(JYLL1OLD%U7%.#E];Q
MG+#CY*'SF@E+]-R)R E7N*7D!"DE^&BBR.P/\>X:79;$$#1A&?*U<?*6N632
M;_WYR:54F@?#7I1B!O=&'=I. 4HZN^:-IM5&[?%U-O8*V=B=&N/7%1=,I#EP
M,YO;:>N%O+-<2E$$>A%6.E@63/K5U'Y'RBC:NMI&>G:&/NJ&7-3DA;Z9DENR
M)BCD3:6Q2XQ8'DK1)5%39VH.3-7$X1=SHX<4&B?5^ BH'5#,D U)?J\O;NKH
MA@FOXC7)G4S1+61"_1A[BDCC8!L1F0Y=<3AQ3_J[6X;RO;H05L@@./#\!ZWG
MY!4:C[$,'&=@0JFMW:FIW*[S3;S0Y@2U6W/W;<J\#O!C;:S04DR@[:PO]BH7
M^[%R=_HTO9)KS,4Q*S%9Q#ND#*;T2CQQZ-X-L40-MI147MF0*Y5Z7KAV7%9+
M'@Y,*>(2DFU9:83JR,$PKU+:Y)JX$)T;;5EH%\P$S%HV#()$'WM=.8:%=%M(
M-)&G3?:+3-K*+X+.E?!)2@C/3<:I+N\Y'(=;J04T-SK6<( A E3I(PYK#CQ8
M4#2JVL51X##(UL17O;9?UBJJX>UZ*E6@L30%Y]2%H7@*@JF63;IQ+5XNREE,
M1U/B*G:P5WC1,4A0EUR_&_<#]X-+%=?<& B_8FG/? ZVCO:6 !60@KNKB?MU
M"9^V]H,6, +,"JLWT(A(1S7'AEI.<&8O-DPBK"_E,D+"JT#KK "#/\$_ZGEC
ML$';IQ?,2]S6G0/PU^F0(VBA*$2X5-#=QQ%'-'VCXM:* 6^7*:[@E'ZR=DJO
MG=)WPBG]9.V4_CZYS*>K7A' D.'@: 8BMC()M%U12ZFRR/.-&YEQ8*65LQ$>
M1L%"G4!0+$UMN@\\X[2-.LW9<6PCR)0XX;+I'":'*91/R2#'=[7^0*H=_0(%
M3CE"6X&-N K]Q.0_,S:=P]]DW P66OR.GGAO8+X*:%L4W[9^Z* OYT)RAS&+
M'E.(:<M#T'A8/W:"M)[GJKHF*V5A&P>3+[O5[K55:&AA%0V^9Y-^$%N'\YXL
M]@FF%(H";%4)RDO$!'VP6*2EALU4A=\VI!J'?D4I- \*: .3UL"_>EK269H5
MN%)+00@#N[1G!-#1.1F- JUJUFNSZJCXL;/MK-]ALVBRN:D/R9+FN!@_#P(0
MHIX'"/,>AT^<2DB*38T9CEZS9U*9?+PE<0H-!P1^D[02S?EP<+8SFVM.+<"6
M+N\\O6"=W"*:>OFC/0:)AWGJI>E9$KY/NM>G<\4.*LDQ.1Y<]2;O]9%)*ODM
M%JN+&R@!EQ!_!A$/>S$LPISP!J0S[]"1V2P*D_710P+2^,14DL\7%0+NX&.2
MO".7<!SXQU8W2R47Q;IS^/;UUYGSPKE&&$N,\ ;BORDETP?KE8SY[MR$0Q:X
M*Y:/Q"8+UZ\]6P;R;E4YA<&AG@WN6U+@ANA;07#]/F8)L?WNNNUA-$QLI;82
MB%]5C3.)TUE#$N925DW-+G<$S!%G.P^C0UEAPZ)B9AK:LT9D($NH&RH72RVC
MT,X&FJ"328'N> 13+[?)VUG;]$AH><W%5N%B3[M<#"$O40(1$SO6Z5AL=M][
MOE=<K^*^WO>C-B89LJ'1*+")JA9FWMN\>%=92)^M,^:FC:!\K8]TA2-]UCY2
M/YY+_OQC\0\NDT$8'V[2C/+P\?J"2E@@=GPN2>68W<FX)37E*GJ%-P;.A$M5
MQC$4>\I&S!K20$U3>HUNH+#BR ,TO9G:'F(5A7%]$COH9Y;&T6IJ!=JKEX*=
MQJ]:,$GY)AF%_*(U#X6RDQY<X5*XS'#F@ FU<;O4*/CKWD]20K*QE[3N'AMN
M);7K,SDO-3ONO,EY%DT_<$M6>_YC4Q!JMU5F2'T_:(KG(68.;COIY,R$:]+=
M ]4>)Q&>,L&2D2<3!0/W/))N#;5-*C&O,LA@?BW-WF1#O@-4][O &G[LE**G
M<^HO>1+58GH01:+S_+Q5KYCB\?6__,5PJUXCB"F', (<0M/1!V.1(S"WC+=A
MG(JK X,URW3*T4WU'6%(FV(2*W E#OA$2_4[967W+>UG!0?]T[6#?NV@OQ,.
M^J=K!_WWRVF^%,I,RY_*0+#.G4E5KP8!.N;:I&Y2#O="3(*RZJWNM*G?OZ97
MV6PQ,QJ%DU9<_[G?\2?U@81$DAU7?_FFA*WAX!,6T_9I];W.*1P><F+O+&E?
MAP.W28'=LU$_-'HUYW'@(?2.%7,<L;H FD6)V<-C\OZPT9W'0?7N*P3OKH/@
M=0@H-65C@[4L35DE;+5N\?D1C&FWBX][Z++]O+U6_5NMK&Z--J_?@#$";MD6
M^/R)E'4!$SOK8/X,!Y:#MA@- Y1V/A-<^)6^P5?8HL40II7<:2_.E)!/6*#Y
M$]NT1N#UVZ$_CV,+U['5&KTM7SHOFKQO/  O$S.U9Q.6H%.V:_N@(CM$'9R5
M/>P5#R(LHG#!LA@XKBV@K66&65#9[<56_UQ,SG@E=3L'J0LSU=,693CH4&=B
M$'K0-T/>:!L^M!NIO'UL=4ET@=M:[4J'<Q,MA[_M;H8-.H,V*#;,S+MCUT\I
M6HP-XTK<;2;9VDNR"L?JY)!W1,+)8H1P9W(9$8%K-I*,N+@3I:O+Q$,\<7N_
MYL\AV6R,I-\)&/7S/&NH?L%K5YI*YW!^OIA8#'_LU?A0<*%3BU5VDR[#(6Z,
M,R(^2X7YL:7,V6V!;0BR/#CEX4[<S#UM <5*; 18!GDZ;'G\<"!1MOZNMMX"
M3/<:N/5CJCEL3#4&G9E!,RC$%=M^G0)?KG<F?XQP$ QO,=Q4,.RZE?]QMA6D
M6AH.R)V./IV@2-T<$\$*/55ZG&/V":5%"-:&HQFSI40WF!_\660S=C=E1;+Y
M'FC%F_6GT(KW^FW0RIKIK\#T.SW8/IKI]Y'Q1PF Y6T,Z.[&I('Z6L*@]VZR
M<_M;\G35=TTI>^&;\W35<TVM9O;5>/HJK2Z8O:-9\Z7X^^<*=TP$_-J4L"K#
MQ@Y-7XYC]U'"1S!L*PN%$MX;,^&\O-2,N2>!77%I27ZJ6Y3JVFNM\D//^& D
M)A\RE\T/:YM.V&-8\YDOH[F;QGWLC>NAUXXH^INZ9*ZVP<0@U98&A@,),,."
M[U5JSPJQIV?KV-,Z]G0G8D_/UK&G[Y/+?+K>W"D.B?G/ _4C48?289#$**C5
MC#R<>3V-.^(K1)CM!H)6T)OYFQ/3&@LS,V:<I08*\I0;A4<U'Q<[HX50\"RG
M[EGTG!B\YYH>&6&$A;R$G6J7MAY&E2M6$5,;7C5P&JBR%*US"HV;G!6\E':%
M*+%2^)]PBHE4V>H+@R2:9WIAMLS+S5X:R/(3\3BLYN;LP;06<(C2:E?R1!)V
MC)[;9J@TF9M.BH9L7.T^RGU)"[6 2&T8Q]XQ1:V-G:J7L!@Y5M@3;PM2;Q%A
M6G@?2@$71?=1[/*-\-1:)%QD>ZS_R:WA0UBZ]7C6@JWETR"NL4V%B50&6=?U
M=%$UC)_N.:XM/ R7.F7B%_<*YKW]K&\#6_*.\L].&0F91$%HS*7I]H9"I&XD
MKTLY-F>=^,UEVW<K_C37@:&F/C7YL3>9]DF'B..6' R\FLG7J01)AH/,,Y&^
M4#S(%5Y1)Q=;G^_%VM(JP)$@4;)RT"ALZC=>QV!6O1:=N@2O<(^2QX$L.E?$
M(A]2"^]*2VHE-X)QW(R8H/=S&"H-*RIA)AR$:Q-;VG!)$^+C%[7!U+&%# CI
MM&A,M_G^;V<,25-Q'JCU2G"T5DQ> J5>5$56G[<[C*>22HWP>@T5;7%_PIL^
MRRR!\1@SNCFIP'UPIW2O6\"-*ZC5**TUHVV$F-WB>5DX0$I[&4U[2X$5"0JO
M1.4R?1;,TEM(_?)KZ9*Q\/<DSSY@;957ZAGNC@V2M]96F\BI^XU$[?V(],W2
MWWBW.'K/G M6E."#+"$YB[VY-OH%^T!H]2S=1]J!Q=O]ZQ;C]>D0]S:1YXE+
MY/F]Q"-?)^NLSG:?=)-U>!/1=RONU5B&N%-0;G!-8STDZ2!XOR]H:*D@OZ&?
MO7+>R.&@]>)\V=02;&>OYY1[ :PZS\89]U^)=W)]LKEK2^@[SLRG7CK&6HJO
M0DZ=3 I#3GMDT/734O_?O^"!#@=/@P0;7[ BI_[$X(MOCHVICU0@,X!Z64%U
MZJ(7CE@VO(_!Z@L\VWXP_%" 0=<648)2%V*-+>\>%WQ:3H6[0#B79VK+XZ2"
MCH">IP03QLHY[:8/BN!O%^Z-HC:0"\)G Q6A\NT7;W?CA64.>=GDS<*HKH4V
M<1'OXX*-I69:-Z(*M;0Q-H!&UWEZ64=LCDWE\"7E9"VG2TSPAB-(!+C02.4K
M3F0:O.DXFE_@SW5"]2,+\$:QSN D0?G*$%R5;HR',:FXH+X'GC!;S7]BSMQW
MY(Q109$L$IG50Z^^5Q E)^6E;4$7P93<1">@7&._Q0?L,RIZ$CFSRE*0^*A5
M8 RT83P8BK8-U7'>@2:)7V BP:8\8V^>O9?>ZVWH@E35L-T8X"3'RGV2#"L$
MIWY<!Z?6P:D[$9SZ<1V<^CZYS*?KGYVD+D0ND^O@F8<Q662@I@(AXII8Q%73
M"/[5$C&#LOP3Y Q'*3;%D<KA(F_BXIXG-XUX+5FN)AQ+<:*Z*%LF%=MP?5,(
M(&TB6ANWZ;;X5<:9UD+<\HO,V/U:Z9P0Y!F2R**_>P4+RU)$I==?K>=IQ;DY
M9 S*OM*VW3NQ_.D7IAO-->?)&$&GK2MA+/]628D RQ$Q" *N<6 9<+2EGGQ2
MD=5)-D.([5_3/TNLG#=8QL.!(S+QD!K0#J)W&HUI4N#LL(@]B.,&!DCW^S<X
M(Y(64I$,=&]];D^=S^T]HP12V[NPRF?M@UOM#CYM^> (1Z(N55ZB25<3$??*
M%J_;C.>]Z 8O/!O5).I/LPJ;>XX:Z0LC29U\>3;0/3\<&#.9NMQB-2FC8()X
M,>Y\N>!)Q*SS6BZW;_;S>X8G\:4P1HX$7XT2229:P-;\/!+*_IWHV=P8QBZ$
MX 4TFA+35:)8=ROX"+K\\U9V]2Z>9ZMJ?V]2SAO&LS4GP'!),,#$$Z\BRSH'
M4;'$;;M(.D"G,9%+30E@CHCK)-!8KI;4=!?"K[I,F$ [A(]'X/"-2XM"6!B8
M PD]Z9V#!,,J+3Y]<OPMJ'U;)7JA@%3BF[^$\KN7/A$OT'J'63NV9:8JG>!U
MH)1NEXOL(@N:TL+&VE3@9A<9=G.M;ZQ=4ALAN"OHVAO;-H'=P"(6+9?MS="M
MW6VV4_$O(*UO1[[7)AVB)Y?:/;?CU3WW60X&<8#D//]<%'A F"F15AG\HZX7
M0##BFN_6"[_Q#O[09J/QL-1DSVW[:AE]5!:I"XG\X"_^R5-RK843[L4@4Q6K
M0D;=ZX#'M1Y8\EGLQB!!J16)AR?BJ.>F)3Z\;PQT!3_B3VL_XMJ/>"?\B#^M
M_8C?+Z?Y9%5M'*IJA\3PD;%C/)KR<JF1T9AJ*1&(E#(L,?O,_IF1=V*/4:18
M_L@PT-+3 *2K]9;X">E!WK)+X*;@WLTJ^WT3+U^J%_->3NU]\?PX$[M/6:0,
MTK:T7R6'H%2<VBCZA%,PP@$P/$X==6$8PBY?'^@G]6%%<'XMI8[MT^FHB&HI
MHG#0RFT)JMEM^.ANX:3DR[&^'E2GTFF^'#5].LGG$2LS8JYL!!UA)G[$ 9Y>
MP7YJGV:OHFX\W<:DFRC/$V,+@.$V<__F"^.8GK:#/>A=$V\86D:2$#(O+UW1
MB2DKZK72.C$9BO>@;5])G0:#=M.+85*%GQ2UL[NS,7H(UB,E3E'()D\OT2I_
M@T$D:2C8MX[BNN_@>KF>+-8+X6"]B<1M?.1XDX2/RP(]Z=XZW)\YA_NQ]>X9
M*"WIB>DC#(9YEYY#D&77O=W'']T^<A/==:3B(X3IC]ULX2-@'__0A:YL'J<%
M>_> U[AQEF3#<3(_=S+F!,U._8/O\&FHP))]FSR4!U8_PR*&C4HWBPHF0OGS
M\\:4&&BCS+F>I=AY@G#R$1B3P%-83*3<)86!Y_$K\&Q!BCJVY<IT)5&/<5D@
M8\?ZRW1<9[!K%'/4- ^"II]E-:&)L ?()3$:T(G$]%QU)96M0#X&;RJMU22]
MKJ4]!C=0GN?I6-N.M/C)!#O8X']@=B3,@YRN9A=HIZ:+&OM@PY[*K^F5V&[(
M"C]B/V*;$>P!3I7R",GA)ZT-)*,Q)4OGFA,0S)]JU],%^]<L"JE8Y "7]4YC
M65BDX6R9H"\EJ]0_*9\S48^WMK;48:[V@;Q!@!UKS-AXE4_.-M4N$/4BPXR,
MG:VM!&SYO%2@[&.D%RX0S*+(4O73[N.MIXDZQ!U^KD8X]N:?-/;?SV$S0-8U
MH*]G=5G5FS!?.@*O*-+T<D@[?5\=DX8KBG\<#CS?=MJH7%,:,=R0C>TM6?6K
M19T19,D!$H;-@0\@33C[UF*:L,U";8XI-U=F)&W,$*EK3FU[-FQZ*-;CHNS
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M+EVMHH1C;HT\3#$>O&"M0\1L&!ITR73@Z]C%8;PB'HWMVIN#ZIZ@7,S1 I[
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M=\$"^**6*.W=]H]?6CU_^AT%J+ZXX\%H$H=7U+%2[3G=X0M_P4S\"P_?DZ9
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M$M31U.^-P8$M*=YNIU=B?B3V86GURV$AZ:O6V!H$UCZGJH[<U7(TZ15\QW0
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M+FAT;>U=>W,;-Y+_GU7\#EC57DJJHF@];&\B*:JCI%'$.XG4DE1B5VHK!<Z
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M72X#)N[@4@S<9)Z(W4B.D2UP?1H)Z#2"J_"8S\8"F-!BD]3WEVS.I4?##<(
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MN@NKS@KKU863XL%=I:AK?030U2"7H(_#,6IQX3W>Q*WA5S[RA*W1LS$4,?]
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M"[]N=K9/MMCFNZW_X/5-#/X7V.G!5_*E=[ZZ-T\4 "/8CV2 +#%K-I2<A4H
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MIYG\5R?]L_<$ZU^,KBZ/_P]02P,$%     @ PT-#63H+@)2%'@  ('@  !T
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MCMM1?!TBQL "'USQ/]4;O)PRBQ'M+X1\AJK<()@44JR_I "_^O;I7VFX;6D
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M]T]65"G(#VG_HR8;Q+$52E(<G<9F&@&":*\\9A1)S.9B]]9I:3D?$P%#X,C
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M+PZK53?8$:4;>ZT,@$@K@ _W^,,=@H^TTPJ704N!+JSDYK;P$3T'#(!%A[A
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MTMO:\UB%A#3UF6F1K]0W1[".J=LLA??:S-X+PFRD,#6$O2\R=Z93=V(7+E^
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M?+)+?^%7_N0O_67@_P502P$"% ,4    " ##0T-9UK.+F\P#  #J#@  $0
M            @ $     871N9BTR,#(T,#DR.2YX<V102P$"% ,4    " ##
M0T-9-7Y*XP )  "5:   %0              @ '[ P  871N9BTR,#(T,#DR
M.5]D968N>&UL4$L! A0#%     @ PT-#68;#GKWQ"P  %)   !4
M     ( !+@T  &%T;F8M,C R-# Y,CE?;&%B+GAM;%!+ 0(4 Q0    ( ,-#
M0UFZR(8 1P@  "]C   5              "  5(9  !A=&YF+3(P,C0P.3(Y
M7W!R92YX;6Q02P$"% ,4    " ##0T-90#D=#DDX  !Q-@$ &
M    @ ',(0  96$P,C$V-# S+3AK7S$X,&QI9F4N:'1M4$L! A0#%     @
MPT-#6>1$IEBDE   Y \$ !P              ( !2UH  &5A,#(Q-C0P,S Q
M97@R+3%?,3@P;&EF92YH=&U02P$"% ,4    " ##0T-9T]T+=BQ*   5T $
M'               @ $I[P  96$P,C$V-# S,#%E>#,M,5\Q.#!L:69E+FAT
M;5!+ 0(4 Q0    ( ,-#0UG?*!:&AQP  +"6   <              "  8\Y
M 0!E83 R,38T,#,P,65X-"TQ7S$X,&QI9F4N:'1M4$L! A0#%     @ PT-#
M63H+@)2%'@  ('@  !T              ( !4%8! &5A,#(Q-C0P,S Q97@Y
E.2TQ7S$X,&QI9F4N:'1M4$L%!@     )  D =P(  !!U 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>ea0216403-8k_180life_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180lifesciences.com/20240929"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20240929.xsd" xlink:type="simple"/>
    <context id="AsOf2024-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2024-09-29</startDate>
            <endDate>2024-09-29</endDate>
        </period>
    </context>
    <context id="From2024-09-292024-09-29_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-29</startDate>
            <endDate>2024-09-29</endDate>
        </period>
    </context>
    <context id="From2024-09-292024-09-29_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-29</startDate>
            <endDate>2024-09-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-09-29" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AsOf2024-09-29" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-09-29" id="Fact000005">0001690080</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-09-29" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-09-29" id="Fact000011">2024-09-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-09-29" id="Fact000012">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-09-29" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-09-29" id="Fact000014">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-09-29" id="Fact000015">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-09-29" id="Fact000016">3000 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-09-29" id="Fact000017">Bldg. 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2024-09-29" id="Fact000018">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-09-29" id="Fact000019">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-09-29" id="Fact000020">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-09-29" id="Fact000021">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-09-29" id="Fact000022">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-09-29" id="Fact000023">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-09-29" id="Fact000024">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-09-29" id="Fact000025">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-09-29" id="Fact000026">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-09-29" id="Fact000027">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2024-09-292024-09-29_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-09-292024-09-29_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000029">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-09-292024-09-29_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-09-292024-09-29_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000031">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-09-292024-09-29_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000032">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-09-292024-09-29_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-09-29" id="Fact000034">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
